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ABSTRACT 
Bone morphogenetic factor 15 (BMP15) and growth differentiation factor 9 (GDF9) are 
two oocyte-secreted factors with well documented effects on ovarian follicular 
development and ovulation-rate. The aims of these studies were to: (i) identify the 
molecular forms of BMP15 and GDF9 that are produced and secreted by both the ovine 
and bovine oocyte using highly specific monclonal antibodies; (ii) assess the biological 
activity of some recombinant molecular forms of BMP15 and GDF9; (iii) visualise the 
various molecular forms using protein modelling techniques and; (iv) provide a 
hypothetical model of how oocyte-secreted form(s) of BMP15, GDF9 and their cell surface 
receptors may interact.  
Using genetic modifications and transformations of HEK293 cells, recombinant forms of 
ovine (o) BMP15, including a BMP15 (S356C) mutant capable of forming covalent 
dimers, and oGDF9 were produced. The bioactivity of these proteins was established using 
a rat granulosa cell proliferation bioassay. The specificity of the monoclonal antibodies 
MN2-61A (anti-BMP15) and 37A (anti-GDF9) used in these studies, and determination of 
the forms they recognise, was examined by Western blotting. The recombinant forms of 
oBMP15 were further interrogated by purification using both immobilised metal affinity 
chromatography (IMAC) and reverse phase HPLC. The BMP15 and GDF9 proteins 
produced and/or secreted by ovine and bovine oocytes, before and after in vitro incubation, 
were identified and compared with the molecular forms(s) of recombinant oBMP15 or 
oGDF9 using Western blotting under non-reducing, reducing and cross-linking conditions. 
The molecular forms of recombinant oBMP15 and oGDF9 comprise mainly mature 
monomers with a lesser amount of the uncleaved pro-mature form. Mature domains, in the 
dimeric mature form, were detected for oGDF9 and oBMP15 (S356C), but not oBMP15. 
These mature domains were almost entirely located within high molecular weight 
multimeric complexes, which likely also contain the pro-region. In contrast, BMP15 and 
GDF9 secreted from ruminant oocytes under in vitro conditions were found mainly in an 
unprocessed promature form, along with some fully processed mature domains that did not 
interact to form detectable mature homodimers or heterodimers. Throughout ovarian 
follicular development, BMP15 and GDF9 are co-expressed and it has been established 
that these two factors have synergistic effects on granulosa cell proliferation both in vitro 
and in vivo and also on follicular maturation and ovulation-rate in vivo. Moreover, the 
recombinant proteins oBMP15 and oGDF9 generated for this study, when added together, 
iv 
also demonstrated a synergistic effect in the granulosa cell proliferation assay but this was 
not observed for oBMP15 (S356C) and oGDF9.  
 
Currently, no adequate model has been proposed to explain how interactions between the 
cell membrane and forms of oocyte-derived BMP15 and GDF9 achieve their synergistic 
effects. To investigate this, two homology models of the promature BMP15 and GDF9 
proteins were generated using promature porcine TGFB1 and human BMP9 as templates. 
These models, together with the previously determined forms of GDF9 and BMP15 
produced by the ruminant oocyte, were used to visualise their potential interactions, both 
with each other and with their receptors. This report describes a model showing the 
possible interactions involved in a synergistic response. In this model, the mature domain 
is presented to the type II receptor by the proregion and heterodimers form at the level of 
the receptor. Differences, following heterodimerisation in the conformation and orientation 
between GDF9 and its type I receptor, as well as between type I and type II receptors, 
relative to that in homodimers, could explain how heterodimerisation leads to increased 
Smad3 phosphorylation and subsequent down-stream somatic cell responses.  
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1 
1. CHAPTER 1: INTRODUCTION 
 
The subject matter in this thesis is concerned with the biological functions of two protein 
members of the transforming growth factor beta (TGFB) superfamily, namely bone 
morphogenetic protein 15 (BMP15) and growth differentiating factor 9 (GDF9). Over the 
past 15-20 years, BMP15 and GDF9, either alone or together, have emerged as being 
essential for: ovarian follicular development; determining the number of eggs (oocytes) 
released at each ovulation (ovulation rate) and; most likely, the quality of the oocyte at the 
time of fertilization. 
 
In this introductory chapter, the general principles of ovarian and follicular development 
together with oocyte characteristics will be reviewed, followed by our current 
understanding of the biological actions of the TGFB superfamily, including that of BMP15 
and GDF9.  
 
1.1 The ovary 
In mammals, ovaries are two paired organs/glands each of which is attached to the uterus 
by a uterine ligament and in close proximity to the end of the fallopian tube. One of the 
main roles served by the ovary is the production of oocytes, each of which is enclosed 
within a follicular structure consisting of two main somatic cell-types. The cells 
immediately adjacent to the oocyte are known as the granulosa cells and those immediately 
adjacent, but outside the basement membrane of the follicle, as the theca cells. These 
somatic cells together with the oocyte all need to develop in a highly synchronized manner 
to ensure oocytes are capable of being fertilised following ovulation, and developing into 
an embryo. Moreover, following ovulation, the follicular somatic cells are transformed into 
luteal cells and these are needed to support the early maintenance of pregnancy (Peters et 
al. 1975). Another key role for the ovary is to produce steroid and protein hormones which 
act as endocrine, paracrine and autocrine factors. Hormones produced by the ovary play 
diverse roles, such as in the development of secondary sex characteristics (Juul 2001), 
development of follicles and the timing of ovulation (Swerdloff et al. 1972; Richards et al. 
1976), tissue remodelling of the uterus ready for implantation (Thibault et al. 1993), 
maintenance of early term pregnancy (Cumming et al. 1974), suppression of oestrus and 
ovulation during pregnancy (Meites et al. 1951) as well as effects on bone growth (Juul 
2001).  
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1.2 Ovarian follicular development 
1.2.1 The ontogeny of follicular formation 
Sawyer et al. (2002) published a comprehensive study of follicular formation in the ewe. 
The evidence in humans and cattle indicates that the sequence of events leading to 
follicular formation is similar although the timing of events in fetal life is different but 
consistent with the duration of pregnancy in these species (van Wagenen and Simpson 
1965; Garverick et al. 2010). In the mouse, follicular formation differs as it extends into 
early neonatal life but the origins of the somatic cell-types appears to be the same as in the 
aforementioned species (Mork et al. 2012). For the purposes herein, the sequence of events 
leading to follicular formation will be that described for sheep. In ewes, follicular 
formation begins during early fetal life. Briefly, by Day 38 after conception, dividing germ 
cells (oogonia) have migrated into the newly forming ovaries, continue to proliferate and 
also, to establish contacts with mesenchymal (pregranulosa) cells. These oogonia continue 
to migrate towards the cortical regions (outer periphery) of the ovary, where they are most 
numerous. Some are even found within the surface epithelium, previously described, albeit 
incorrectly, as the germinal epithelium. The formation of ovigerous cords, as the result of 
extensive contacts of oogonia with the pregranulosa cells and the formation of a basal 
lamina, is evident by Day 38 and this process continues until Day 75 of gestation. These 
cords are “sock like” in appearance and remain open to the surface epithelium whereby 
proliferating oogonia can recruit only epithelial (pregranulosa) cells within the cord. By 
Day 75, the ovary contains the maximum number of germ cells that it will ever have. 
However, between Day 75 and Day 90 the vast majority of germ cells die, although there is 
no corresponding cell death or proliferation observed in the pregranulosa cells. This 
prompted Sawyer et al. (2002) to propose that the surviving pregranulosa cells then form 
new associations with the remaining germ cells so that the process of germ cell death is a 
mechanism by which oocytes can acquire additional numbers of pregranulosa cells. 
Beginning on Day 55, some of these germ cells enter the prophase of the first meiotic 
division (meiosis I) and consequently to become oocytes. These were found mainly at the 
base of the ovigerous cords (the toe of the sock) located at the presumptive cortical-
medulla interface. This process continues progressively up the cord, in an outwards 
direction, towards the surface of the ovary and by Day 75, large numbers of oogonia have 
entered meiosis I and become oocytes. Between Days 75 and 100, fully formed primordial 
follicles consisting of an oocyte surrounded by a single layer of granulosa cells, all 
encompassed in a basement membrane, begin to bud off from the “toe” of the ovigerous 
cord. This process continues progressively up the cord with the first primordial follicles to 
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form being located at the deepest region of the cortex and the last follicles to be formed 
being found adjacent to the surface epithelium. By Day 100, the process of follicular 
formation is complete. The earliest forming follicles are likely to have granulosa cells of 
mesenchymal origin (~5-10% of follicles in sheep) whereas the remainder contain 
granulosa cell of epithelial origin. 
 
These primordial follicles remain in this state until growth is initiated. This begins around 
the time the first follicles are formed during fetal life and thereafter continues in a 
sequential manner throughout the life of the animal. However, while follicles remain at the 
primordial state, they are not completely quiescent as they actively transcribe genes. For 
example, in sheep, the mRNA for over 2300 genes have been isolated from primordial 
follicles (Kezele et al. 2005). Perhaps the term “developmentally arrested” would be a 
more accurate portrayal of the state of a primordial follicle. For example, proliferating cell 
nuclear antigen (PCNA) has been located in both the oocyte and the granulosa cells of 
primordial follicles in the sheep. (Lundy et al. 1999). PCNA plays a role not only in cell 
proliferation but also in cell repair (Essers et al. 2005). The ultimate role of the oocyte is to 
pass on an accurate copy of the genetic code to the next generation and as such it is not 
unreasonable to find proteins present which are involved in DNA repair.  
 
1.2.2 Follicular development 
Follicular development starts with the initiation of growth of a primordial follicle. Both the 
process by which an individual follicle is recruited for growth, and the mechanism 
responsible for initiating growth, are unknown. However, once this process has begun it is 
irreversible and unceasing with primordial follicles being recruited sequentially for further 
development (Peters et al. 1975). Moreover, a primordial follicle, once recruited, will 
continue to grow, without pause, until the follicle either reaches a stage where the oocyte is 
ovulated or undergoes atresia (Peters et al. 1975). This process of follicular development 
continues unabated throughout life even during the periods of anoestrus and pregnancy 
(Peters et al. 1975). 
 
Once growth has been initiated, the diameter of the oocyte enlarges and the number of 
granulosa cells continue to increase and both occur in a coordinated manner (Lundy et al. 
1999). As mentioned earlier, a primordial follicle consists of an oocyte surrounded by a 
single layer of granulosa cells, containing at least one flattened granulosa cell.  
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This follicle will be approximately 40µm in diameter and contain an oocyte with a 
diameter of about 35µm (Figure 1.1A; Sawyer et al. 2002). The first morphologically 
distinct sign that a follicle has been selected to grow is when the single layer of granulosa 
cells has become composed solely of cuboidal shaped cells 
(Figure 1.1B). Using sheep as an example of the events 
occurring during follicular development, Lundy et al. (1999) 
has termed follicles at this stage of development as type 2 or 
primary follicles. In addition, the diameter of the oocyte 
increases by about 50% during the transition from a 
primordial to a primary follicle (Lundy et al. 1999). Follicles 
at this phase of growth continue to develop as pre-antral 
follicles. The largest pre-antral follicles consist of 4-6 layers 
of granulosa cells surrounding an oocyte which has now 
obtained a diameter of ~90µm, some 2.5 fold greater than 
when it was enclosed in a primordial follicle (Figure 1.1C). 
By this stage of follicular development, all oocytes have 
formed a completed zona pellucida and theca cells have been 
recruited from the surrounding stromal cells to enclose the 
follicle (Peters and McNatty 1980; Lundy et al. 1999). 
Small, fluid-filled, intracellular spaces also start to appear 
between the granulosa cells (Peters and McNatty 1980). The 
production and accumulation of this fluid continues in a 
progressive manner until the spaces coalesce and a fluid-
filled antrum is formed. At this stage, the follicle has 
reached, what is referred to, as the small antral follicle stage 
(Figure 1.1D): these follicles will now contain an average of 
11,000 granulosa cells. This represents more than a 700-fold 
increase in granulosa cell number from that of a primordial 
follicle, and has taken 9-10 cell doublings to achieve this 
state. 
 
Figure 1.1 Schematic of ovarian follicles at the (A) primordial, (B) primary, (C), pre-
antral, (D) small antral and (E) large antral stages of development. The cell types 
comprising the follicle are marked; oocyte (o), granulosa cells (g) and theca (t).  
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The oocyte now will have reached 120µm, almost its maximum diameter and the follicle 
will have a diameter of approximately 350µm (Lundy et al. 1999). As the follicle 
continues to develop and the antrum becomes larger, the granulosa cells segregate into two 
distinct phenotypes. The first, referred to as the mural granulosa, are located around the 
periphery of the follicle near to the basement membrane. The second, referred to as the 
cumulus cells, are those cells surrounding the oocyte (Figure 1.1E). It is uncertain as to 
how this segregation of phenotypes occurs. One view is that the oocyte actively induces 
the cumulus cell phenotype by the production and secretion of specific factors. The other 
view is that up to this stage all granulosa cells are “cumulus cells” and those (i.e mural 
granulosa cells) that become more distant from the oocyte as the follicle grows, default to a 
different phenotype as they escape the action or influence of the oocyte-secreted factors. 
Whichever view is correct, either a mural granulosa cell actively changing to a cumulus 
cell, or a cumulus cell passively defaulting to a mural granulosa cell, the one point they 
have in common is the involvement of the oocyte. The theca cells have also segregated into 
a highly vascularised, well-defined theca internae and a relatively avascular, and less well-
defined, theca externae. 
 
Antrum formation is a perilous time for a follicle. While very few follicles undergo atresia 
prior to this stage, many follicles fail to survive during the transition to antrum formation 
or during early antral development and those that fail, enter an apoptotic pathway. In the 
sheep, follicles are able to grow up to 3 mm in diameter without the requirement for 
gonadotrophins. Although granulosa cells can respond to gonadotrophins prior to reaching 
3 mm in diameter, they become gonadotrophin-dependent for continued growth beyond 
this stage (Figure 1.2; McNatty et al. 1990). In order to develop into a preovulatory 
follicle, granulosa cells must develop a functional receptor for luteinising hormone (LH) 
(Webb and England, 1981). Should an ovine follicle avoid atresia, it will ultimately 
develop into a preovulatory follicle with a diameter of 5-7mm, and contain approximately 
5x106 granulosa cells. The number of granulosa cells present in preovulatory follicles 
varies between species. For example in humans, the preovulatory follicle is >15 mm 
diameter and contains >50 x 106 granulosa cells (Gougeon 2010) 
 
The oestrous or menstrual cycle in mammals includes a series of endocrine events 
coordinated through hormonal signals between the hypothalamus, pituitary and ovary. In 
sheep and cattle, the oestrous cycle lasts 17 and 21 days respectively.  
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A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Developmental 
stage 
First appearance of mRNA or protein 
Developmentally 
arrested 
GDF9(o), BMP6(o), BMPR1A(o, g), TGFBR1(o), BMPR1B(o), BMPR2(g), 
Betaglycan(o), Follicle stimulating hormone receptor (FSHR)(g), 
Steroidogenic factor-1 (SF-1)(g), Steroidogenic acute regulatory protein 
(StAR)(o), 3β-hydroxy steroid dehydrogenase (3β-HSD)(g)  
Non-responsive to 
gonadotrophins 
BMP15(o), BMPR1B(g), ACVR2B(o, g), Inhibin beta B(g), Inhibin alpha (g) 
Gonadotrophin-
responsive 
TGFB1(t), TGFB2(t), BMPR1A(t), TGFBR1(g, t), BMPR1B (t), ACVR2B(t), 
BMPR2(t), TGFBR2(t), Betaglycan(g, t), Follistatin(g, t), Follistatin-related 
protein (FSRP)(g, t), SF-1(t), StAR(t), Cholesterol side-chain cleavage 
enzyme (P450scc)(g, t), 17α-Hydroxylase (17αOH) (t), 3β-HSD(g),LHR(t), 
FSHR(g), Inhibin beta A(g) 
Gonadotrophin- 
dependent 
BMP6(g, t)? inconsistent expression, StAR(g), P450arom(g) 
LH-dependent LHR(g) 
 
Figure 1.2 Schematic diagram depicting the recruitment and growth of follicles 
throughout an oestrous cycle, illustrating how a single follicle may continue its 
growth towards ovulation. (A) Primordial follicles are continually and sequentially 
recruited to enter the growing pool. These may either progress to ovulation or 
undergo atresia at some point along the way (as shown by upward then downward 
pointing arrows). As follicles reach the large antral stage and become gonadotrophin 
dependent, they secrete more estradiol which at the later stages of the oestrous cycle, 
feeds back on the pituitary to suppress FSH, and increase LH secretion. This 
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ultimately culminates in the LH surge and ovulation. Adapated from (Peters and 
McNatty 1980). (B) The ontogeny of expression of selected genes during follicular 
development. Members of the TGFB superfamily family (Juengel and McNatty 2005), 
steroidogenic pathway (Logan et al. 2002), LHR (Logan et al. 2002), FSHR (Tisdall et 
al. 1995) and Inhibins (Montgomery et al. 2001) genes/proteins within the oocyte (o), 
granulosa cells (g) and theca (t) compartments of the ovine follicle). 
 
The cycle is regulated by the hypothalamus secreting episodic pulses of gonadotrophin-
releasing hormone (GnRH) that act on the anterior pituitary, which in turn, secretes 
follicle- stimulating hormone (FSH) in a wave-like manner and LH in pulses synchronised 
to those of GnRH. 
 
The circulating levels of gonadotrophic hormones exert their actions on the ovary. By 
acting on granulosa cells, FSH promotes follicular maturation, while LH stimulates 
androgen synthesis in thecal cells. At the same time, oocyte-secreted factors (such as 
BMP15; see Section 1.4.3) regulate the actions of FSH and LH on the granulosa cells. The 
secreted androgen, mainly in the form of androstenedione, is secreted into the blood stream 
and also metabolized to oestradiol by the granulosa cells under the influence of FSH. 
Likewise, antral follicles and specifically the granulosa cells also produce inhibin. 
Follicular development to the preovulatory stage leads to increasing plasma concentrations 
of both oestradiol and inhibin, which, in turn, initiates feedback effects on the 
hypothalamus and/or pituitary. The increasing oestradiol levels, through positive feedback 
results in an increase in the pulse frequency of LH secretion, and together with inhibin, by 
negative feedback, a decline in FSH levels. The levels of circulating inhibin are highly 
correlated with the number of granulosa cells present in the large antral follicles (McNatty 
et al. 1993). At this stage, the dominant oestrogen-secreting follicle(s) develop a functional 
LH receptor on their granulosa cells. This enables the oestrogen-secreting follicle(s) to 
continue development, by maintaining aromatase activity, in the face of declining FSH 
levels. In contrast, any remaining follicles (at the gonadotrophin-dependent stage of 
development), but without LH-responsive granulosa cells, are unable to sustain growth and 
undergo atresia (Figure 1.2). Ultimately, the increasing levels of oestradiol secretion from 
the preovulatory follicle(s) reach a threshold that triggers a large preovulatory surge of 
both LH and FSH (Baird and McNeilly 1981). This gonadotrophin surge induces ovulation 
(i.e. the rupture of the dominant follicle(s) and release of the oocyte-cumulus cell complex) 
together with luteinisation of both the granulosa and theca cells leading to formation of a 
corpus luteum (CL). During the luteal phase, the secretion of CL-derived plasma 
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progesterone limits the ability of follicular-derived oestradiol to stimulate gonadotrophin 
secretion. However, if pregnancy does not eventuate, the CL regresses leading to a rapid 
decline in progesterone levels. 
 
1.2.3 Oocyte maturation 
As mentioned earlier, follicular somatic cell development occurs concurrently with the 
closely-associated process of oocyte maturation. Somatic cell development results in the 
formation of a mature follicle capable of ovulating. Moreover, oocyte maturation involves 
the oocyte gaining the ability to resume meiosis and upon fertilization, to develop into a 
viable embryo (developmental competency). These processes require a highly coordinated 
degree of communication between the oocyte and the somatic cells. This ‘intra-follicular’ 
communication is carried out, not only by molecules acting in a paracrine fashion between 
oocytes and cumulus/granulosa cells, but also by molecules which are transported through 
gap junctions between the cell-types. Cumulus/granulosa cell processes occur between the 
granulosa cells, granulosa and cumulus cells and also extend through the zona pellucida to 
form attachments with the oocyte (Thibault et al. 1993). The zona pellucida plays 
important roles during fertilization and preimplantation development (Wassarman and 
Litscher 2012).  
 
Oocyte maturation culminates in the oocyte gaining the competence to undergo meiotic 
maturation. During the growth phase of the follicle, the ovine oocyte increases 3.5 fold in 
diameter from 35µm to >120µm. This equates to an increase in volume of over 40-fold. 
Generally, the oocyte needs to reach 80% of its maximum size before it is capable of 
meiotic maturation (Thibault et al. 1993). However, the oocyte remains in meiotic arrest 
awaiting the signal to resume meiosis, that is, the preovulatory LH surge. Following the 
surge, gap junctional connectivity between the oocyte and its granulosa/cumulus cell 
syncytium is broken, resulting in a rapid decline of cAMP concentrations within the oocyte 
(Sela-Abramovich et al. 2006). This allows the oocyte to resume meiosis by moving from 
diakinesis, where it has been arrested during the growth phase of the follicle and into 
metaphase of meiosis I (Thibault et al. 1993). 
 
1.3 Transforming Growth Factor-Beta (TGFB) super family 
1.3.1 General characteristics 
The transforming growth factor-beta (TGFB) super family comprised of structurally 
similar proteins, with diverse functions, and consists of over 35 members. The members 
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can be classified further, into the TGFB, activin, bone morphogenetic protein (BMP) and 
growth differentiation factor (GDF) sub-families, as well as more distant members such as 
Mullerian inhibiting substance (also known as anti-Mullerian hormone, AMH), and inhibin 
α (Massague 1998). Members of the TGFB family are produced as pre-proproteins 
consisting of a signal peptide, a prodomain and a mature domain (Massague 1990). 
 
 
 
 
Figure 1.3 Monomer and dimer ribbon structures. (A) The monomer of ovine BMP15 
(oBMP15) has been likened to the shape of a left hand which consists of two “fingers” 
composed of anti-parallel beta strands (blue), a “wrist” region constructed from an 
alpha helix (green). Two disulphide bridges (red) complete a ring of covalent bonds 
that is bisected by a third disulphide bond (purple) to form the cysteine knot. This 
forms a rigid “palm” (Daopin et al. 1992). (B) The structure of a dimer of BMP2. The 
covalent bond between the seventh conserved cysteine (yellow) linking the two 
monomers is shown. The BMP2 dimer was obtained from the Research Collaboratory 
for Structural Bioinformatics Protein Data Bank (www.pdb.org; Accession number 
1ES7; Kirsch et al. 2000b). The oBMP15 was created using the Swiss model 
comparative protein modelling server (Schwede et al. 2003; Arnold et al. 2006; Kopp 
and Schwede 2006; Kiefer et al. 2009) using BMP2 (1ES7) as a template.  
 
One of the defining characteristics of this family is the presence of a “cysteine knot” within 
the mature region, formed from disulphide bonds among six conserved cysteines. (Figure 
1.3A; Daopin et al. 1992). It is thought that the fully mature and biologically active form 
of most family members consists of dimers of the mature region. Most exist as 
homodimers, however some such as activin AB, inhibin A and inhibin B are heterodimers. 
It has also been shown that coexpressed recombinant BMP2, with BMP5, 6 or 7 are able to 
form heterodimers that are more biologically active than their homodimer counterparts 
(Israel et al. 1996). BMP15 has also been shown to act in a synergistic manner with GDF9, 
possibly as heterodimers (McNatty et al. 2005b). These dimers are usually bound 
covalently through a seventh conserved cysteine (Figure 1.3B; McDonald and Hendrickson 
1993). However in some family members such as BMP15, GDF9, GDF3, lefty 1, and lefty 
2, this seventh cysteine has been mutated to a serine, therefore any dimers that exist 
between these forms must be due to a non-covalent association. 
 
A B 
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1.3.2 Role of the proregion 
In general, the role of the proregion of the TGFB family members has not been well 
defined. However, for some members of the family, interactions between the proregion and 
the mature domains have been demonstrated (Young and Murphy-Ullrich 2004; McIntosh 
et al. 2008; Walton et al. 2009). Moreover, mutations within the proregion of the TGFB 
superfamily members have been linked to disease states. For example, mutations in: AMH, 
result in persistant Mullerian duct syndrome (Belville et al. 2004); GDF1, results in heart 
defects (Karkera et al. 2007); GDF5, leads to a brachydactyly condition (Schwabe et al. 
2004) and; BMP15 to hypergonadotropic ovarian failure (Di Pasquale et al. 2004). With 
respect to normal physiological functions, it is thought that the pro-region folds around and 
binds non-convalently to the mature region, thereby causing or assisting the mature domain 
to fold correctly (Walton et al. 2009). The mature region is cleaved from the pro-region by 
furin-like proprotein convertases (Dubois et al. 1995; Thomas 2002; Jin et al. 2004). It has 
also been suggested that the pro-region, while still attached non-covalently to the mature 
region, plays a role in dimer formation and in export from the cell (Walton et al. 2009) 
with two proregions and a mature dimer being secreted as a complex. Exceptions to this do 
occur as uncleaved GDF8 has been found bound to the extracellular matrix surrounding 
skeletal muscle cells (Anderson et al. 2008). The proregion is also thought to be involved 
in the presentation of these dimers to receptors on target cells or to anchor them to the 
extracellular matrix (Brown et al. 2005; Anderson et al. 2008; Sengle et al. 2008a). The 
proregion of some family members, such as TGFB and myostatin (Brown et al. 2005) bind 
strongly to and thus inhibit the action of the mature dimer, thereby acting as a latency 
protein. Moreover, the proregion of TGFB1 is also known as latency-associated protein 
(LAP). 
 
1.3.3 Receptors  
Receptors for the TGFB family members are composed of two types of serine-threonine 
kinases. Type I receptors (also known as activin receptor like kinases: ALK) are comprised 
of seven members, ALK1 (ACVRL1; activin A receptor, type II-like I), ALK2 (ACVR1; 
activin A receptor, type I), ALK3 (BMPR1A; bone morphogenetic protein receptor, type 
IA), ALK4 (ACVR1B; activin A receptor, type IB), ALK5 (TGFBR1; transforming 
growth factor beta receptor 1), ALK6 (BMPR1B; bone morphogenetic protein receptor, 
type IB) and ALK7 (ACVR1C; activin A receptor, type IC). The five type II receptors are 
ACVR2A (activin A receptor, type IIA), ACVR2B (activin A receptor, type IIB), BMPR2 
(bone morphogenetic protein receptor, type II (serine/threonine kinase)), TGFBR2 
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(transforming growth factor, beta receptor II (70/80 kDa)), and AMHR2 (anti-Mullerian 
hormone receptor, type II) (de Caestecker 2004). The onset of expression of some of these 
receptors in the ewe are shown in Figure 1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 A BMP2 homodimer: type II receptor: type I receptor complex. Adapted 
from (McNatty et al. 2004) and (Lin et al. 2006). The BMP2 homodimer was obtained 
from the Research Collaboratory for Structural Bioinformatics Protein Data Bank 
(1ES7; Kirsch et al. 2000b). 
 
A receptor ligand complex consists of a dimer of mature proteins bound to two type I 
receptors and two type II receptors (Figure 1.4). Upon formation of the complex, the 
constitutively-active type II receptor phosphorylates and activates a highly conserved 
glycine- and serine-rich region of the type I receptor, termed the GS domain (Wrana et al. 
1994). In turn the type I receptor recruits and phosphorylates intracellular signalling 
molecules called Smads. (Miyazono 1998; Fujii et al. 1999). 
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Table 1.1 Relationships between ligands, receptors and the Smad signalling 
pathways of TGFB superfamily members 
Ligand aka 
Type II 
receptor 
Type I 
receptor 
Co-
Receptor 
R-Smad References 
Inhibin(s)  
ACVR2A 
ACVR2B 
BMPR2 
 Betaglycan  
Lewis et al. 2000; 
Bernard et al. 2001;  
Wiater and Vale 2003 
Activin(s)  
ACVR2A 
ACVR2B 
ACVR1B  Smad2/3 
Attisano et al. 1996; 
Macias-Silva et al. 1998; 
Bernard et al. 2001 
Activin B  
ACVR2A 
ACVR2B 
ACVRIC  Smad2/3 
Bernard et al. 2006; 
Bertolino et al. 2008 
TGFB1  TGFBR2 
ACVRL1 
TGFBR1 
Endoglin 
Betaglycan 
Smad2/3 
Boyd et al. 1990; 
Yamashita et al. 1994; 
Altomonte et al. 1996; 
Nakao et al. 1997b; 
Lux et al. 1999 
TGFB2  TGFBR2B TGFBR1 Betaglycan Smad3 
Boyd et al. 1990; 
Rotzer et al. 2001; 
Zode et al. 2009) 
TGFB3  TGFBR2 ACVRL1 Endoglin Smad2 /3 
Altomonte et al. 1996; 
Lux et al. 1999; 
Dudas et al. 2004 
BMP2 BMP2a BMPR2 
BMPR1A 
BMPR1B 
Betaglycan, 
Repulsive 
Guidance 
Molecule 
(RGM) 
Smad1/5/8 
Sieber et al. 2009;  
Babitt et al. 2005; 
Kirkbride et al. 2008 
BMP3 Osteogenin ACVR2B ACVR1B  
No signal 
transduction 
Gamer et al. 2005; 
Allendorph et al. 2007 
BMP4  BMPR2 
BMPR1A 
BMPR1B 
Betaglycan, 
RGMa 
Smad1/5/8 
Baade Ro et al. 2004; 
 ten Dijke et al. 1994;  
Nohno et al. 1995;  
Babitt et al. 2005;  
Gromova et al. 2007;  
Kirkbride et al. 2008) 
BMP5  ? ?  Smad1/8 Zuzarte-LuIs et al. 2004 
BMP6 Vgr1 
ACVR2A 
BMPR2 
ACVR1 
(EGF-CFC 
factor) 
Smad1/5 
Baade Ro et al. 2004; 
Ebisawa et al. 1999;  
Cheng et al. 2003 
BMP7 OP1 
ACVR2A 
ACVR2B 
ACVR1 Betaglycan Smad1/5 
Sieber et al. 2009;  
ten Dijke et al. 1994;  
Macias-Silva et al. 1998;  
Kirkbride et al. 2008 
Baade Ro et al. 2004;  
Motazed et al. 2008 
BMP8a OP2 similar to BMP7  ? Zhao et al. 2001 
BMP8b 
BMP8/ 
OP2/Op3 
? ?  Smad1/5 Jorgez et al. 2005 
BMP10  
ACVR2A 
BMPR2 
BMPR1A 
BMPR1B 
 Smad1/5/8 Mazerbourg et al. 2005 
BMP15 GDF9b BMPR2 BMPR1B  Smad1/5/8 Moore et al. 2003 
Nodal  ACVR2B 
ACVR1B 
ACVR1C 
Cripto 
(EGF-CFC 
factor) 
Smad2 
Reissmann et al. 2001;  
Yeo and Whitman 2001 
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Table 1.1 continued. Relationships between ligands, receptors and the Smad 
signalling pathways of TGFB superfamily members. 
Ligand aka 
Type II 
receptor 
Type I 
receptor 
Co-
Receptor 
R-Smad References 
GDF1  ACVR2B ACVR1B 
(EGF-CFC 
factor) 
Smad2 Cheng et al. 2003 
GDF2 BMP9 BMPR2 ACVRL1 Endoglin Smad1/5 Scharpfenecker et al. 2007 
GDF3 Vgr2 
ACVR2A 
ACVR2B 
ACVR1C Cripto  
Andersson et al. 2007; 
Andersson et al. 2008 
GDF5 CDMP1 
BMPR2 
ACVR2A 
BMPR1A 
BMPR1B 
Betaglycan Smad1/5/8 
Nishitoh et al. 1996; 
Aoki et al. 2001;  
Kirkbride et al. 2008; 
 Upton et al. 2008 
GDF6 
BMP13/ 
CDMP2 
ACVR2A 
BMPR2 
BMPR1A 
BMPR1B 
 Smad1/5/8 Mazerbourg et al. 2005 
GDF7 BMP12 
ACVR2A 
BMPR2 
BMPR1A 
BMPR1B 
 Smad1/5/8 Mazerbourg et al. 2005 
GDF8 Myostatin ACVR2B 
ACVR1B 
TGFBR1 
 Smad2/3 Rebbapragada et al. 2003 
GDF9  BMPR2 TGFBR1  Smad2/3 
Vitt et al. 2002; 
 Kaivo-Oja et al. 2003;  
Mazerbourg et al. 2004;  
Wang et al. 2009 
GDF10 BMP3b ? ?  ?  
GDF11 BMP11 
ACVR2A 
ACVR2B 
TGFBR1  Smad2 
Oh et al. 2002;  
Andersson et al. 2006 
GDF15 MIC-1 ? ?  Smad2/3 Xu et al. 2006 
AMH MIS AMHR2 
ACVRL1
BMPR1A 
BMPR1B 
 Smad1 
di Clemente et al. 1994;  
Gouedard et al. 2000;  
Clarke et al. 2001;  
Jamin et al. 2002 
? Not described in the literature 
 
Generally, ligands bind first to the type II receptor which then recruits and trans-
phosphorylates the type I receptor. However, exceptions to this occur and both BMP2 and 
BMP4 have been shown to bind to a type I receptor first, and to then recruit the type II 
receptor to the complex (de Caestecker 2004). It has also been reported that type I and type 
II BMP receptors can form complexes in the absence of ligand (Gilboa et al. 2000). 
Several studies using BMP2 have shown that it can bind either to the type I receptor and 
recruit the type II receptor or that it can bind to pre-formed receptor complexes of type I 
and II receptors (Gilboa et al. 2000; Hassel et al. 2003; Sieber et al. 2009). Moreover, the 
intracellular signalling pathway which is activated by BMP2 is dependent upon the method 
by which BMP2 associates with its receptors. BMP2 binding to preformed receptor 
complexes initiates the canonical Smad pathway. In contrast, when binding first to the type 
I receptor and recruiting the type II receptor, the mitogen-activated protein kinase (MAPK) 
pathway is activated (Sieber et al. 2009). 
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Numerous combinations between type I and II receptors are possible, and each of these 
combinations may also bind more than one member of the TGFB superfamily. In addition 
to the type I & II receptors, there are also co-receptors which interact with TGFB 
superfamily members and these may be required for correct signalling (Table 1.1). One 
such molecule is betaglycan, and has been named as a TGFB type III receptor (de 
Caestecker 2004). Betaglycan plays a role in presenting ligands to their receptor. This may 
be a positive role when presenting TGFB2 to its receptor but it may play a more negative 
role when presenting inhibin to ACVRIIA, where it acts as an antagonist to the action of 
activin and possibly other BMPs (de Caestecker 2004; Juengel and McNatty 2005). 
 
Conversely, receptors can also act as inhibitors of signalling by sequestering ligands in a 
non-signalling receptor complex. For example ACVR1 can block the action of activin by 
binding to its type II receptor and prevent activin from signalling. Moreover, this action 
can itself be blocked by overexpression by AMHRII, which is postulated to sequester 
ACVR1. This would allow the activin type II receptor to recruit the correct type I receptor 
and activate the activin signalling pathway (Renlund et al. 2007).  
 
1.3.4 Signalling pathways 
The canonical signalling pathway for members of the TGFB superfamily is through the 
Smad pathway. There are eight Smads in total with Smads 1, 2, 3, 5 and 8 being activated 
upon phosphorylation by a type I receptor. These are known as receptor-regulated Smads 
(R-Smads). The R-Smads fall into two categories namely Smads2/3 which are activated by 
TGFB/Activin/Nodal via ACVRL1, ACVR1B, TGFBR1 or ACVR1C and Smads1/5/8 
which are activated by BMPs via ACVR1, BMPR1A or BMPR1B (Table 1.1). Once 
phosphorylated, these R-Smads, in the form of homodimers, interact with Smad4. Smad4 
is a binding partner to all of the R-Smads and is known as the common Smad (Co-Smad). 
Upon complex formation with the Co-Smad, R-Smads translocate to the nucleus where 
they bind to Smad response elements as part of a larger transcriptional complex. For 
example, Smad3 in complex with Smad2 and Smad4 binds to the palindromic Smad 
binding element GTCTAGAC (von Gersdorff et al. 2000). Smad2 has been shown (in 
complex with Smad4) to recruit histone acetylases as well as ATP dependent chromatin 
remodelling complexes to the DNA and to orchestrate chromatin remodelling prior to 
recruitment of the RNA pol II transcription machinery to promoter regions. Not only does 
Smad2 cause remodelling of chromatin but it also shows an absolute requirement for 
chromatin and is unable to activate transcription from naked DNA (Ross et al. 2006).  
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Smad-independent pathways are also activated by members of the TGFB superfamily. The 
mitogen-activated protein kinase (MAPK) pathway(s) including c-Jun N-terminal kinases 
(JNKs), extracellular signal-regulated kinases (ERKs) and p38 MAPK are all activated by 
TGF-beta-activated kinase 1 (TAK1) (Attisano and Wrana 2002). The activation of TAK1 
is downstream of receptors for both BMP and TGFB (Moustakas and Heldin 2005). 
Mullerian-inhibiting substance has been shown to work through nuclear factor-B (NFB) 
to inhibit androgen-stimulated growth of LNCaP cells (Tran et al. 2006). Moreover 
BMP15 and GDF9 together have also been shown to activate non-Smad signalling 
pathways in a species-specific manner (Reader et al. 2011; Mottershead et al. 2012; 
Reader et al. 2014). 
 
Signalling is mediated by a wide range of receptor combinations (with and without co-
receptor modification). Although there is the appearance of a potential bottleneck in the 
signalling pathway with a limited number of Smads signalling through one of two main 
groupings (Smads1/5/8 or Smads2/3), the interactions and crosstalk between Smad and 
non-Smad mediated pathways enables a wide range of responses to be mediated by 
members of the TGFB superfamily. In addition, signalling may be modified by Smad 
binding proteins. These binding proteins consist of proteins with extremely diverse 
functions. They include membrane receptors, cytoskeletal components, nuclear transport 
proteins, cytoplasmic proteins, transcriptional coactivators and repressors, and transcripton 
factors (Itoh et al. 2000). Given the numerous ligand/receptor complexes which are 
capable of being formed, often with antagonising actions, it may no longer be enough to 
simply ask what action a particular ligand mediates. “...á la John F. Kennedy: ask not what 
the signal does with the cell, but what the cell does with the signal.” (Joan Massagué, 
2006) 
 
1.3.5 Intra- and extracellular regulators of TGFB family members 
The actions of TGFB superfamily members are regulated at most points of the signalling 
pathway(s). In some cases, such as for TGFB and GDF8, the mature dimer is secreted in a 
latent form with the pro-region bound strongly to the mature dimer thus preventing access 
to receptors. This is achieved either by binding to and covering the receptor binding area of 
the mature domain or by sequestering the mature dimer to the extracellular matrix by 
binding to both the mature domain and extracellular matrix proteins, creating an 
extracellular store. However, many family members do not bind strongly to their pro-
region and their actions can be regulated by other inhibitors. Numerous extracellular 
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inhibitors have been identified, such as follistatin (Shimonaka et al. 1991), noggin 
(Zimmerman et al. 1996), decorin (Yamaguchi et al. 1990), the cerberus/Dan family of 
secreted BMP inhibitors consisting of DAN, cerberus, gremlin, protein related to DAN and 
cerberus (PRDC) (Balemans and Van Hul 2002), sclerostin (Kusu et al. 2003), sclerostin 
domain containing 1 (SOSTDC1, also known as ectodin) (Laurikkala et al. 2003) and coco 
(Bell et al. 2003) and the chordin family, chordin, chordin-like (Balemans and Van Hul 
2002), brorin (Koike et al. 2007) and brorin-like (Miwa et al. 2009). Even members of the 
TGFB superfamily itself can act as extracellular inhibitors to other members. GDF3 can act 
as a BMP inhibitor by forming inactive heterodimers (Levine and Brivanlou 2006). Inhibin 
on the other hand acts to sequester type II activin receptors in a complex with betaglycan, 
thus blocking the action of activin (Shimasaki et al. 2004). 
 
To add another level of complexity, pseudoreceptors such as BAMBI (BMP and activin 
membrane-bound inhibitor) exist. BAMBI is structurally similar to the extracellular 
domain of type I receptors but lacks an intracellular kinase domain. BAMBI can form 
stable complexes with type II receptors and thus prevent signal transduction (Onichtchouk 
et al. 1999). Although all of the above act to inhibit the action of TGFB superfamily 
members, it should be remembered that members of this family exert their effect by means 
of concentration gradients. The role of the inhibitors is probably to help create these 
gradients and ensure that the correct signal strength is delivered to the target cell and not 
simply to block their action.  
 
Intracellular regulation of the signalling pathway also occurs. Smads 6 and 7 are inhibitory 
Smads (I-Smads) and exert their inhibitory effects in several distinct ways. Smad7 is a 
general inhibitor of TGFB superfamily signal transduction, while Smad6 appears to be an 
inhibitor of BMP signalling (Itoh et al. 2000). I-Smads interact with activated type I 
receptors and thereby prevent phosphorylation of the R-Smads (Imamura et al. 1997; 
Nakao et al. 1997a). In addition, Smad7 forms a complex with Smurf (Smad ubiquitination 
regulatory factor) 2, and upon binding to the type I receptor, both Smad7 and the receptor 
are ubiquitinated (Itoh and ten Dijke 2007). Moreover, Smad7 can also recruit a complex 
containing protein phosphatise (PP) 1c which dephosphorylates and inactivates the 
TGFBR1 receptor. In a similar manner, ACVRL1 is also dephosphorylated by PP1α in a 
Smad7-dependent manner (Itoh and ten Dijke 2007). An accessory molecule, STRAP 
(serine/threonine kinase receptor-associated protein), interacts with and recruits Smad7 to 
the receptor (Datta and Moses 2000) although no protein performing a similar role for 
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Smad6 has yet been discovered. However, AMSH (associated molecule with the SH3 
domain of STAM) has the reverse effect and is a negative regulator of both I-Smads (Itoh 
et al. 2001). Smad6 competes with the Co-Smad (Smad4) for activated Smad1 and thereby 
specifically inhibits BMP activated Smad1 (Hata et al. 1998). Smad7 acts as an adaptor 
molecule for Smurfs 1 and 2, Nedd4-2 and WWP1/Tiul1 and thereby promotes the 
degradation of both R-Smads and the Co-Smad (Itoh and ten Dijke 2007). Smad6 also acts 
as a transcriptional co-repressor by forming a complex with the homeobox Hoxc-8 thereby 
inhibiting the formation of a Smad-1:Hoxc-8 complex and Smad1 induced transcription 
(Bai et al. 2000). In addition, Smad6 has also been reported to bind directly to TAK1 
(TGFB-activated kinase 1) and interfere with BMP induced non-Smad mediated apoptosis 
in MH60 cells (Kimura et al. 2000). 
 
1.3.6 The role of TGFB family members in follicular development and ovulation rate 
In recent years, members of the TGFB superfamily have become increasingly recognised 
as key regulators of ovarian follicular development as well as influencing ovulation-rate 
and thus the number of offspring. Their importance in this role has come from studying 
naturally-occurring mutations in sheep, mouse knockout models as well as in vivo and in 
vitro studies (Chang et al. 2002; Findlay et al. 2002; Juengel and McNatty 2005; Knight 
and Glister 2006) 
 
The first TGFB superfamily member that was identified affecting fecundity in sheep was 
BMP15. Originally, two independent germ-line point mutations were reported. The first 
resulted in a non-conserved amino acid substitution in the mature domain and was termed 
the Inverdale gene while the second resulted in a premature stop codon and was termed the 
Hanna gene (Galloway et al. 2000). Subsequently, four other BMP15 mutations that 
influence follicular development and ovulation-rate have been identified in other highly 
prolific sheep breeds (Hanrahan et al. 2004; Bodin et al. 2007; Monteagudo et al. 2009). 
Two mutations in GDF9 have also been found to influence ovarian follicular development 
and ovulation-rate in sheep in a similar manner to that for BMP15. For both the BMP15 
and GDF9 heterozygous mutant ewes, higher ovulation rates occur whereas the 
homozygous animals are sterile (Galloway et al. 2000; Hanrahan et al. 2004; Nicol et al. 
2009). Another mutation affecting fecundity was originally identified in Booroola sheep: 
this was present in the TGFB, type I receptor, BMPR1B, (otherwise known as ALK6) 
(Mulsant et al. 2001; Souza et al. 2001; Wilson et al. 2001). The Booroola mutation in 
BMPR1B causes an increase in ovulation-rate in a dose-dependent manner (i.e. wild-type < 
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hetrozygote < homozygote). Heterozygous carriers of any of the above mutations, all have 
increased ovulation-rates, showing that they participate in a pathway(s) involved in the 
recruitment of follicles for ovulation.  
 
While some members of this super family play a role in the recruitment of follicles for 
ovulation, others appear to influence follicular development, if not ovulation-rate. By 
comparing mice null for anti-Mullerian hormone (AMH) with wild-type, it was found that 
AMH null mice have an increased rate of recruitment of primordial follicles into the 
growing pool. This suggests that AMH plays an important role in regulating the number of 
growing follicles (Durlinger et al. 1999; Visser and Themmen 2005). Likewise, a similar 
approach identified inhibin α as a negative regulator of stromal cell proliferation in gonads 
(Matzuk et al. 1992). Mice null for inhibin α, develop tumours of mixed granulosa and 
thecal cell origins. Like sheep (Hanrahan et al. 2004), mice lacking GDF9 are infertile 
(Dong et al. 1996; Yan et al. 2001) as follicular growth is unable to proceed from the 
primary stage of growth. Moreover, there are possibly indirect roles for GDF9 for both the 
formation of the theca and for oocyte meiotic competence (Yan et al. 2001). Activins, 
BMP6, GDF9 and BMP15 have all been implicated in modulating the actions of FSH and 
promoting proliferation of granulosa cells (Knight and Glister 2006). Likewise, the various 
TGFB isoforms have been shown to have roles in granulosa cell proliferation and to also 
modulate some FSH actions. It is important to note at least some of these roles are species-
dependent (Juengel and McNatty 2005). TGFB also inhibits androgen production by thecal 
cells by down regulation of 17α-hydroxylase and steroidogenic acute regulatory protein 
(Juengel and McNatty 2005). Members of the TGFB family, their receptors and binding 
proteins are all produced by cell types within the mammalian ovary, and have been the 
subject of several articles (Kristensen et al. 2014) and reviews (Findlay et al. 2002; 
Erickson and Shimasaki 2003; Knight and Glister 2003; Shimasaki et al. 2004; Juengel and 
McNatty 2005; Knight and Glister 2006). 
 
1.4 Bone Morphogenetic Protein 15 (BMP15) 
1.4.1 General characteristics 
Bone morphogenetic protein 15 (BMP15), also known as growth differentiation factor 9B 
(GDF9B), was identified by two independent groups, in 1998. The first group used 
polymerase chain reaction (PCR), utilising degenerate oligonucleotides, based upon 
consensus sequences from known BMP’s, to identify both the mouse Bmp15 and human 
BMP15 genes (Dube et al. 1998). The second group searched the GenBank Expressed 
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Sequence Tag (EST) database with the mouse GDF9 sequence. From this search, they 
identified a putative member of the TGFB superfamily from a mouse 2-cell embryo 
library, which they named GDF9B (Laitinen et al. 1998). BMP15 has also been reported as 
ovarian dysgenesis 2 (ODG2) (Di Pasquale et al. 2004) and as premature ovarian failure-4 
(POF4) (Dixit et al. 2006). 
 
Human BMP15 (hBMP15) is encoded by a gene on the X chromosome at location Xp11.2 
(Dube et al. 1998). The gene consists of two exons. Exon 1 codes for part of the pro-region 
while exon 2 codes for the remainder of the proregion and the entire mature region. The 
gene product of hBMP15 is a 391 amino acid (aa) preproprotein consisting of a 17 aa 
signal peptide, a 251aa proregion and a 124aa mature region. Like other members of the 
TGFB superfamily, BMP15 is synthesized as a prepropeptide that requires cleavage, by a 
furin-like proprotein convertase, at an arginine rich cleavage site (RRXR), to produce a 
mature protein. However, the specific proprotein convertase that functions in this capacity 
is presently unknown.  
 
1.4.2 Role in fertility 
The effect of BMP15 on fertility has now been documented in human (Di Pasquale et al. 
2004), mouse (Yan et al. 2001), sheep (Galloway et al. 2000), cow (Juengel et al. 2009), 
goat (Chu et al. 2007) and chicken (Elis et al. 2007). Previously, follicular development 
and ovulation-rate was thought to be controlled mainly by gonadotrophins. However, in 
more recent times, it has been recognised that oocyte-secreted factors and therefore the 
oocyte itself, plays a significant role in follicular development and ovulation-rate (Eppig et 
al. 2002) Juengel and McNatty 2005). The discovery of the oocyte-secreted factor, 
BMP15, along with the phenotypes expressed in sheep, either by naturally-occurring 
inactivating mutations (Galloway et al. 2000) or from immunisations against BMP15 
(McNatty et al. 2004), have shown that the oocyte regulates both follicular development 
and ovulation-rate. Ewes heterozygous for inactivating mutations in BMP15, whereby 
BMP15 levels are reduced, have increased fecundity due to an increase in ovulation rate 
while homozygous ewes, with no biologically-active BMP15, are sterile. The absence of 
biologically-active BMP15 has been shown to block follicular development from the 
primary stage of development in the sheep (Galloway et al. 2000; Juengel et al. 2002; 
Hanrahan et al. 2004). However, the number of primordial follicles remaining in the non-
growing pool of follicles is the same as in wild-type animals at both two and five years of 
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age, suggesting that BMP15 does not play a crucial role in the initiation of follicular 
growth (McNatty et al. 2001). 
 
Heterozygous mutations in the BMP15 gene have been linked to premature ovarian failure 
(POF) in woman (Di Pasquale et al. 2004; Di Pasquale et al. 2006). Compared to sheep 
homozygous for inactivating BMP15 mutations, BMP15 knockout mice are fertile with 
little effect on follicular development (Yan et al. 2001), although reduced litter size and an 
altered interaction with GDF9 was reported (Yan et al. 2001). The reason(s) for this 
difference is unknown. However, it demonstrates that there are species differences in the 
role(s) of BMP15 and other TGFB family members in mono- versus polyovulatory species 
(McNatty et al. 2001; Shimasaki et al. 2004). 
 
1.4.3  Actions of BMP15 
Several actions of this growth factor have been revealed through in vitro experiments using 
recombinant BMP15. Both recombinant murine and human BMP15 stimulate rat granulosa 
cell (GC) proliferation as determined by 3H-thymidine incorporation (Otsuka et al. 2000; 
Moore et al. 2003; McNatty et al. 2005a). However, ovine BMP15 which had a minimal 
effect on its own, had a synergistic effect when added with either murine or ovine GDF9 
(McNatty et al. 2005a). In contrast, ovine BMP15 alone stimulated proliferation of both 
ovine and bovine GC. From co-culturing experiments with rat GC, incubated with rat 
oocytes, the effect of neutralising antibodies showed that only GDF9 caused GC 
proliferation, and blocking BMP15 had no effect (Lin et al. 2012), probably due to little, if 
any, BMP15 being expressed and secreted (Crawford and McNatty 2012). However, from 
rat GC incubated with sheep oocytes, neutralising antibodies showed that both GDF9 and 
BMP15 were able to cause GC proliferation. Thus, the ability of BMP15 to increase GC 
proliferation is dependent upon the species of both BMP15 and of the target GC. In sheep, 
the lack of BMP15 blocks folliculogenesis in vivo while addition of recombinant BMP15 
promotes in vitro granulosa cell proliferation.  
 
The second biological effect of BMP15 is its ability to modulate the way granulosa cells 
respond to gonadotrophins. Human Flag-tagged BMP15 mature domains have been shown 
to inhibit follicle-stimulating hormone receptor (FSHR) expression in rat granulosa cells 
(Otsuka et al. 2001). This study also showed that this subsequently inhibited the expression 
of mRNA for StAR, P450SCC, 3βHSD, LH receptor and the inhibin α and activin βA & βB 
subunits (Otsuka et al. 2001; Figure 1.5). In the absence of FSH, oBMP15 alone had no 
21 
effect on inhibin production by rat granulosa cells. However, co-culture with oGDF9 and 
oBMP15, containing a mixture of promature and mature forms, synergistically increased 
production of inhibin (McNatty et al. 2005a). BMP15 was also recognised as a 
luteinization inhibitor based on its ability to inhibit FSH-induced progesterone synthesis 
(Otsuka et al. 2001; Shimasaki et al. 2004). The extent of LH contamination in the human 
FSH preparation in the above studies was not indicated. In contrast, no effect of BMP15 on 
granulosa cell responsiveness to an LH-free, FSH preparation was observed in sheep. 
Inverdale ewes heterozygous (I+) for the inactivating BMP15 mutation (FecXI) showed no 
significant differences from wild-type ewes in FSH-responsiveness at any stage of 
follicular development or stage of the oestrus cycle (McNatty et al. 2009). Although there 
was no difference in the response to FSH in I+ ewes, there was an increased proportion of 
follicles that developed a functional luteinizing hormone receptor (LHR) earlier than in 
wild-type ewes (McNatty et al. 2009). This is consistent with the notion that BMP15 can 
act to suppress LHR formation in granulosa cells. 
 
 
 
Figure 1.5 Role of BMP15 in cross-talk between oocytes and rat granulosa cells. 
Adapted from Otsuka and Shimasaki (2002). In the rat, BMP15 binds to its receptor 
on granulosa cells and inhibits FSH-R expression, the consequence of this is that 
mRNA for StAR, P450SCC, 3βHSD, LH receptor and the inhibin-α and activin βA & 
βB subunits are all subsequently inhibited in response to FSH. BMP15 also stimulates 
mitosis both directly and possibly via a kit ligand (KL)/c-kit mediated pathway. In 
turn KL acting via c-kit inhibits the expression of BMP15 in a negative feedback loop. 
It is not known what signal(s) stimulate BMP15 expression. 
 
The third action of BMP15 is the stimulation of kit ligand (KL) expression in rat granulosa 
cells (Otsuka and Shimasaki 2002). Kit ligand, also known as stem cell factor or steel 
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factor, is produced by granulosa cells and is the ligand for the tyrosine receptor kinase, c-
kit, which is located on the oocyte (Zsebo et al. 1990). BMP15 secreted by the oocyte 
binds to its receptors on granulosa cells to stimulate KL expression. KL subsequently acts 
through its receptor on the oocyte to inhibit BMP15 expression, thus creating a negative 
feedback loop (Otsuka and Shimasaki 2002). Due to the need to have both granulosa cells 
and oocytes present in the culture (only oocytes express c-kit), it is possible that BMP15 is 
not the only mitogenic factor secreted by the oocyte that is influenced by kit ligand (Figure 
1.5; Otsuka and Shimasaki 2002). The KL-c-kit pair is also present in ovine granulosa cells 
and oocytes respectively (Tisdall et al. 1999; Juengel et al. 2000). A reduction in BMP15, 
as found in I+ ewes, had no effect on the ontogeny of expression for both c-kit and KL 
compared to wild-type ewes. (Juengel et al. 2000). However, the levels of protein 
expression were not investigated in this study. 
 
1.5 Growth Differentiation Factor (GDF9) 
Growth differentiation 9 (GDF9) was first identified by (McPherron and Lee 1993) using 
degenerate oligonucleotides, based upon conserved regions of known members of the 
TGFB family, in order to probe a range of tissues. From this study, they found that that 
GDF9 was located specifically to ovarian tissue. In later studies, GDF9 mRNA was also 
located in the hypothalamus and testis in mice, rodents and humans (Fitzpatrick et al. 
1998). Both ovine and human GDF9 are encoded by a gene on chromosome 5, with the 
human gene being located at 5q31.1, whereas the bovine gene is located on chromosome 7. 
The human, bovine and ovine genes consist of six, three and two exons, respectively. Both 
the ovine and bovine genes encode a preproprotein consisting of a 453 amino acid (aa), of 
which 135aa comprises the mature domain. GDF9 is thought to signal through the type II 
receptor BMPR2 (Vitt et al. 2002) and the type I receptor TGFB1 (Mazerbourg et al. 
2004) to activate the Smad2/3 pathway (Mottershead et al. 2008). 
 
As mentioned, in part earlier, GDF9 has important effects on fertility in mice (Dong et al. 
1996), sheep (Juengel et al. 2002; Hanrahan et al. 2004; Nicol et al. 2009) and chicken 
(Huang et al. 2015) and to be associated with premature ovarian failure in woman (Dixit et 
al. 2005; Laissue et al. 2006; Kovanci et al. 2007; Zhao et al. 2007). Ovarian GDF9 is 
located specifically within oocytes (Crawford and McNatty 2012) and is found at all stages 
of follicular development beginning during follicular formation and from the earliest 
primordial follicle stage onwards (Bodensteiner et al. 2000). GDF9 has been found to be 
essential for ovarian folliculogeneis in all species studied so far. A lack of biological GDF9 
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activity, as a result of homozygous inactivating mutations (sheep: Thoka, Nicol et al. 2009; 
Belclare, Hanrahan et al. 2004); gene knockout mice (Dong et al. 1996) or immunisations 
against GDF9 in sheep; (Juengel et al. 2002), all share a similar phenotytpe. A lack of 
GDF9 results in a disruption of normal follicular development from the primary stage 
causing sterility. In contrast, ewes heterozygous for inactivating mutations in GDF9 
express a phenotype, similar to that with heterozygous BMP15 mutations, whereby 
ovulation rate is increased. 
 
GDF9 has also been shown to play a role in a range of regulatory functions such as: 
inhibition of 3'5'-adenosine monophosphate-stimulated steroidogenesis in human granulosa 
and theca cells (Yamamoto et al. 2002), enhanced cell transition from G(0)/G(1) to S and 
G(2)/M phases (Huang et al. 2009), suppression of the effect of activin A on StAR 
expression and progesterone production by upregulating expression of inhibin B (Shi et al. 
2010), suppression of follistatin and follistatin-like 3 production (Shi et al. 2011a) and in 
conjunction with BMP15, promoted follicular development in humans (Kedem et al. 2011) 
and granulosa cell proliferation in vitro (McNatty et al. 2005a;b).  
 
1.6 Aims of this study 
The aims of this study were to: (i) identify the molecular forms of BMP15 and GDF9 that 
are produced and secreted by both the ovine and bovine oocyte; (ii) assess the biological 
activity of these molecular forms; (iii) visualise the various molecular forms using protein 
modelling techniques and; (iv) provide a hypothetical model of how oocyte-secreted 
form(s) of BMP15, GDF9 and their cell surface receptors may interact.  
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2 CHAPTER 2: MATERIALS AND METHODS 
 
Unless stated below, additional details including sources of equipment and reagents used 
are described in Appendix 5. The methodological details described below are relevant for 
Chapters 3 and 4. Additional methodology used for the modelling studies are described in 
Chapter 5. 
 
2.1 Sequence alignments 
Protein sequences (accession number) used in this study were obtained from the National 
Center for Biotechnology Information biosystems database (www.ncbi.nlm.nih.gov): 
mouse Gdf9 (NP_032136); rat Gdf9 (NP_067704); porcine GDF9 (NP_001001909); 
cat GDF9 (NP_001159372); ovine GDF9 (AAC28089); caprine GDF9 (AAU09020); 
bovine GDF9 (NP_777106); water buffalo GDF9 (ACL68182); human GDF9 
(NP_005251); shrew GDF9 (ACE77690); Callicebus moloch GDF9 (ACB21290); bat 
GDF9 (ACC68858); Otolemur garnettii GDF9 (ACH53052); mouse Bmp15 
(NP_033887); rat Bmp15 (NP_067702); porcine BMP15 (NP_001005155); cat BMP15 
(NP_001159370); ovine BMP15 (NP_001108239); caprine BMP15 (ACJ61256); bovine 
BMP15 (NP_001026922); water buffalo BMP15 (ABN05299); human BMP15 
(NP_005439); chimpanzee BMP15 (XP_529247); rhesus BMP15 (XP_001083980); 
human INHα (NP_002182); human ActA (NP_002183); human ActB (NP_002184); 
human ActC (NP_005529); human ActE (NP_113667); human TGFB1 (NP_000651); 
human TGFB2 (AAA50405); human TGFB3 (NP_003230); human BMP2 
(NP_001191); human BMP3 (NP_001192); human BMP4 (NP_570912); human BMP5 
(NP_066551); human BMP6 (NP_001709); human BMP7 (NP_001710); human 
BMP8a (NP_861525); human BMP8b (NP_001711); human BMP10 (NP_055297); 
human BMP15 (NP_005439); human NODAL (NP_060525); human GDF1 
(NP_001483); human GDF2 (NP_057288); human GDF3 (NP_065685); human GDF5 
(CAB89416); human GDF6 (NP_001001557); human GDF7 (NP_878248); human 
GDF8 (NP_005250); human GDF10 (NP_004953); human GDF11 (NP_005802); 
human GDF15 (NP_004855); human MIS (NP_000470); human LEFTY1 (NP_066277) 
and human LEFTY2 (NP_003231). The protein sequences for Inverdale (V299S; 
(Galloway et al. 2000); Belclare (S367I; (Hanrahan et al. 2004) and Laucune (C321Y; 
(Bodin et al. 2007) BMP15 were generated by modifying ovine BMP15 (NP_001108239) 
26 
and the protein sequence for Thoka (S427R; (Nicol et al. 2009) GDF9 by modification of 
ovine GDF9 (NP_001136360). Sequence alignments were generated using Clustal W 
(Thompson et al. 1997). 
 
2.2 Preparation of recombinant proteins. 
2.2.1 Preparation of cloning vectors. 
The DNA sequence encoding the human proregion/ovine mature BMP15 (S356C) mutant 
(h/oBMP15 (S356C); Appendix 1) inserted into the cloning vector pGEM-T Easy was 
kindly gifted from Dr D.G. Mottershead (Robinson Institute, The University of Adelaide, 
Adelaide, Australia). The DNA sequence encoding the human BMP15 pro-region 
(hBMP15pro, Appendix 3), was amplified from h/oBMP15 (S356C) using the primers, 5’ 
primer; [5’-ACTCGAGGCCACCATGAAGTG-3’] and 3’ primer; [5’-
GAATTCAGGAGAAGAGATTCCCTTTC-3’] prepared by Invitrogen custom primers, 
(Invitrogen, Auckland, New Zealand). Polymerase chain reaction (PCR) was carried out 
using the GC-RICH PCR system (Roche Applied Science, Auckland New Zealand) as per 
manufacturers instructions. Each PCR reaction mixture contained 0.2 mM deoxynucleotide 
triphosphates (dNTPs; 0.05 mM each of dATP, dTTP, dGTP and dCTP), 0.5 M GC-RICH 
resolution solution, 1x GC-RICH PCR reaction buffer (includes 1.5 mM MgCl2), 2 U GC-
RICH enzyme mix, 0.3 µM of each primer and <0.3 µg template DNA. Two additional 
reaction mixtures were prepared and run concurrently, the first of which included ovine 
cDNA as the template and primers for β-actin [5’ primer; (5’-
GCATGGGCCAGAAGGACTCC-3’) and 3’ primer; (5’-
CGTAGATGGGCACCGTGTGG-3’)] (Invitrogen custom primers). The second reaction 
mixture combined all four of the above primers in the absence of a template. The PCR 
conditions were 1 cycle of 3 minutes (min) at 94°C, followed by 10 cycles of 20 seconds 
(s) at 94°C, 20 s at 60°C, 20 s at 72°C; followed by 25 cycles of 20 s at 94°C, 20 s at 60°C, 
20 s (extended by 5 s after each cycle) at 72°C and finished with a 7 min incubation at 
72°C. Both the presence and the expected size of the PCR product(s) was confirmed by 
agarose gel electrophoresis. The PCR product(s) was pre-incubated with SYBR® Green 
(Invitrogen), following the manufacturers instructions, for 5 min at room temperature 
before being run on a 1% (w/v) agarose gel at 85 volts for 40-60 min. Thereafter, the bands 
were visualised with ultra violet (UV) light. Images of the gel were obtained using a 
UVIPRO gel doc system (UVItec Limited, Cambridge, United Kingdom). Human 
BMP15pro DNA was extracted from the gel using a QIAprep gel extraction kit (QIAGEN 
Pty. Ltd) as per the manufacturers instructions. DNA was stored at -20°C until it was 
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ligated into the cloning vector pGEM-T Easy using the LigaFast™ Rapid DNA Ligation 
System (PROMEGA, Sydney, Australia) as per the manufacturers instructions. Briefly, 
vector (pGEM-T Easy) DNA and insert (hBMP15pro) DNA were combined in a 1:3 ratio 
in the presence of T4 DNA ligase in 1x rapid ligation buffer and incubated for 2 h at room 
temperature. The sequence of the insert (Appendix 3) was confirmed by the Waikato DNA 
Sequencing Facility, University of Waikato, Hamilton, New Zealand. 
 
2.2.2 Generation of expression plasmids 
Inserts (h/oBMP15 (S356C) or hBMP15pro) contained within pGEM-T Easy were 
subcloned into the expression vector pEFIRES-P. Competent E. coli (DH5α strain) cells, 
provided by Mr A. Bibby, (Victoria University of Wellington, Wellington, New Zealand), 
were transformed by incubating with the insert containing the pGEM-T Easy plasmid on 
ice for 30 min, followed by a 2 min heat shock at 37°C, after which the cells were placed 
back on ice for an additional 2 min. The cells were made up to 1 mL with lysogeny broth 
(LB broth) and incubated for 1 hr at 37°C, with shaking at 250 rpm, after which they were 
centrifuged at 1800 g for 5 min, then re-suspended in 0.1 mL LB broth and spread out on 
LB agar plates coated with 1mg X-Gal. Blue-white selection was used to determine those 
colonies derived from transformed clones and a single white colony was selected and 
grown in LB broth containing 50 µg/mL ampicillin. Plasmid DNA was subsequently 
purified using a QIAprep spin miniprep kit (QIAGEN), as per the manufacturers 
instructions. The h/oBMP15 (S356C) insert was released from the plasmid DNA by the use 
of XhoI and XbaI restriction enzymes, and the hBMP15pro insert was released with the 
restriction enzymes XhoI and EcoRI. A total of 2.2 µg of plasmid DNA was incubated 
with both restriction enzymes concurrently for 2.5 h at 37°C. Both the presence and the 
expected size of the released insert was confirmed by running the enzyme cut plasmid, pre-
incubated with SYBR® Green, on a 1% (w/v) agarose gel. Thereafter, the DNA band was 
visualised with UV light. The DNA was extracted from the band using a QIAprep gel 
extraction kit, as per the manufacturers instructions, and the sequence was confirmed by 
sequencing (Waikato DNA Sequencing Facility). The gel-purified DNA was subsequently 
ligated into linearised pEFIRES-P using T4 DNA ligase as described above. The 
expression vector, pEFIRES-P, used to ligate the h/oBMP15 (S356C) mutant, was 
previously linearised using the restriction enzymes XhoI and XbaI by Mr Adrian Bibby. 
The DNA sequence for the ovine prodomain/ovine mature BMP15 (o/oBMP15; Appendix 
2) that was inserted into pEFIRES-P plasmid was also provided by Mr Bibby. The empty 
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pEFIRES-P plasmid was provided by Dr S.M. Hobbs at the CRC Centre for Cancer 
Therapeutics, Institute of Cancer Research, Surrey, UK. (Hobbs et al. 1998). 
 
2.2.3 Transfection of HEK293 cells. 
The human embryonic kidney cells [HEK293; American Type Culture Collection, 
Manassas, VA, USA, (CRL-1573TM)] were grown in 3 mL growth medium, namely 
Dulbecco´s Modified Eagle Medium (D-MEM), supplemented with 10% (v/v) fetal calf 
serum (FCS), penicillin (50 IU/mL), streptomycin (50 µg/mL) [PenStrep] and Glutamax at 
1x strength in a 6-well culture plate at 37°C in 5% CO2 in air until the cell monolayer was 
approximately 90% confluent. A total of 2 µg of pEFIRES-P-h/oBMP15 (S356C), 
pEFIRES-P-o/oBMP15, or empty pEFIRES-P plasmid DNA was incubated with 8 µL 
Fugene HD (Roche) transfection reagent for 15min at room temperature in 100 µL serum 
free medium (SFM; D-MEM plus Glutamax) prior to being added dropwise to the 
HEK293 monolayers. Negative controls comprising of SFM alone and SFM plus Fugene 
HD were also included. The cells were incubated at 37°C in 5% CO2 in air for an 
additional 24 h. Cells were detached from the surface of the well using TrypLETM Express 
(a recombinant trypsin alternative), then split 1:2 and 1:6 and each replated in the presence 
of 1 µg/mL puromycin dihydrochloride. Puromycin selection was continued on the 
transfected (surviving) cells, such that cells were allowed to reach 90% confluence before 
being again split 1:3 into three new wells. The puromycin concentration was increased 1-5 
fold at each split until 50 µg/mL was reached; thereafter the puromycin concentrations 
were increased by 10-50% until a final concentration of 100 µg/mL was achieved.  
 
2.2.4 Production and harvesting of recombinant proteins secreted by HEK293 cells. 
HEK293 cells transfected with the pEFIRES-P-h/oBMP15 (S356C) mutant, pEFIRES-P-
o/oBMP15 or empty pEFIRES-P plasmid were cultured in growth media plus 100 µg/mL 
puromycin to 80-90% confluency in a total of twenty culture flasks, each with a growth 
area of 150 cm2. The growth medium was then removed and the cells washed gently, twice 
with sterile 0.15 M phosphate buffered saline, pH 7.4 that had been pre-warmed to 37°C. 
To each flask, 25 mL expression medium (EM) was added (D-MEM:Hams F12 (1:1) 
supplemented with penicillin (50 IU/mL), streptomycin (50 µg/mL), Glutamax (1x), 
bovine serum albumin (BSA; 0.01%, w/v) and heparin (100 g/mL), and the flasks 
incubated at 37°C in 5% CO2 in air. The EM containing the recombinant (oBMP15-EM, 
oBMP15 (S356C)-EM or Null-EM) proteins was harvested 96.0 ± 2.4 h (mean ± S.E.M.) 
later. Whole cells present in the EM were removed by centrifugation for 5 min at 200g and 
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the resultant supernatant was subsequently cleared by centrifugation for 10 min at 3200g. 
The protease inhibitors (i.e. complete, EDTA-free protease inhibitor cocktail, Roche) were 
added to the cleared media at the dosage recommended by the manufacturer and the media 
stored at -20OC. 
 
2.3 Protein analysis. 
2.3.1 Preparation of samples for SDS-Polyacrylamide gel electrophoresis (PAGE). 
SDS-PAGE was run under non-reducing, reducing or cross-linking/reducing conditions. 
Preparation of samples for cross-linking using the non-cleavable cross-linker 
bis(sulfosuccinimidyl)suberate (BS3) followed the protocol described in (McIntosh et al. 
2008). EM containing either o/oGDF9 (supplied by Dr Kenneth P. McNatty, Victoria 
University of Wellington), o/oBMP15, h/oBMP15 (S356C), o/oGDF9 + o/oBMP15 (1:1) 
or o/oGDF9 + h/oBMP15 (S356C) (1:1) were incubated overnight at room temperature. 
Subsequently the EM, lysates of oocytes and oocyte incubation medium were cross-linked 
by the addition of BS3 to a final concentration of 2 mM and incubated for 2h at room 
temperature. Cross-linked samples were then mixed with 5x reducing sample buffer. Non 
cross-linked samples were mixed with either 5x reducing sample buffer or 5x non-reducing 
sample buffer, (Appendix 5). Under reducing, but not non-reducing, conditions, the sample 
plus sample buffer was heated to 100°C for 5 min. This was followed by a short incubation 
on ice in order to condense water vapour, and then centrifugation at 6000 g for 5 s to 
collect all liquid in the bottom of the tube, prior to loading the solution onto the gel.  
 
2.3.2 Separation of proteins by SDS-PAGE. 
Utilising solutions listed in Appendix 5, 13.5% (w/v) polyacrylamide gels were prepared as 
described in Table 2.1. The gels were prepared, as per the manufacturer’s instructions 
utilising the Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). The separating gel 
solution was poured between two glass plates held apart by a 1mm spacer and allowed to 
polymerise under a layer of distilled water. After polymerisation was complete, the water 
overlay was tipped off and residual moisture removed by use of blotting paper inserted 
between the glass plates. Subsequently, a stacking gel solution was added and a comb was 
inserted to form sample wells within the gel. Usually, the gels were prepared on the day of 
use. However, on some occasions, the gels (with comb still in place) were wrapped in wet 
paper towels and stored at 4oC within a sealed plastic bag but were always used within 2 
days of preparation. The samples were loaded onto gels (typically the two outside lanes 
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were occupied by molecular size markers) and electrophoresis carried out in Tris-glycine 
buffer, pH 8.5 at 180 V for 60min at room temperature. 
 
Table 2.1 Table of reagents and recipe for 13.5% polyacrylamide gels 
 13.5% Separating gel 4% stacking gel 
Distilled water 2.85 mL 3.0 mL 
1.5 M TRIS-HCl (pH 8.8) 2.50 mL - 
0.5 M TRIS-HCl (pH 6.8) - 1.25 mL 
10% (w/v) SDS 100 L 50 L 
30% Acrylamide/Bis solution (37.5:1) 4.50 mL 0.65 mL 
10% (w/v) Ammonium persulphate 50 L 25 L 
 
TEMED 
5 L 5 L 
 
 
  
 
2.3.3 Western blotting 
The Western blotting procedure involved the transfer of proteins from a PAGE gel to a 
nitrocellulose membrane, using the Mini-PROTEAN Tetra Electrophoresis System. 
Briefly, 1x blotting paper, 1x PAGE gel (with staking gel removed), 1x nitrocellulose 
membrane (pore size 0.45 µm) and 1x blotting paper were sandwiched between 2x Scotch 
pads (Bio-Rad) and placed into the transblot sandwich holder (orientated so that the 
nitrocellulose membrane was positioned between the gel and the positively charged 
electrode). Transfer was carried out at 100 volts for 1 h on ice, in 192 mM Tris-glycine 
buffer containing 20% (v/v) methanol at 4°C. Following removal of the membrane from the 
transblot sandwich holder, the location of molecular size markers on the membrane were 
marked by pencil. Thereafter, the membranes were washed twice for 10 minutes in low salt 
buffer (20 mM Tris-HCl containing 0.876 mg/L NaCl and 0.1% (v/v) Tween 20, pH 7.5; 
Appendix 5) at room temperature.. They were then blocked with 5% blocking buffer (low 
salt buffer containing 5% (w/v) low fat milk powder) for 1 h and finally, incubated with the 
selected primary antibody diluted in 5% blocking buffer overnight. The primary antibodies 
were monoclonal antibodies to either BMP15 (clone MN2-61A; 1 µg/mL; McNatty et al. 
2005a) or GDF9 (clone 37A; 0.5 µg/mL; Juengel et al. 2002). The membranes were then 
washed three times for 10 minutes each in low salt buffer, incubated with horseradish 
peroxidase conjugated rabbit anti mouse IgG (1:6000), for 2 h and then washed again three 
times for 10 minutes each in low salt buffer. Chemiluminescent detection of proteins was 
performed using the Western Blotting detection system (Western BrightTM ECL spray) as 
per the manufacturer’s instructions. The images were captured using an Omega Lum G 
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(Aplegen, Pleasanton CA) gel documentation system. The images were routinely captured 
at the following exposure times, 0.75, 1.5, 2.25, 3.0, 3.75, 4.5, 5.25, 6.0, 6.75, 7.5 and 10 
min. 
 
On some occasions, membranes were incubated in 0.1 M Tris-HCl buffer containing 1.25 
mM Luminol, 0.2 mM p-coumaric acid and 0.01% (v/v) hydrogen peroxide, pH 8.5 for 60 s, 
blotted dry, encased a plastic (saran) wrap (Gladwrap) and then exposed to X-ray film for 
10-300 s within a X-ray cassette. The film was developed for 4 min in both developer and 
fixer (KODAK). The locations of the molecular size markers were copied directly from the 
membrane onto the film. All incubations were performed at room temperature.  
 
2.3.4 Densitometry of Western blots 
The freeware ImageJ (http://rsb.info.nih.gov/ij/index.html) was used to determine the 
density and area of bands within Western blots. The method employed is fully described in 
(Miller 2010) 
A 
 
 
 
 
B 
 
C  
Peak  
Number 
 
Peak 
Area 
 
Percent 
Area 
  
1 
 
6840 
 
47.08 
  
2 
 
503 
 
3.51 
  
3 
 
6978 
 
48.73 
 
Figure 2.1 Density plot of a Western blot. Showing peaks (1-3) without (A) and with 
(B) artificial baselines (       ). (C) Relative peak area and percent area for peaks 1, 2 
and 3. 
 
Briefly, all images were first converted to 8-bit grey scale and identically-sized rectangular 
slices were taken of each lane within a Western blot. From these, a density plot was 
generated showing the relative density along the length of each lane; with peaks within this 
plot corresponding to each band in the lane. Where the peaks did not reach down to the 
baseline (perfect white) due to background noise, an artificial baseline was created to close 
off the peak. (Figure 2.1A and B). The area under the curve for each peak was then 
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determined. Thereafter, the percent area for each peak was calculated relative to the total 
area under the curve (Figure 2.1C). 
 
2.4 Statistical analysis 
Results from 3H-thymidine incorporation bioassay were expressed as the mean ± S.E.M. 
(fold difference relative to control) of at least 6 separate experiments, with triplicate 
determinations for each treatment. Differences between treatment groups were analyzed 
for statistical significance by using ANOVA or paired t tests (SPSS: IBM Corp. Released 
2013. IBM SPSS, Statistics for Windows, Version 22.0. Armonk, NY, USA). P values 
<0.05 were accepted as statistically significant. 
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3. CHAPTER 3: PRODUCTION AND CHARACTERISATION OF RECOMBINANT 
FORMS OF BONE MORPHOGENETIC PROTEIN 15 (BMP15) 
 
3.1. Introduction 
Members of the TGFB superfamily, such as BMP15, are produced as preproproteins and 
cleaved at an arginine rich cleavage site (RRXR) by a furin-like proprotein convertase to 
release the mature domain. Consequently, several molecular forms are possible: (i) an 
uncleaved promature form (covalently bound promature; mature domain yet to be cleaved 
by a proprotein convertase); (ii) a cleaved promature form (mature domain cleaved from 
the prodomain by a proprotein convertase, yet still attached to the prodomain in a non-
covalent complex) and; (iii) a free mature domain (mature domain not attached to the 
prodomain). While members of the TGFB superfamily exert their biological activity in the 
form of homo- or heterodimers of mature domains, some members, such as BMP15, lack 
the conserved cysteine integral to the maintenance of these dimers. Although GDF9 also 
lacks this cysteine, recombinant GDF9 has been shown to form homodimeric mature 
complexes (Edwards et al. 2008). Recombinantly-derived mature hBMP15, with either a 
N-terminal FLAG tag (Liao et al. 2004; Hashimoto et al. 2005), a N-terminal MycHis tag 
(Rossetti et al. 2009) or from re-introduction of the missing cysteine (Pulkki et al. 2012), 
have all been shown to include a mature dimeric form. Moreover, cross-linked purified 
recombinant hBMP15 has also been reported to form homodimers (Pulkki et al. 2012). 
Therefore, should unmodified oBMP15 mature domains also form non-covalent 
homodimers, various dimeric combinations of those mentioned above may result. 
 
Several different approaches have been taken to immuno-detect BMP15 by Western 
blotting techniques. Several reports have used recombinant mature BMP15 tagged with 
either N-terminal FLAG tag (Liao et al. 2004; Hashimoto et al. 2005), or a N-terminal 
MycHis tag (Rossetti et al. 2009). With antibodies to these tags, BMP15 has been detected 
indirectly by Western blotting. A commercially available polyclonal antibody, raised 
against the first 83 amino acids of mature hBMP15, has been used in Western blotting to 
detect BMP15 in the follicular fluid of both porcine (Paradis et al. 2009) and bovine 
(Behrouzi et al. 2016) pre-ovulatory follicles. The specificity of this polyclonal antibody 
was inferred from the lack of staining when either the polyclonal antibody was omitted or 
when the polyclonal antibody was replaced with preimmune rabbit IgG. The same bands 
were observed when using an alternative antibody, although the antibody used was not 
reported. Western blots using this polyclonal antibody showed a mature BMP15 band at 25 
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kDa. This was different than the expected 15-17 kDa molecular size that had previously 
been demonstrated (McNatty et al. 2005a; Pulkki et al. 2012). Pullki et al. (2012) reported 
the use of a monoclonal antibody (Mab28) which was raised against the hBMP15 sequence 
SAEVTASSSKHSGPENNQC. This antibody was capable of detecting both monomeric 
and dimeric forms of hBMP15. The monomeric form was reported as corresponding to two 
bands at 16 and 17 kDa, with the dimeric form consisting of three bands corresponding to 
bands at 30 -34 kDa. 
 
(Mab28) hBMP15 268 QADGISAEVTASSSKHSGPENNQCSLHPFQISF 300  
(MN2-61A) oBMP15 269 QAGSIASEVPGPSREHDGPESNQCSLHPFQVSF 301 
    ** .*::** . * :*.***.*********:** 
Figure 3.1 Comparison of sequences recognised (yellow) by the antibodies Mab28 
(Pulkki et al. 2011) and MN2-61A (McNatty et al. 2005a). 
 
The monoclonal antibody (MN2-61A) recognises an epitope within the oBMP15 sequence 
SEVPGPSREHDGPES (Figure 3.1). This lies in a region homologous to the antigen that 
the Mab28 antibody was raised against. Moreover, MN2-61A recognises promature and 
mature forms in Western blotting (Edwards et al. 2008). Additionally, antibodies raised 
against the same sequence as the MN2-61A antibody are capable of inhibiting antral 
follicular growth in both sheep (McNatty et al. 2007) and cattle (Juengel et al. 2009). 
Therefore, since MN2-61A was proven to recognise biologically active forms of ovine and 
bovine BMP15, this monoclonal antibody was chosen for this present study. 
 
Although the MN2-61A antibody has been shown previously to be specific for ovine 
BMP15 (McNatty et al. 2005a; Edwards et al. 2008) these studies did not detect any 
dimeric forms of BMP15. It was not determined whether this was due to a lack of dimeric 
forms or an inability of the clone MN2-61A to recognise them. Therefore, the major aim of 
this current study was to establish which molecular forms of BMP15 are recognised by the 
monoclonal antibody MN2-61A. To assist this aim, a mutant form of oBMP15 was 
created, whereby S356 was replaced with a cysteine [oBMP15 (S356C)], thereby 
permitting BMP15 to create covalently-bound homodimers. A human prodomain was used 
to increase the concentrations of BMP15 forms present in expression medium (Dr D.M. 
Mottershead, personal communication). From this cell line, it was anticipated that the 
expressed BMP15 (S356C) proteins could be used to confirm that the monoclonal antibody 
(MN2-61A) was capable of detecting such forms and as a positive control for detecting any 
dimeric forms in non-mutated oBMP15. 
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3.2. Methodology 
Unless stated below, additional details including sources of equipment and reagents used 
are described in Appendix 5. The methodological details describing preparation of 
expression plasmids, transfection and culture of HEK293 cells and the production of 
recombinant proteins used in this study are described in Chapter 2. 
 
3.2.1. Immobilised Metal ion Affinity Chromatography (IMAC) 
An IMAC protocol supplied by Dr D.M. Mottershead (personal communication), 
employing a liquid chromatography approach, was modified to a batch process (Table 3.1). 
This modified protocol was used to further purify the expression medium from HEK293 
cells transfected with either pEFIRES-P-h/oBMP15 (S356C), pEFIRES-P-o/oBMP15wt, 
or empty pEFIRES-P plasmid. 
 
Table 3.1 Step wise IMAC protocol (All buffer recipes can be found in Appendix 5) 
Step 
Purpose 
Resin 
volumes 
Buffer 
1 
Ni-NTA-agarose 
preparation 
50x Distilled H2O 
2 25x W5 buffer 
3 25x W5 buffer 
4 
Loading sample 250x 
Expression medium containing: 
50 mM TRIS-HCl.pH 7.4 + 300 mM NaCl +  
5 mM Imidazole,  
5 Rotating mixer (end over end) 
8 rpm, for 2 hours @ 4oC 
6 Wash 10x W10 Buffer 
7 Wash 10x W20 Buffer 
8-22 
Elute 1: 
(mature domains) 
5x 
E1 Buffer 
5 minute incubation, with intermittent mixing 
23 Wash 10x W20 Buffer 
24 Elute 2: 
(Pro- & promature 
domains) 
10x E2 buffer 
25 10x E2 buffer 
26 Wash 10x W0 buffer 
27 Wash 10x W0 buffer 
28 
Ni-NTA-agarose 
storage (4oC) 
10x W0 buffer + 70% (v/v) Ethanol 
 
Unless otherwise stated, all incubations with Ni-NTA-agarose were performed at room 
temperature for 30 s and the supernatants were recovered after centrifugation (200 g x 
5min). Each batch of Ni-NTA-agarose was dedicated to purifying proteins from the 
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expression medium (EM) from cells producing BMP15, BMP15 (S356C) or cells with 
empty transfected vector (i.e. control) (Section 2.2.4). 
 
3.2.2. High Performance Liquid Chromotography (HPLC) 
IMAC purified fractions were further purified by HPLC using a method described by 
Pulkki et al. (2011) with minor modifications, namely an increased flow rate (1 mL/min) 
and more than one acetonitrile (ACN) gradient was used, (Table 3.2). Fractions 8-22 
(Table 3.1) were pooled. Thereafter, trifluoroacetic acid (TFA) and ACN were added to a 
final concentration of 0.1% (v/v) and 6% (v/v), respectively and the resultant preparation(s) 
was passed through a 0.22m filter (Corning Inc., Corning, NY). Subsequently, 5 mL of 
this preparation was loaded onto a reverse phase HPLC column (Jupiter, 5m, C4, 300Å; 
Phenomenix) fitted with an upstream security guard cartridge (Widepore, C4, Phenomenix) 
which had been previously equilibrated with 0.1% (v/v) TFA and 6% (v/v) ACN in water 
(HPLC grade). Differing molecular forms of BMP15 were eluted from the column by 
employing a series of linear gradients of ACN while keeping the TFA concentration 
constant (Table 3.2) at a flow rate of 1 mL/min. One mL fractions were collected into 
microcentrifuge tubes and evaporated to dryness using an Eppendorf® centrifugal vacuum 
concentrator (SIGMA, model 5301) at room temperature. 
Table 3.2  Composition of linear gradients of acetonitrile applied to HPLC column 
  Linear gradients 
Length of 
gradient 
(min) 
Cummulative 
time 
(min) 
ACN percentage at 
start of time period 
ACN percentage at 
end of time period 
0 0 6 6 
10 10 6 6 
5 15 6 30 
30 45 30 60 
1 46 60 80 
3 49 80 80 
1 50 80 95 
2 52 95 95 
1 53 95 6 
2 55 6 6 
STOP 60 6 6 
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3.2.3. Bone morphogenetic protein 15 relative densitometry assay 
An assay to determine the concentrations of BMP15 was developed based on the 
densitometry readings of the BMP15 immunoreactive bands on Western blots under 
reducing conditions (see Section 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Example of the BMP15 relative densitometry assay. Western immunoblots 
under reducing conditions showing the molecular forms of recombinant HEK293- or 
E. coli-derived oBMP15. Expression medium (EM) from HEK293 cells transfected 
with an empty pEFIRES-P (lane 1; 10L), pEFIRES-o/oBMP15 (Lane 2; 10L, 
Lane 3; 5L, Lane 4; 2L), pEFIRES-h/oBMP15 (S356C) (Lane 5; 5L, Lane 6; 
2L), E. coli-derived oBMP15 mature domains (Lane 7; 0.78pg, Lane 8; 1.56pg, Lane 
9; 3.13 pg, Lane 10; 6.25pg, Lane 11; 12.5pg and Lane 12; 25pg). Molecular size 
markers (kDa) are shown to the left of the image. 
 
The Western blots included at least one lane with a preparation of E. coli-derived ovine 
BMP15 mature domain of known concentration (kindly gifted by Dr Jenny Juengel; 
Agresearch, Mosgiel, New Zealand). This was utilised as the standard against which 
preparations of unknown BMP15 concentration were measured. The area under the 
densitometry curve for the bands corresponding to the mature monomer for both the 
standard and sample preparations were determined and the percent area for each band was 
then calculated (General methods 2.4.4; Figure 2.C). From these, a relative density figure 
for each peak was produced using the formula: 
%(𝑆)
%(𝑆𝑡𝑑)
= 𝑅𝐷 
where: %(𝑆) = percent area for sample band; %(𝑆𝑡𝑑) = percent area for standard band 
and; RD = relative density.  
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A final sample concentration was determined using the formula:  
𝑅𝐷 𝑥 [𝑆𝑡𝑑] 𝑥 ( 𝑉𝑜𝑙(𝑆𝑡𝑑))
𝑉𝑜𝑙(𝑆)
= [𝑆] 
where: RD = relative density; [Std] = concentration of standard (ng/mL); Vol(Std) = volume 
of standard loaded on gel (L); Vol(S) = volume of sample loaded on gel (L) and; [S] = 
concentration of sample (ng/mL). 
 
As previously reported by McNatty et al. (2005b), E. coli-derived oBMP15 mature 
domains resolved at a different size to those produced by mammalian cells. This is most 
likely due to the E. coli construct containing a His tag and differences in the degree of 
linearisation of the polypeptide chains under the reducing conditions of the SDS-Page gel. 
The E. coli-derived proteins also formed aggregates which could not be fully dissociated. 
 
3.2.4. Rat granulosa cell 3H-Thymidine incorporation bioassay 
The rats used in this study were kindly supplied by the Department of Psychology, VUW 
and sacrificed in compliance with the VUW Animal Ethics Committee (VUW AEC 
10695). Prepubertal female Sprague-Dawley rats (21-27 days of age) were euthanized by 
CO2 asphyxiation, followed by cervical dislocation. A 70% ethanol solution was applied 
liberally to the abdominal region prior to dissection and collection of the ovaries. The 
ovaries along with a portion of oviductal tissue were collected into dissection medium (i.e. 
Medium A; DMA; see Appendix 5) at 37oC. Ovaries were kept at 37oC until dissection. 
Upon dissection, they were transferred into a 35x10 mm petri dish containing fresh 
Medium A and isolated from non-ovarian tissue under a dissection microscope at room 
temperature. The trimmed ovaries were transferred into a new petri dish containing fresh 
Medium A and visible follicles punctured (with additional gentle scraping) with a 20G 
needle fitted to a 1 mL syringe to encourage release of both granulosa cells and oocytes 
into the medium. Oocytes were removed by use of a 10 µL micro-pipette and the granulosa 
cells were kept at 37oC until dissections from all ovaries had been performed. Granulosa 
cells from all ovaries were harvested within 2 hours of ovary collection. Granulosa cells 
were then washed twice in incubation medium (i.e. Medium B; McCoys 5a containing 
glutamine, NaHCO3, poly (vinyl alcohol) and antibiotics; see Appendix 5) by 
centrifugation at 453 g for 5 min. The supernatant was carefully decanted and the pelleted 
cells were re-suspended in 0.5 mL Medium B. 
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The number of clear (live) and blue (dead) cells were counted and the cell viability was 
determined by trypan blue exclusion. Briefly, 5 L trypan blue, 0.4% (w/v), was mixed with 
50L cell suspension and loaded onto a haemocytometer. The cell suspension was then 
diluted with Medium B to give a concentration of 0.5x106 live granulosa cells/mL. 
Aliquots of twenty thousand live cells (40 L) were pipetted into individual wells of a flat-
bottomed 96 well plate (NUNC). Additional Medium B, containing the treatments 
described below were added to give a final volume of 55 L. For each bioassay, the test 
reagents in expression medium (EM) were investigated in triplicate, and included the 
following treatments: recombinant human activin A(10 ng/mL; R&D Systems), 
o/oBMP15-EM (19 ng/mL); h/oBMP15 (S356C)-EM (19 ng/mL); o/oGDF9-EM (50 
ng/mL); o/oBMP15-EM and o/oGDF9-EM (19 ng/mL + 50 ng/mL, respectively); 
o/oBMP15-EM and o/oGDF9-EM (19 ng/mL + 50 ng/mL, respectively); and media 
control (EM from an untransfected HEK293 cell line). On some occasions, additional 
treatments of [h/oBMP15 (S356C)-EM, (90 ng/mL)] and [h/oBMP15 (S356C)-EM and 
o/oGDF9-EM (90 ng/mL + 50 ng/mL, respectively)] were also included. The volume of 
EM (5L/well, 9.1%) was kept constant for all treatments. The granulosa cell preparations 
were incubated at 37oC in 5% CO2 for 16 h. Thereafter to each well, 0.4 L 3H-thymidine 
(1 mCi/mL; Perkin-Elmer) in 10L Medium B was added, giving a final concentration of 
350 nM of thymidine, and incubated for a further 6 hours. The cells were then washed 
from the multi-well plates using a cell harvester (TOMTEC, model No. MACH 3-FM 
series) and the radiolabelled DNA captured on a filter mat (glass fibre filter mats, 90x120 
mm, printed Filtermat A; Perkin Elmer). The filter mat together with 5 mL of scintillation 
fluid (Beta Scint; Perkin Elmer) was placed within a plastic sample bag (Perkin Elmer) and 
heat sealed. The level of 3H-thymidine incorporation was measured over a 2 minute 
interval, as counts per min (cpm) using a beta counter (Perkin Elmer; 1450-SLC MicroBeta 
Trilux). Mean values (cpm) for Medium B alone (negative control) were subtracted from 
test results. Results were then expressed as a fold-increase relative to the media control 
(i.e. EM from an untransfected HEK-293 cell line). 
 
3.2.5. Surface Plasmon Resonance (SPR) 
Surface Plasmon Resonance was used to investigate the ability and degree, of both 
promature and mature forms of o/oBMP15 and h/oBMP15 (S356C), to specifically interact 
with BMPR2. IMAC purified o/oBMP15 and h/oBMP15 (S356C) were further purified by 
HPLC (BIO-RAD, BioLogic DUOflow) using a reverse phase HPLC column (Jupiter, 
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5m, C4, 300Å; Phenomenix). The samples were eluted from the column over a 30 min 
period at a flow rate of 1 mL/minute using a linear gradient from 0-100% ACN, whilst 
keeping the TFA concentration constant at 0.1%. Aliquots of the resultant fractions were 
loaded onto a SDS page gel and electrophorised for 35 min at 280 volts. The gel was 
silver-stained and those fractions containing the promature and/or mature forms of BMP15 
were freeze-dried, and reconstituted with 50 L distilled water. The o/oGDF9-EM was 
dialysed 3x24 hours against 2 L Biocore running buffer (see Appendix 5). The o/oBMP15- 
and h/oBMP15 (S356C)-EM in 50L water were diluted further with the addition of 
240L water and 290L of 2x Biocore running buffer. The diluted o/oBMP15-, 
h/oBMP15 (S356C)- and o/oGDF9-EM, samples were then serially diluted 1:2 with 1x 
Biocore running buffer to produce dilutions at 1:2, 1:4, 1:8, 1:16 and 1:32.  
 
Surface Plasmon Resonance experiments were performed using Biacore 2000 system 
(Biacore, GE Healthcare, Chalfont, St. Giles, GB) (McDonnell 2001; Pattnaik 2005). The 
biosensor was prepared by attaching N-biotinylated, human BMPR2 extra-cellular domains 
to a Biacore sensor chip using equimolar concentrations of sulfo-NHS-LC-biotin (Pierce, 
Thermo Scientific, Rockford, IL, USA) using the method previously reported (Shen et al. 
1996). The formation of ternary complexes and their subsequent dissociation from the 
biosensor was measured and recorded as described previously (Zhang et al. 2002).  
 
3.3. Results 
3.3.1. Production of pEFIRES-hBMP15 (S356C) 
Utilizing the method outlined in Section 2.2.2, the h/oBMP15 (S356C) insert contained 
within pGEM-T Easy was sub-cloned into the expression vector pEFIRES-P and used to 
transform E. coli. The plasmid DNA was extracted from four replicate cultures of E. coli 
transformed with pGEM-T Easy-h/oBMP15 (S356C). The insert from one of these was 
excised from the plasmid, and pEFIRES-P was linearised, with two distinct pairs of 
restriction enzymes, EcoRI with XbaI and XhoI with XbaI (Figure 3.3A). The two bands 
corresponding to the pGEM-T Easy vector (upper band) and the h/oBMP15 (S356C) insert 
(lower band) are visualised in Figure 3.5A (Lanes 1 & 2). Using the regression equation 
(Figure 3.3B), the size of the released insert was calculated to be 1198 bp. This correlates 
well with the expected value of 1270bp. 
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Figure 3.3 Restriction enzyme digests of pGEM-T Easy-h/oBMP15 (S356C) and 
pEFIRES-P. (A) Restriction enzyme digests of pGEM-T Easy-h/oBMP15 (S356C) cut 
from pGEM-T Easy with EcoRI and XbaI (Lane 1), h/oBMP15 (S356C) cut from 
pGEM-T Easy with XhoI and XbaI (Lane 2), pEFIRES-P linearised with EcoRI and 
XbaI (Lane 3), pEFIRES-P linearised with XhoI and XbaI (Lane 4). The numbers on 
the side refer to number of base pairs. (B) Graphical depiction of the DNA ladder 
(diamonds). The values shown in blue diamonds were used to generate the regression 
line Y = -16.4 ln(x) + 158.3, R2 = 0.995  
 
The insert and linearised pEFIRES-P (Figure 3.3A, Lanes 1 and 3, respectively), both cut 
with the restriction enzyme pair EcoRI and XbaI were extracted from the gel, ligated and 
used to transform E. coli bacteria. However no colonies were formed indicating that the 
linearisation, ligation or transformation failed. To test the linearization of pEFIRES-P, 
duplicate ligations were performed. This was undertaken by ligating the insert with either  
the linearised pEFIRES (Figure 3.3A; Lanes 2 and 4, respectively) or the pEFIRES-P that 
had been previously linearised with XhoI and XbaI (provided by Mr A. Bibby, Victoria 
University of Wellington). Successful transformation was only achieved with the ligation 
using the previously linearised pEFIRES-P. So it appears that for unknown reasons the 
linearisation of pEFIRES-P was unsuccessful. However from the successful 
transformation, the plasmid DNA from eight replicate cultures was extracted (Table 3.3).  
The insert of pEFIRES-h/oBMP15 (S356C) from samples 1 and 3 were released by XhoI 
and XbaI and their sizes determined by agarose gel electrophoresis (Figure 3.4A). 
However, only the insert from sample 3 was released. From the regression equation 
(Figure 3.4B), the size of the released insert from sample 3 was calculated to be 1258 base 
pairs (bp), This is in agreement with the theoretical value of 1207bp. Sample 3 was 
sequenced to confirm the identity of the insert (Appendix 4) and subsequently, pEFIRES-
h/oBMP15 (S356C) was used to transfect HEK293 cells. 
 
  
A B 
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Table 3.3 Quality of extracted pEFIRES-h/oBMP15 (S356C) plasmid DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Restriction enzyme digests of pEFIRES- h/oBMP15 (S356C). 
(A) Enzyme digests, Sample 1 (Table 3.3) cut with XhoI and XbaI (Lane 1), Sample 3 
(Table 3.3) cut with XhoI and XbaI (Lane 2). Numbers on side refer to number of 
base pairs. (B) Graphical depiction of DNA ladder (diamonds). The values shown in 
blue diamonds were used to generate the regression line 
Y = -20.5 ln(x) + 193.9, R2=0.9924 
 
3.3.2. Comparison of h/oBMP15 (S356C)-EM, o/oBMP15-EM and E. coli derived 
oBMP15 mature domains in the BMP15 relative densitometry assay 
Experiments were performed to determine if the monoclonal antibody, MN2-61A, 
recognised the mature domains found in expression medium (EM) from HEK293 cells 
transfected with pEFIRES-o/oBMP15 or pEFIRES-h/oBMP15 (S356C) and E. coli-
derived oBMP15 equally. Serial dilutions of h/oBMP15 (S356C)-EM, o/oBMP15-EM and 
E. coli-derived oBMP15 mature domains were analysed by Western blot under reducing 
conditions. Triplicate Western blots, each containing, a single replicate per dilution per test 
sample were performed. The density of the band corresponding to the monomeric mature 
 DNA 
 mg/mL A260/A280 ratio 
Sample 1 0.35 1.87 
Sample 2 0.65 1.81 
Sample 3 0.62 1.80 
Sample 4 0.63 1.79 
Sample 5 0.61 1.79 
Sample 6 0.65 1.82 
Sample 7 0.55 1.77 
Sample 8 0.66 1.82 
A B 
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domain was determined for each sample and dilution, as described in Sections 3.2.3 and 
3.2.4. The relative density (RD) of these bands underwent a logit transformation using the 
formula: 
𝑙𝑜𝑔𝑖𝑡 = 𝑙𝑛
(
𝑅𝐷
8 )
(1 − (
𝑅𝐷
8 ))
 
Where the constant 8, is an arbitrary number used to generate a proportion, thus allowing 
the derived RD values to fit the equivalent equation: 
𝑙𝑜𝑔𝑖𝑡 = 𝑙𝑛
(𝑝)
(1 − 𝑝)
 
The slopes of the log-logit plots of h/oBMP15 (S356C)-EM (slope = 0.798x) and E. coli-
derived oBMP15 (slope = 0.719x) were tested for parallelism by residual sum of squares 
and found to be not significantly different (P>0.05, Figure 3.5). 
 
 
 
 
 
 
 
 
Figure 3.5 Parallelism between h/oBMP15 (S356C)-EM and E. Coli-derived oBMP15. 
Log-logit plot of h/oBMP15 (S356C)-EM (   ) and E. coli-derived oBMP15 mature 
domains (    ) 
 
It was not possible to analyse a similar dilution series of o/oBMP15, due to the low levels 
of expression by the pEFIRES-o/oBMP15-transfected HEK293 cells. Therefore, an 
alternative approach was used whereby Western blots were run under reducing conditions 
and the density of the reference and sample bands were then determined. Bands of three 
different concentrations of E. coli-derived BMP15 (625, 1250 and 2500 ng/mL) were each 
used to calculate the concentration in three different solutions of o/oBMP15-EM. This was 
performed using triplicate Western blots (Table 3.4). Having established that only a single 
reference standard was required, only one concentration of E. coli-derived oBMP15 (625 
ng/mL) was used as a reference standard on all subsequent Western blots.  
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Table 3.4 Summary of calculated o/oBMP15 concentrations when using different 
reference standards 
o/oBMP15-EM 
Sample number 
BMP15 concentration (ng/mL): calculated 
using different concentrations of E. coli 
derived BMP15 as the reference standard  
Difference 
between 
standards 
P= 625 ng/mL 1250 ng/mL 2500 ng/mL 
1 213 ± 64 238 ± 75 244 ± 118 0.906 
2 489 ± 60 529 ± 84 529 ± 159 0.878 
3 402 ± 57 438 ± 86 441 ± 164 0.895 
 
3.3.3. Production of o/oBMP15 and h/oBMP15 (S356C) proteins 
Expression medium (EM) from HEK293 cells transfected with an empty pEFIRES-P, 
pEFIRES-o/oBMP15 or pEFIRES-h/oBMP15 (S356C) were harvested as described in 
Section 2.2.4. The o/oBMP15-EM and h/oBMP15 (S356C)-EM contained 414 ± 42 ng/mL 
(n = 5 replicate assays) and 1954 ± 171 ng/mL (n = 6 replicate assays) of E. coli-mature 
monomer equivalents.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Composite image showing western blot detection of molecular forms of 
o/oBMP15 and h/ oBMP15 (S356C). 
Expression medium from HEK293 cells transfected with empty pEFIRES-P plasmid 
(Lane 1), pEFIRES-P-o/oBMP15 (Lane 2) or pEFIRES-P-h/oBMP15 (S356C) (Lane 
3) under reducing or non-reducing conditions. Molecular size markers (kDa) are 
shown to the left of the image. 
 
Western blot analyses of these EM showed bands corresponding to monomeric mature 
(~15 kDa) forms under reducing conditions in both o/oBMP15-EM and h/oBMP15 
(S356C)-EM but not in pEFIRES-EM. Bands corresponding to uncleaved promature (~52 
kDa ovine promature domain or ~56 kDa human/ovine promature domain) were also 
present. Under non-reducing conditions, the promature forms remained, however a band of 
45 
(~30 kDa) corresponding to the dimeric mature form was detected in h/oBMP15 (S356C)–
EM but not o/oBMP15-EM. Higher molecular weight forms appeared under non-reducing 
conditions. Two bands in o/oBMP15-EM and one in h/oBMP15 (S356C)-EM 
corresponded to bands also seen in the empty pEFIRES-EM. Interestingly, two additional 
bands appeared in h/oBMP15 (S356C)–EM: one of these corresponds in size to a dimeric 
promature form while the other corresponds to a complex between a promature and a 
mature monomeric form (Figure 3.6). 
 
3.3.4. Purification of o/oBMP15 and h/oBMP15 (S356C) proteins 
3.3.4.1. IMAC purification 
Both h/oBMP15 (S356C) and o/oBMP15 bound to the Ni-NTA–agarose (Figures 3.7 and 
3.8 respectively), via the N-terminal 8His tag on the prodomain and the mature domains, 
were eluted in the presence of 7 M urea. For increased clarity, the Figures below depict the 
use of a column, however the centrifugal batch methodology that was described in Section 
3.2.1 was used in these experiments. Both the amount and composition of the eluted 
h/oBMP15 (S356C) material varied during sequential elution with 7 M urea. The eluted 
dimeric mature domains detected in Fractions 5-11 (Figure 3.7), also included very large 
amounts (>70%) of eluted monomeric mature domains (Table 3.5; page50). Furthermore, 
the proportions of the mature BMP15 (S356C) domains relative to the uncleaved pro-
mature domains also varied. The Fractions 5-11, 12-14 and 15-19 contained 62.8 ± 1.3, 
85.0 ± 4.9 and 40.1 ± 1.0 (mean ± S.E.M.) percent mature domains, respectively. All the 
fractions eluted with 7 M urea included both uncleaved promature and mature domains 
(Figure 3.7). Overall, these fractions contained 1908 ± 220 ng/mL monomeric mature 
domain (mean ± S.E.M., n = 5). Residual materials bound to the column, containing 
promature, mature monomers and mature dimers were eluted in the presence of imidazol. 
 
Similarly, o/oBMP15 was found predominantly as mature monomers and eluted mainly in 
Fractions 5-11 (Figure 3.8). Within these fractions, the uncleaved pro-mature domains 
comprised 7.8 ± 1.6 (mean ± S.E.M.) % of the immunoreactive BMP15 that was present. 
Fractions 12-14 and 17-19 contained no detectible BMP15, however Fractions 15 and 16 
contained predominately uncleaved pro-mature domains, comprising 58% of all uncleaved 
promature forms that were eluted with 7 M urea. 
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Fure 3.3stern blot of fractions collected from IMAC purification of o/oBMP15. 
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3.3.4.2. HPLC purification  
The pooled eluates of h/oBMP15 (S356C) in 7 M urea were further fractionated by HPLC, 
as described in Section 3.2.2. The BMP15 within these fractions proved difficult to recover 
when evaporated to complete dryness. When reconstituted with water, these fractions 
contained no soluble BMP15 when aliquots were removed and tested by Western blotting. 
In contrast, if the water was removed and replaced with reducing sample buffer (Appendix 
5) and heated to 100°C (as per standard protocol, Section 2.3.1), immunoreactive BMP15 
bands were detectable in the Western blots (results not shown). Likewise, if the freeze-
drying process was halted when only 20-30L of the HPLC elution solvent was still 
present, then BMP15 was also detectable (Figure 3.9). A protocol similar to that used to 
purify human BMP15 (Pulkki et al. 2012) and human cumulin (Mottershead et al. 2015) 
was used, however it appeared that ovine BMP15 has a greater propensity to bind to the 
walls of the microcentrifuge tubes in which they were completely evaporated.  
 
Aliquots (1L) of the residual HPLC elution solvent (after evaporation to near dryness) 
were diluted to 12L with Milli-Q H2O and then analysed by Western blotting under both 
reducing and non-reducing conditions. Under non-reducing conditions, promature forms 
eluted at 44-45% ACN (Figure 3.11A, Lanes 2-3 and 9-10) whereas the mature domains 
(predominantly in dimeric form) were eluted with ≥45% ACN (Figure 3.11A; Lanes 3-4 
and 10-12). The loading material, previously purified by IMAC, also showed the presence 
of bands corresponding to both promature and dimeric mature domains (Figure 3.9A; Lane 
7), along with two high molecular weight forms. Under reducing conditions, the loading 
material resolved fully into uncleaved promature and monomeric mature domains (Figure 
3.9B, Lane 7). Similarly, uncleaved promature domains were still observed in Lanes 2-3 
and 9-10 (Figure 3.9B) as they were under non-reducing conditions. Mature domains were 
present mainly as monomers and were identified in fractions eluted with ≥45% ACN 
(Figure 3.9B; Lanes 2-4 and 9-12). Additional bands, intermediate to the dimeric mature 
and the promature domains also appeared under non-reducing conditions. These bands 
were not present in the loading material. The most likely explanation for this was the 
concentration difference between the IMAC- and HPLC-purified fractions. The identity of 
these bands was not determined. 
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Figure 3.9 Molecular forms of HPLC purified BMP15 (S356C). 
Western blots of fractions from HPLC under (A) non-reducing and (B) reducing 
conditions. Fractions eluted from replicate runs at 43% ACN (Lanes 1 and 8), 44% 
ACN (Lanes 2 and 9), 45% ACN (Lanes 3 and 10), 46% ACN (Lanes 4 and 11), 47% 
ACN (Lanes 5 and 12) and 48% ACN (Lane 6). The pooled IMAC purified material is 
shown in Lane 7. The molecular size references (kDa) are shown to left of the images. 
3.3.5. Bioactivity of o/oBMP15, h/oBMP15 (S356C) and o/oGDF9 
A 3H-thymidine incorporation bioassay using rat granulosa cells was used to determine the 
bioactivities of o/oBMP15-EM, h/oBMP15 (S356C)-EM alone and also in combination 
with o/oGDF9-EM. 
 
In response to human activin A, 3H-thymidine incorporation increased more than ten-fold 
(10.61 ± 2.08; mean ± S.E.M.; p<0.001). This confirmed that the incubation conditions for 
the rat granulosa cells were conducive to proliferation and that the cells were able to 
respond to a purified TGFB family member. Factors produced and secreted into expression 
medium by un-transfected HEK-293 cells, at the volume used in the bioassay, had no 
significant impact on the amount of 3H-thymidine incorporation by rat granulosa cells. 
Incubation media with and without addition of HEK-293 expression medium resulted in 
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mean cpm of 249 ± 23 (n=9) and 293 ± 16 cpm (n=9) respectively: these values were not 
significantly different from one another. The results presented as fold-differences relative 
to the media control, are shown in Figure 3.12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Rat granulosa cell 3H-thymidine incorporation bioassay. 
The effects of addition of activin A (10 ng/ml), oGDF9 (50 ng/mL), oBMP15 (19 
ng/mL), BMP (S356C) (19 ng/mL), BMP15 + GDF9 (19 and 50 ng/mL respectively), 
oBMP (S356C) + oGDF9 (19 and 50 ng/mL respectively), oBMP15 (S356C) (high; 90 
ng/mL) and oBMP15 (S356C) (high) + oGDF9 (90 and 50 ng/mL respectively) on 3H-
thymidine incorporation by rat granulosa cells. Values represent mean ± S.E.M. 
relative to control medium. Numbers above each histogram refer to number of 
independent rat granulosa cell pools tested. Different letters denote significant 
difference relative to control; a, P<0.001; b, P<0.005. The additive effect of oGDF9 
and oBMP15 versus co-culture of oBMP15 + oGDF9 indicated a synergistic response; 
c, P<0.02. 
 
The o/oGDF9-EM (0.97 ± 0.09 fold) had no effect on 3H-thymidine incorporation, 
however o/oBMP15-EM (19 ng/mL) increased 3H-thymidine incorporation both without 
(2.42 ± 0.28 fold; p<0.005) and with o/oGDF9-EM (3.76 ± 0.35 fold; p<0.001). Neither 
the low dose (19 ng/mL) of h/oBMP15 (S356C)-EM alone, or in combination with 
o/oGDF9-EM affected 3H-thymidine incorporation (1.00 ± 0.08 and 1.15 ± 0.12 fold, 
respectively). Likewise, a high dose (90 ng/mL) of h/oBMP15 (S356C)-EM, neither alone, 
nor in combination with o/oGDF9-EM affected 3H-thymidine incorporation (1.30 ± 0.17 
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and 1.32 ± 0.23 fold, respectively). Increasing the dose of h/oBMP15 (S356C) from 19 to 
90 ng/mL increased the fold increase over control from 1.00 ± 0.08 to 1.30 ± 0.17. 
Although this was not significantly different, this modest increase may be attributable to a 
small concentration of mature monomer present in this preparation (Figure 3.9A). 
 
To test for interactions between oBMP15 and oGDF9, paired t-tests were performed 
comparing the 3H-thymidine incorporation between the additive effect of oBMP15 and 
oGDF9 when added alone, compared to that when co-cultured. The additive effect of 
o/oBMP15-EM (19 ng/mL) and o/oGDF9-EM (2.39 ± 0.35 fold) was less than found when 
they were co-cultured (3.76 ± 0.35 fold; paired t-test, p<0.02) demonstrating a synergistic 
response. However, the additive effect of o/oBMP15 (S356C)-EM (19 ng/mL) and 
o/oGDF9-EM when each was added alone (0.97 ± 0.15 fold), compared to that when co-
cultured (1.15 ± 0.12) was not different. Thus, an interaction between o/oGDF9-EM and 
o/oBMP15-EM (19 ng/mL), but not with h/oBMP15 (S356C)-EM (19 ng/mL) was 
observed.  
 
An original aim of this thesis was to assess the biological activity of differing BMP15 
molecular forms. However, the HPLC purified mature and promature forms of oBMP15 
and oBMP15 (S356C) were not tested. This was due to the failure to obtain soluble 
BMP15 from HPLC fractions, following evaporation to dryness (see Section 3.3.5.2). 
Moreover, when testing BMP15 activity in media with residual TFA in the fractions (i.e. 
those samples used for Figure 3.9), there was significant suppression of rat granulosa cell 
proliferation in the 3H-thymidine incorporation bioassay. The residual fractions eluted 
from the HPLC contained 1.3x10-2 M TFA prior to drying. Tests showed rat granulosa 
cells were particularly sensitive to TFA. When exposed to 0, 4.5x10-5 M or 4.5x10-4 M 
TFA in the presence of 100 ng/mL activin A, the level of 3H-thymidine incorporation by 
rat granulosa cells was 15710 ± 4163 [100%], 5269 ± 1609 [66.4%] or 905 ± 266 [94.3%] 
(mean ± S.E.M., [% suppression relative to no TFA control], n=3) cpm respectively. These 
values were signficantly different, P<0.001. Several future strategies that may alleviate this 
problem of insolubility are: (i) the addition of a carrier protein e.g. bovine serum albumin, 
to the HPLC purified BMP15 prior to freeze drying (ii) the inclusion of a carrier protein 
when the lyophilised BMP15 is reconstituted and (iii) altering the charge on the BMP15 by 
reconstituting with dilute acid i.e. 4mM HCl. These strategies could be trialled either 
singularly or in combination. 
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3.3.6. Surface Plasmon Resonance (SPR) 
HPLC-purified h/oBMP15 (S356C) and o/oBMP15 failed to bind to a BIAcore sensor chip 
loaded with hBMPR2 extracellular domains. However, both a recombinant porcine (p) 
BMP15 (supplied by Dr Janet Pitman, Victoria University of Wellington) and an o/oGDF9 
preparation were able to associate and disassociate from the sensor chip in a dose- 
dependent manner Figure 3.11).  
 
A B 
 
 
 
 
 
 
 
 
 
 
C D 
 
 
 
 
 
 
 
 
Figure 3.11 SPR sensograms of o/oBMP15, h/oBMP15 (S356C), o/oGDF9 and 
p/pBMP15 binding to human BMPR2. Binding profiles of (A) o/oBMP15, (B) 
h/oBMP15 (S356C), (C) o/oGDF9 and (D) p/pBMP15 binding to BMPR2 at 1:2 
dilution (L4A2), 1:4 dilution (L4A3), 1:8 dilution (L4A4), 1:16 dilution (L4A5) and 
1:32 dilution (L4A6). Biotinylated human BMPR2 captured on a BIAcore chip was 
equilibrated with running buffer (time <0 sec), injection of test ligands and complex 
formation with BMPR2 (time 0-120 sec) and disassociation of the complex (time 120 – 
250 sec). RU, response units.   
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The reasons for these discrepancies were unclear. However, both oGDF9 and pBMP15 
were prepared by simply dialysing the expression medium against the BIAcore running 
buffer. In contrast, both ovine BMP15 preparations, were purified by HPLC followed by 
freeze-drying to remove ACN and TFA, prior to SPR analysis. It is possible that by using 
this procedure, the oBMP15 was irretrievably bound to the tubes in which they were 
freeze-dried. This was thought to have occurred also when ovine BMP15 HPLC fractions 
were evaporated to dryness under vacuum (Section 3.3.5.2). 
 
3.4 Discussion 
HEK293 cells secrete oBMP15 largely as cleaved and uncleaved promature forms. Under 
non-reducing conditions, o/oBMP15-EM and h/oBM15 (S356C)-EM contained promature, 
but no monomeric mature, bands. However under reducing conditions both promature and 
monomeric mature domain were observed (Figure 3.6). It may be argued that the absence 
of observable monomeric mature bands under non-reducing conditions is due to a lack of 
sensitivity of clone MN2-61A (anti BMP15) and/or its inability to recognise this form 
under these conditions. The question of sensitivity, i.e. the level of detection of the 
different molecular forms, is one that cannot presently be answered. This will require the 
production of soluble purified forms of a known concentration. However MN2-61A was 
able to detect monomeric and dimeric forms of E.coli derived ovine mature BMP15 under 
both reducing and non-reducing conditions (Figure 3.12). 
 
A B 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  Western immunoblots showing the molecular forms of E. coli derived 
mature oBMP15 under (A) non-reducing and (B) reducing conditions. The blots 
depict bands from a dilution series where the total protein loaded onto the gel 
comprised 50ng (Lane 1); 25ng (Lane 2); 12.5ng (Lane 3); 6.25ng (Lane 4); 3.13ng 
(Lane 5) or 1.56ng (Lane 6). The molecular size references (kDa) are shown to the left 
of the images. 
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Moreover, HPLC-purified monomeric mature forms of oBMP15 (S356C) were also 
detected under non-reducing conditions (Figure 3.10). This same antibody was also able to 
immuno-neutralise thymidine incorporation when ovine oocytes were incubated with either 
rat or ovine granulosa cells (Lin et al. 2012). Assuming mature domains are indeed among 
the biologically active forms produced and secreted by ovine oocytes then MN2-61A is 
able to recognise this form under native, non-reducing conditions. 
 
Although some of these mature domains in EM may be comprised within the high 
molecular weight complexes, the HPLC-purified forms showed much of the promature 
form was in a cleaved (non-covalently linked pro- and mature domains) state (Figure 3.9). 
This confirms that both cleaved and uncleaved promature forms were present. This is in 
agreement with published data for the mouse (McIntosh et al. 2008). However published 
data for recombinant ovine BMP15 have either: not commented on the promature forms 
(McNatty et al. 2005a), or not reported the presence of uncleaved promature forms 
(Edwards et al. 2008). Additional bands, not observed in o/oBMP15-EM, were present in 
h/oBMP15 (S356C)-EM (Figure 3.6). The size of these bands corresponded to forms that 
may represent dimeric mature protein, a complex between a promature and mature 
mononomer and dimeric promature protein. Although the identities of these bands have not 
been confirmed, it is likely they are the result of covalent cysteine bonding between mature 
domains, which do not exist in o/oBMP15. 
 
The IMAC procedure is based on the specific covalent bonding of amino acids, particularly 
histidine, to metals (Porath et al. 1975). The expected manner by which both o/oBMP15 
and h/oBMP15 (S356C) bind to, and elute from, Ni-NTA-agarose, would have been via the 
8His tagged pro- and promature domains binding directly to the Ni-NTA-agarose. 
Conversely, untagged proteins such as the mature domains would not bind. Thus cleaved 
promature domains should resolve into both pro- and mature domains in the presence of 7 
M urea allowing for the mature domains to be eluted. While the remaining pro- and 
uncleaved promature domains would be expected to elute in the presence of imidazole 
which competes for the Ni2+ ions on the Ni-NTA-agarose. However this was not what was 
observed (Figures 3.7 and 3.8). Both h/oBMP (S356C) (Figure 3.9) and o/oBMP15 (Figure 
3.8) eluted from the Ni-NTA-agarose in the presence of urea as promature and mature 
domains over an extended period, This pattern of elution may be explained by a complex. 
This complex could consist of various BMP15 molecular forms being bound together by 
both covalent and non-covalent bonds and then binding to the Ni-NTA-agarose via the 
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8His tag on a single pro- or promature domain. Indeed, high molecular weight complexes 
which resolve into promature and mature domains were observed in both the o/oBMP15-
EM and h/oBMP15 (S356C)-EM preparations (Figure 3.6) Moreover, oBMP15 multimers 
have been reported previously (Edwards et al. 2008).  
 
Table 3.6 Molecular forms of BMP15 recognised by clone MN2-61A in expression 
medium, IMAC-purified or HPLC-purified material. 
  Molecular forms corresponding 
to Western blotting bands in: 
Molecular forms recognised by clone MN2-61A 
Expression
medium 
IMAC 
purified 
HPLC 
purified 
 
 
Dimeric promature    
 
 
OR 
 
Covalently bound 
mature monomer 
with promature. 
OR 
Dimeric 
mature:Prodomain 
complex 
   
     
 
Monomeric 
uncleaved 
promature 
   
 
Monomeric cleaved 
promature complex 
 ND  
 
 
Dimeric mature 
domains 
   
 
Monomeric mature 
domains 
   
() detected, () not detected, (ND) not determined.  
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Notwithstanding the above, some degree of separation of promature and mature domains 
of h/oBMP15 (S356C) was achieved with the use of HPLC (Figure 3.9). The first fraction 
eluted contained both cleaved and uncleaved promature domains, the second fraction 
contained a mixture of promature and mature forms and the third fraction contained mostly 
the mature domains (Figure 3.9). The two high molecular weight bands observed in the 
IMAC purified material loaded onto the HPLC column (Figure 3.9, Lane7) were not 
present in fractions eluted from the HPLC column.  
 
Interestingly, the promature bands of h/oBMP15 (S356C) found in both the IMAC- (Figure 
3.9) and HPLC- (Figure 3.11) purified material appear to be composed of two bands 
located close together. The predominant form was found in the higher band under non-
reducing conditions and in the lower band under reducing conditions. Not all associations 
between proteins were disrupted under reducing conditions as can be observed by the 
presence of some dimeric mature domains under reducing conditions (Figure 3.8 and 
Figure 3.9B). This raises the possibility that the lower of the two bands was composed 
largely of uncleaved promature domains along with some cleaved promature domains. 
Whereas the upper band was composed of mature dimers bound covalently or non-
covalently to a single prodomain. It is also worth noting the presence of bands in Fractions 
4-8 (Figure 3.8) corresponded in size to a dimeric promature form, similar to what was 
observed in h/oBMP15 (S356C)-EM (Figure 3.6). Western blotting using the monoclonal 
antibody MN2-61A identified many of the potential forms of BMP15 (S356C) (Figure 
3.5). The most predominant forms were the promature and mature forms. Importantly, 
clone MN2-61A was able to detect the dimeric mature form of h/oBMP15 (S356C) but 
was unable to detect a corresponding band of o/oBMP15 (Table 3.5). This suggests that 
o/oBMP15 is different to hBMP15, in which mature dimers were detected (Pulkki et al. 
2012). 
 
Experiments using the 3H-thymidine incorporation bioassay and rat granulosa cells 
demonstrated o/oGDF9 and o/oBMP15 were biologically active. Moreover, co-incubating 
o/oBMP15-EM and o/oGDF9-EM confirmed the synergistic response that has been 
reported by others (Yan et al. 2001; Hanrahan et al. 2004; McNatty et al. 2005a; Edwards 
et al. 2008; McIntosh et al. 2008; Reader et al. 2011; Mottershead et al. 2012). The 
molecular form(s) responsible for this synergism were not able to be determined in the 
present study. However, for BMP15, it is likely to be the cleaved promature or monomeric 
mature forms, as these were the forms present in o/oBMP15-EM (Figure 3.6). Although 
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the uncleaved promature form was also present, this is known to be a biologically inactive 
form (Souza et al. 2014). 
 
The response to human activin A was several fold greater than that observed with 
o/oBMP15 either alone or with o/oGDF9.  Several factors may contribute to this 
difference. Different receptors are utilised by activin A compared to those used by 
oBMP15 or oGDF9. Furthermore, if cell proliferation is mediated by the Smad 2/3 
pathway, then dimeric activin would signal through two type I receptors per receptor-
ligand complex where as a BMP15-GDF9 receptor complex would contain just a single 
type I receptor capable of signalling via the Smad 2/3 pathway.  
 
Interestingly, h/oBMP15 (S356C)-EM, unlike o/oBMP15, when cultured alone did not 
demonstrate biological activity. This is in agreement with Mottershead et al. (2015) who 
also reported the hBMP15 (S357C) variant, was unable to stimulate proliferation in mouse 
granulosa cells, either with or without co-culture with hGDF9. In contrast the hBMP15 and 
the hBMP15 (S357C) variant, were equally able to stimulate the Smad 1/5/8 activity and 
inhibin B production in COV434 cells (Pulkki et al. 2012). The reason(s) for these 
differences are unknown. However one reason may be the different end points examined. 
In the previous study, Smad1/5/8 activation and inhibin B production were investigated 
whilst this study investigated proliferation which is mediated via the Smad 2/3 pathway. 
Consequently, it will be important to determine in subsequent bioassays, that the biological 
activity of h/oBMP15 (S356C)-EM is dependent upon Smad 1/5/8 activity before its 
apparent inability to synergise with oGDF9 can be confirmed. Additionally, if the 
promature form is important for biological activity then the interaction between a human 
proregion and an ovine mature domain [h/oBMP15 (S356C)] may be sub-optimal in the 
thymidine incorporation bioassy. Indeed the synergistic response of BMP15 and GDF9 has 
been shown to involve, in addition to Smad 2/3, different non-smad signalling pathways. 
Which pathways are involved, appear to be dependent upon both the species of growth 
factors, and the species of the target granulosa cells (Reader et al. 2011; Mottershead et al. 
2012; Reader et al. 2014). 
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CHAPTER4: DETERMINATION OF OOCYTE-DERIVED MOLECULAR 
FORMS OF BMP15 AND GDF9 
 
4.1 Introduction 
Oocyte-secreted factors and thus the oocyte itself are well-recognised to play a significant 
role in ovarian follicular development (Eppig et al. 2002). Two closely-related members of 
the TGFB superfamily, BMP15 and GDF9, are perhaps the best studied of these factors. In 
general, members of the TGFB superfamily are produced as proproteins, with both the pro- 
and mature regions being enzymatically cleaved from one another to form non-covalently 
linked pro-mature complexes (Massague 1998). A characteristic “cysteine knot” stabilising 
the structure of the mature growth factor domain is formed by six conserved cysteine 
residues and a seventh cysteine residue is involved in forming covalent bonds between 
mature dimers (McDonald and Hendrickson 1993). However, BMP15 and GDF9 belong to 
a small sub-family of TGFB proteins where this seventh cysteine has been substituted with 
a serine. Consequently, any mature homo- or hetero-dimers can only associate in a non-
covalent manner. 
 
Although the dimeric form of recombinant mature ovine and mouse GDF9 has been 
identified (Edwards et al. 2008), (McIntosh et al. 2008), the dimeric form of mature ovine 
BMP15 has not. However, the secreted forms of mature recombinant hBMP15, either 
without tags (Pulkki et al. 2012) or with either a N-terminal FLAG tag (Liao et al. 2004), 
(Hashimoto et al. 2005) or a N-terminal MycHis tag (Rossetti et al. 2009) have been 
reported to include mature dimers. It has been suggested that the synergistic effect from the 
combined action of BMP15 and GDF9 on the proliferation of granulosa cells may result 
from the formation of heterodimers (McNatty et al. 2004). Indeed, a covalently linked, 
biologically-active recombinant heterodimer (termed cumulin) was produced to test this 
hypothesis (Mottershead et al. 2015). However it should be noted that to date, neither 
homodimers of BMP15 nor heterodimers with GDF9 have been identified as being 
produced or secreted by oocytes of any species. Thus, a major aim of these studies was to 
determine the molecular forms of BMP15 and GDF9 that are being produced and/or 
secreted by ovine and bovine oocytes. Recombinant o/oBMP15, h/oBMP15 (S356C) and 
o/oGDF9 are useful tools to aid identification of these molecular forms. 
 
Monoclonal antibodies, clone MN2-61A (anti-BMP15) and clone 37A (anti-GDF9) have 
previously been shown to be specific for ovine growth factors (McNatty et al. 2005a) but 
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this has not previously been determined for bovine (b)BMP15 and bGDF9. Both MN2-
61A and 37A were raised against the E. coli-derived mature domains of ovine BMP15 
(McNatty et al. 2005a) and ovine GDF9 (Lin et al. 2012), respectively. Epitope mapping 
revealed that MN2-61A recognised a region within the sequence SEVPGPSREHDGPES 
(McNatty et al. 2005a), which shares 100% homology between ovine and bovine. Whilst 
epitope mapping has not been performed with MN2-37A, the mature domains of ovine and 
bovine GDF9 share 131 of the 135 amino acid sequence and thus >97% homology. 
Therefore, based on these degrees of homology, each antibody should recognise bovine 
BMP15 or GDF9 with a high degree of specificity. 
 
4.2 Methodology 
Unless stated below, additional details including sources of equipment and reagents used 
are described in Appendix 5. The methodological details describing preparation of samples 
for SDS-PAGE and Western blotting are described in Chapter 2. 
 
4.2.1 Ovary collection 
In brief, ovine and bovine ovaries (from animals of unknown age) were collected at a local 
abattoir (Taylor Preston, Ngauranga, Wellington, New Zealand) and were transported to 
the laboratory at room temperature. Subsequently, ovine ovaries were dissected free of 
extraneous oviductal tissue and rinsed twice in sterile PBS (0.15M, pH7.4; SIGMA). 
Bovine ovaries were rinsed twice in PBS but did not have non-ovarian tissue removed 
prior to oocyte collection. The ovaries remained immersed in PBS at room temperature 
until oocyte collection. 
 
4.2.2 Oocyte collection and incubation 
Upon removal from PBS, ovine ovaries were dissected free of the medullary blood supply 
to aid follicular visualisation under a dissecting microscope. Cumulus cell-oocyte-
complexes (COC) were recovered by flushing all the visible antral follicles on the ovarian 
surface with the dissection medium (i.e. Medium C; M199 containing Hepes, Glutamax 
(L-alanyl-L-glutamine dipeptide) and PenStrep, pH 7.4) using a 20G needle fitted to a 5 
mL syringe. 
 
Bovine ovaries were removed from the PBS and COC were collected by aspiration of the 
follicular contents directly into dissection medium using a 20G needle connected to a 
Venturi vacuum pump attached to a low pressure water supply.  
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A mixture of “naked oocytes” (oocytes devoid of a complete layer of cumulus cells) and 
COC were collected from the resultant media/follicular fluid, which will hereafter be 
referred to collectively as oocytes. Oocytes were extracted from the aspirated fluid by use 
of a 10 µL micro-pipette and washed twice by transfer to fresh Medium C. 
 
Subsequently, both the bovine or ovine oocytes were washed once in incubation medium 
(i.e. Medium D; M199 containing Glutamax, PenStrep and NaHCO3; pH 7.4). Thereafter, 
pools of 100-130 oocytes in 50 µL incubation medium were either immediately frozen at 
20oC (hereafter, referred to as freshly collected oocyte lysate) or cultured for 18 h in 1.7 
mL microcentrifuge tubes at 37oC in 5% CO2. To help maintain sterility whilst ensuring 
gas exchange, the microcentrifuge tube was uncapped and the top was covered in a single 
layer of parafilm (Bemis flexible packaging, Neenah, WI, USA) that was punctured twice 
with a 20G needle. Following culture, the incubation medium was removed from the 
incubation tube containing the cultured oocytes and stored separately. This contains the 
BMP15 and GDF9 forms secreted by the oocytes.To keep storage conditions the same for 
all samples, 50 µL of fresh Medium D was added back to the cultured oocytes, containing 
BMP15 and GDF9 forms present in oocyte lysates following culture. Samples were stored 
at -20oC until analysed. Prior to freezing at -20oC, all samples had 2 µL of a 26x protease 
inhibitor cocktail (Appendix 5) added. In all instances, oocytes that were either frozen or 
placed in culture were done so within 5 hours of collecting ovaries from the abattoir.  
 
4.2.3 Antibody specificity 
The specificity of Western blot immunostaining was tested by using antibodies that had 
been pre-adsorbed with their respective antigens. For clone MN2-61A (anti-BMP15) and 
clone 37A (anti-GDF9), E. coli-derived mature ovine BMP15 and ovine GDF9 were used, 
respectively. On the day before use in Western blotting, a 20x antibody solution was 
incubated overnight at 4oC with 20x mass of the respective antigen (e.g. 10 g Clone 
MN2-61A was incubated with 200 g antigen). Immediately before use, the pre-adsorbed 
antibody was centrifuged at 6000 g for 5 min and the supernatant diluted 1:20 with 
blocking buffer prior to being incubated with the nitrocellulose membrane (see Section 
2.4.3). Western blots for the blocking studies had previously been used to identify the 
molecular forms of BMP15 or GDF9. These were chemically stripped of the previous 
antibodies used, prior to the Western blotting technique being repeated, using pre-adsorbed 
antibodies. Chemical stripping consisted of incubating the membrane for 30 min in 50 mL 
of 62.5 mM Tris-HCl containing 2% (w/v) sodium dodecyl sulphate and 0.75 M 2-
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mercaptoethanol, pH 6.7 at 50oC. At room temperature, the membrane was washed 
vigorously by manual shaking three times for 20 seconds, and then on a rocking platform 
(15o incline, 30rpm) three times for 10 min, replacing the low salt buffer after each wash 
step (Appendix 5). Thereafter, membranes were subjected to the previously described 
Western blotting procedure (see Section 2.3.3).  
 
4.2.4 Western blot band determination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Use of ImageJ to identify the presence of faint bands in Western blots. 
Density plots for each lane in the Western blot (using the same image as described in 
the Results section, see Figure 4.4A, upper image). Conditioned medium from 
HEK293 cells transfected with either ovine GDF9 (lane 1), wild-type ovine 
proregion/ovine mature BMP15 (o/oBMP15, lane 2), mutant human proregion/ovine 
mature (S356C) (h/oBMP15 (S356C), lane 3) lysates from freshly collected oocytes 
(lane 4), medium from incubated oocytes (lane 5) and lysates from incubated oocytes 
(lane 6). The area enclosed by the dashed lines enlarged (lower image) used to 
objectively define a peak from a faint band () 
 
It became apparent that some Western blots contained immunoreactive bands that were 
visible when viewed on a monitor screen, but on some occasions became less clear or 
barely visible when printed. This was despite attempts to maximise contrast and brightness 
of the images. Therefore, the freeware ImageJ (http://rsb.info.nih.gov/ij/index.html) was 
used to objectively identify and record the presence of these faint bands. The method used 
was that outlined by Miller (2010). Briefly, identical-sized areas were selected from each 
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lane of the Western blot. From these, a density plot was generated corresponding to the 
changing density along the length of each lane. The peaks within this plot corresponded to 
each band within the lane (Figure 4.1). 
 
4.3 Results 
4.3.1 Specificity of the monoclonal antibodies MN2-61A (anti BMP15) 
and 37A (anti GDF9) 
A B 
 
 
 
 
 
 
 
 
 
 
 
C D 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Immuno-blocking of monoclonal MN2-61A by E. coli-derived mature 
oBMP15. Western immunoblots under cross-linking/reducing conditions (A, B) and 
reducing conditions (C, D) showing the molecular forms of BMP15 produced and 
secreted by bovine oocytes and recombinant proteins. For A and C, lane 1 = 
o/oGDF9; lane 2 = wild-type ovine proregion/ovine mature BMP15 (o/oBMP15); lane 
3 = mutant human proregion/ovine mature (S356C) [h/oBMP15 (S356C)]; lane 4 = 
o/oBMP15 + o/oGDF9; lane 5 = h/oBMP15 (S356C) + o/oGDF9; lane 6 = bovine 
oocyte lysate at the start of incubation; lane 7 = oocyte lysate at the end of incubation; 
and lane 8 = medium in which oocytes were incubated and for B and D, the 
corresponding immunoblots where the BMP15 antibody (clone MN2-61A) was 
preabsorbed with E. coli-derived mature ovine BMP15. . Order of lanes for C and D 
were allocated so as to match lanes in A and B.Molecular sizes are shown to the left of 
the image (kDa).  
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As mentioned earlier, clones MN2-61A and 37A had previously been validated for use on 
ovine oocytes (Lin et al. 2012) but not for the bovine. The specificity of MN2-61A, using 
the Western blotting procedure, was tested by preadsorption of the antibody with an E. 
coli-derived, mature oBMP15. This was undertaken once under reducing (Figure 4.2A and 
B) and once under cross-linking/reducing conditions (Figure 4.2C and D). 
 
Likewise the specificity of clone 37A was established by preadsorption with an E. coli-
derived, mature GDF9 (Figure 4.3A and B). Generally, the immunostained bands were 
abolished by pre-incubation with the specific antigen. However, when the blots were 
incubated with pre-absorbed anti BMP15 (MN2-61A), some residual immunostaining was 
present in the mature band in Figure 4.2C, lane 5 (i.e. co-incubated BMP15 (S356C) and 
GDF9). Also, under reducing conditions, non-specific binding to a band within BMP15 
(S356C), larger than the promature band, was detected (Figure 4.2D, lane 3). 
A B 
 
 
 
 
 
 
 
 
 
Figure 4.3 Immuno-blocking of monoclonal 37A by E. coli-derived mature oGDF9. 
Western immunoblots under reducing conditions showing the molecular forms of 
BMP15 produced and secreted by bovine oocytes and recombinant proteins. For 
image A: Lane 1=o/oGDF9; Lane 2=o/oBMP15; Lane 3=h/oBMP15 (S356C); Lane 
4=bovine oocyte lysate, at the beginning of incubation; Lane 5=oocyte lysate at the 
end of incubation and; Lane 6=medium in which oocytes were incubated (incubation 
medium) Image B shows the corresponding immunoblots where the GDF9 antibody 
(clone 37A) was preabsorbed with E. coli-derived mature ovine GDF9. Molecular 
sizes are shown to the left of the image (kDa). 
 
Residual immunostaiinng was also detected when blots were reprobed with pre-absorbed 
anti GDF9 (clone 37A) within the mature band of recombinant oGDF9. Nevertheless, all 
forms of BMP15 and GDF9 that were secreted and/or produced by bovine oocytes were 
abolished by pre-incubation with the specific antigens for each antibody.  
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Table 4.1: Frequency of immuno-reactive BMP15 Western blot (WB) bands of 
varying molecular sizes in oocyte lysates and incubation medium under non-reducing, 
reducing and cross-linking conditions. Brackets [ ] refer to the number of samples 
where band was observed/total number of samples]. 
WB 
condition 
Molecular 
form 
COC lysate 
Freshly 
collected 
COC lysate 
Post incubation 
Oocyte 
incubation 
medium 
Bovine Ovine Bovine Ovine Bovine Ovine 
N
o
n
-r
ed
u
ci
n
g
 
>100 kDa [3/3] [3/3] [3/3] [3/3] [3/3] [2/3] 
Promature [0/3] [0/3] [0/3] [0/3] [0/3] [0/3] 
~40 kDa [3/3] [3/3] [2/3] [3/3] [0/3] [1/3] 
mature 
monomer 
[0/3] [2/3] [0/3] [1/3] [0/3] [0/3] 
R
ed
u
ci
n
g
 
>100 kDa [0/3] [1/3] [1/4] [0/3] [0/4] [0/3] 
Promature [3/3] [3/3] [4/4] [3/3] [4/4] [1/3] 
~40 kDa [0/3] [1/3] [0/4] [1/3] [0/4] [0/3] 
mature 
monomer 
[2/3] [2/3] [2/4] [3/3] [2/4] [0/3] 
C
ro
ss
-l
in
k
ed
 
>100 kDa [3/3] [3/3] [2/3] [3/3] [3/3] [2/3] 
Promature [3/3] [3/3] [3/3] [3/3] [3/3] [1/3] 
~40 kDa [1/3] [2/3] [0/3] [2/3] [0/3] [0/3] 
mature 
monomer 
[2/3] [3/3] [3/3] [3/3] [3/3] [1/3] 
 
4.3.2 Molecular forms of BMP15 produced by ovine and bovine oocytes 
Under non-reducing conditions, the only immuno-reactive BMP15 form that was 
consistently detected in all replicate experiments from both bovine (Figure 4.4A) and ovine 
(Figure 4.4B) oocytes was a form(s) present at the >100 kDa band size. Thus, the 
molecular forms of BMP15 secreted from bovine and ovine oocytes were predominately 
detected as high molecular sized bands (Figure 4.4A & B, Lane 5; Table 4.1). However, in 
one ovine replicate, an additional band of ~40 kDa was observed in secreted media (Figure 
4.4B, Lane 5). This ~40 kDa band was also observed in all oocyte lystaes from freshly 
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Mature monomer
Mature dimer
Promature
1      2     3     4             5              6
6
17
34
48
73
115
202
1      2     3     4     6             5   
collected oocytes and in three out of three (ovine), and two out of three (bovine) oocyte 
lysates collected from oocytes following culture for 18 h. An additional band of 15 kDa, 
corresponding to the mature BMP15 monomer was observed in two out three freshly-
collected ovine oocyte lysates (data not shown), and in one out of three ovine oocyte lysate 
samples following an 18 hr incubation (Figure 4.4B, Lane 6), but was not observed in any 
bovine oocyte lysate samples. 
 
A B 
 
 
 
 
 
 
  
Figure 4.4 Western immunoblots under non-reducing conditions showing the 
molecular forms of BMP15 in lysates and incubation medium of (A) bovine and (B) 
ovine oocytes. The blots depict bands from conditioned medium from HEK293 cells 
transfected with either: ovine GDF9 (Lane 1); o/oBMP15 (Lane 2); or h/oBMP15 
(S356C) (Lane 3); as well as lysates from freshly collected oocytes (Lane 4), medium 
from incubated oocytes (Lane 5) and lysates from incubated oocytes (Lane 6). 
Molecular sizes are shown to the left of the image (kDa). 
 
Under reducing conditions, the predominant form of immunoreactive BMP15 produced by 
both ovine and bovine oocytes was in bands corresponding to the unprocessed promature 
form. A small amount of this unprocessed promature form had been cleaved to release the 
mature monomer. The 40 kDa band was still observed although not consistently and only 
within pools of freshly-collected or incubated ovine oocyte lysates (Figures 4.5B. Lane 5 
and Figure 4.5C, Lane4). Only one out of three replicates under reducing conditions 
detected a BMP15 form in secreted media from ovine oocytes, which was the uncleaved 
promature form (Figure 4.5C, Lane 6). In contrast, the uncleaved promature form was 
consistently observed in secretions from bovine oocytes, and the mature monomer was also 
identified in two out of four replicates (Figure 4.5A). 
  
67 
6
17
34
48
73
27
115
202
111111111111111111111
1111111111111111111111111
1     2     3           4        5            6   2    3   1    9      8      6       5      7   
Mature monomer
Mature dimer
Promature
111111111111111111111
1           4            6          5   
6
17
34
48
73
27
115
202
Mature monomer
Promature
A B 
 
 
 
 
 
 
 C 
 
 
 
 
 
Figure 4.5 Western immunoblots under reducing conditions showing the molecular 
forms of BMP15 in lysates and incubation medium of (A) bovine and (B, C) ovine 
oocytes. The blots depict bands from conditioned medium from HEK293 cells 
transfected with either: ovine GDF9 (Lane 1); o/oBMP15 (Lane 2); or h/oBMP15 
(S356C) (Lane 3); as well as lysates from freshly collected oocytes (Lane 4), lysates 
from incubated oocytes (Lane 5), medium from incubated oocytes (Lane 6), lysates 
from incubated oocytes devoid of cumulus cells (naked oocytes) (Lane 7), medium 
from incubated naked oocytes (Lane 8), lysates from freshly collected cumulus cell-
oocyte complexes (COCs) (Lane 9). Molecular sizes are shown to the left of the images 
(kDa). 
 
Note: The use of “oocytes” in lanes 4, 5 and 6 refers to a mix of both naked oocytes 
and COCs as mentioned in Section 4.2.2. 
To determine if forms of BMP15 were being bound within the ECM of cumulus oocyte 
complexes (COCs), a comparison was made between secretions in incubation medium that 
had cultured oocytes with cumulus cells still intact (COCs) and oocytes devoid of cumulus 
cells (naked oocytes) (Figure 4.5A). However, no discernible differences were observed 
between the lysates from incubated COCs and naked oocytes (Figure 4.5A; Lanes 10 and 
7, respectively) or between the secreted forms detected in the medium following 
incubation of COCs and naked oocytes (Figure 4.5A; Lanes 11 and 8 respectively). 
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Figure 4.6  Western immunoblots under reducing conditions showing the molecular 
forms of BMP15 in cross-linked samples of lysates and incubation medium of (A) 
bovine and (B) ovine oocytes. The blots depict bands from conditioned medium from 
HEK293 cells transfected with either: ovine GDF9 (Lane 1); o/oBMP15 (Lane 2); 
h/oBMP15 (S356C) (Lane 3); co-incubated h/oBMP15 (S356C) and oGDF9 (Lane 4); 
or co-incubated o/oBMP15 and oGDF9 (Lane 5), as well as lysates from freshly 
collected oocytes (Lane 6), lysates from incubated oocytes (Lane 7) and medium from 
incubated oocytes (Lane 8). Molecular sizes are shown to the left of the image (kDa). 
 
The cross-linking of proteins prior to their addition on a reducing gel revealed a similar 
pattern to that observed in non-cross-linked samples. Generally, for both the bovine and 
ovine oocyte lysates, BMP15 was located within bands corresponding to the promature and 
free mature monomer forms, with the ~40 kDa band being present in some, but not all, 
oocyte lysates (Figures 4.6A, 4.6B and 4.7A, Lanes 6 and 7). In one instance, the lysate 
from freshly collected bovine oocytes contained additional bands immediately above and 
below the promature band and did not contain any mature monomer (Figure 4.6A, Lane 6). 
Also present in this gel were high molecular weight complexes in both the bovine oocyte 
lysates and incubation media (Figure 4.6A, Lanes 6 - 8). The size of these bands appears 
lower than that found in other bovine replicates or in ovine samples, perhaps indicating 
incomplete cross-linking. Mature, promature and high molecular weight forms, were 
consistently observed secreted by bovine oocytes (Figure 4.6A, Lane 8). Secreted BMP15 
from ovine oocytes was present in much lower quantities than that observed in bovine. In 
one replicate no discernible forms were detected. High molecular weight complexes were 
observed in two of the three replicates (Figure 4.6B and 4.7A, Lane 8). Also, in only one 
out of three replicates of medium following incubation of ovine oocytes, a band 
corresponding to the promature and mature monomer was detected (Figure 4.7A & B, 
Lane 8).  
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Figure 4.7 Western immunoblots under reducing conditions showing the molecular 
forms of BMP15 in cross-linked samples of lysates and incubation medium of (A, B) 
ovine oocytes. (A) The blots depict bands from conditioned medium from HEK293 
cells transfected with either: ovine GDF9 (Lane 1); o/oBMP15 (Lane 2); h/oBMP15 
(S356C) (Lane 3); co-incubated o/oBMP15 and oGDF9 (Lane 4); or co-incubated 
h/oBMP15 (S356C) and oGDF9 (Lane 5), as well as lysates from freshly collected 
oocytes (Lane 6), lysates from incubated oocytes (Lane 7) and medium from 
incubated oocytes (Lane 8). Molecular sizes are shown to the left of the image (kDa). 
(B) Density plots of aforementioned lanes in (A). The faint bands in Lane 8 at high 
molecular sizes and those corresponding to promature and mature domains are 
indicated (    ). 
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4.3.3 Molecular forms of recombinant oBMP15 secreted by HEK-293 cells 
Under non-reducing conditions, wild-type oBMP15 (o/oBMP15) was present mainly as 
high molecular size forms >100 kDa (Figures 4.4A and 4.4B, Lane 2). The cysteine mutant 
form [h/oBMP15 (S356C)] was present as high molecular weight forms as well as with 
molecular weight bands corresponding to promature forms and dimeric mature growth 
factor domains, and on one occasion, a faint band corresponding to the mature monomer 
was also observed (Figures 4.4A and 4.4B, Lane 3). Under reducing conditions (both with 
and without cross-linking), wild-type o/oBMP15 was present as promature and mature 
growth factor domains, (Figures 4.5A, 4.5B, 4.5C, 4.6A, 4.6B, Lane 2). In contrast, 
h/oBMP15 (S356C) was found predominantly in bands corresponding to the promature, 
mature dimer and mature monomer domains along with some higher molecular weight 
forms (Figures 4.5A, 4.5B, 4.6A, 4.6B, Lane 3). With cross-linking, an additional band of 
~17 kDa was observed just above the mature monomer in h/oBMP15 (S356C). Also with 
cross-linking, a greater proportion of o/oBMP15 as well as the h/oBMP15 (S356C) 
proteins were in the promature form. Cross-linking of h/oBMP15 (S356C) or o/oBMP15, 
in either the presence (Figures 4.6A and B, Lanes 4 and 5, respectively) or absence 
(Figures 4.6A and B, Lanes 3 and 2 respectively) of o/oGDF9 did not change the position 
of the pro-mature, mature dimer or mature dimer bands although more material appeared to 
be incorporated in the high molecular weight bands of h/oBMP15 (S356C). 
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Table 4.2 Frequency of immuno-reactive GDF9 bands of varying molecular sizes in 
oocyte lysates and incubation media under non-reducing, reducing and cross-linking 
conditions. Brackets [  ] refer to the number of samples where a band was observed 
/total number of samples]. 
WB 
condition 
Size (kDa) 
COC lysate 
Freshly 
collected 
COC lysate 
Post incubation 
Incubation 
medium 
Bovine Ovine Bovine Ovine Bovine Ovine 
N
o
n
-r
ed
u
ci
n
g
 
>100 kDa [2/3] [3/3] [2/3] [3/3] [3/3] [2/3] 
promature [3/3] [3/3] [3/3] [3/3] [1/3] [2/3] 
mature 
monomer 
[3/3] [3/3] [2/3] [3/3] [1/3] [3/3] 
6-10 kDa [3/3] [3/3] [2/3] [3/3] [1/3] [0/3] 
R
ed
u
ci
n
g
 
>100 kDa [0/3] [0/3] [0/4] [0/3] [0/4] [0/3] 
promature [3/3] [3/3] [4/4] [3/3] [4/4] [1/3] 
mature 
monomer 
[3/3] [3/3] [3/4] [3/3] [1/4] [2/3] 
6-10 kDa [3/3] [3/3] [3/4] [3/3] [1/4] [2/3] 
C
ro
ss
-l
in
k
ed
 
>100 kDa [2/3] [2/3] [2/3] [2/3] [2/3] [2/3] 
promature [3/3] [3/3] [3/3] [3/3] [2/3] [2/3] 
mature 
monomer 
[2/3] [3/3] [1/3] [2/3] [0/3] [2/3] 
6-10 kDa [2/3] [3/3] [2/3] [2/3] [0/3] [1/3] 
 
4.3.4 Molecular forms of GDF9 produced by ovine and bovine oocytes. 
Under non-reducing conditions, the forms of immuno-reactive GDF9 present in lysates 
from both freshly-collected and incubated bovine and ovine oocytes were at molecular 
sizes corresponding to the promature and mature monomer domains, as well as in bands of 
higher and lower (6-10 kDa) molecular sizes (Figures 4.8A and B, Lanes 4 and 5). 
Secreted forms of GDF9 from bovine oocytes were consistently observed in high 
molecular weight complexes (Figures 4.8A, Lanes 6a, 6b & 6c). However, in one replicate, 
secreted bovine GDF9 was also found as promature and fully processed mature monomers 
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(Figures 4.8A & C, Lanes 6a). Secreted forms of GDF9 from ovine oocytes were 
consistently found as fully processed mature monomers and in two replicates were also 
observed in high molecular size bands (>100 kDa) as well as a band corresponding to the 
promature domain (Figures 4.8B, Lane 6). 
 
A B 
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Figure 4.8 Western immunoblots under non-reducing conditions showing the 
molecular forms of GDF9 in lysates and incubation medium of (A) bovine and (B) 
ovine oocytes. The blots depict bands from conditioned medium from HEK293 cells 
transfected with either: ovine GDF9 (Lane 1); o/oBMP15 (Lane 2); or h/oBMP15 
(S356C) (Lane 3); as well as lysates from freshly collected oocytes (Lane 4), lysates 
from incubated oocytes (Lane 5), medium from incubated oocytes (Lane 6 or 6a; and 
replicate Western blots, Lanes 6b and 6c). (C) Density plots of lanes 5 and 6a. Lane 5 
shown to aid orientation relative to (A). The faint bands in Lane 6a at high molecular 
weights and those corresponding to promature and mature domains are indicated  
(   ). Molecular sizes are shown to the left of the image (kDa). 
 
Under reducing conditions, the predominant forms of immunoreactive GDF9 produced by 
both bovine (Figure 4.9A) and ovine (Figure 4.9B) oocytes was in unprocessed promature 
and mature monomer forms, as well as an uncharacterised band at 6-10 kDa. Both bovine 
and ovine oocytes secreted all three of these forms. Bovine oocytes secreted an 
unprocessed promature form consistently and in one out of four replicates a mature form 
was also observed. However, in ovine, the promature form was only observed in one out of 
three replicates and the mature form in two out of three replicates. 
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Figure 4.9 Western immunoblots under reducing conditions showing the molecular 
forms of GDF9 in lysates and incubation medium of (A) bovine and (B) ovine oocytes. 
The figures show conditioned medium from HEK293 cells transfected with either: 
ovine GDF9 in (Lane 1); o/oBMP15 in (Lane 2); and h/oBMP15 (S356C) (Lane 3); 
and in lysates from freshly collected oocytes (Lane 4), lysates from incubated oocytes 
(Lane 5), and medium from incubated oocytes (Lane 6). Molecular sizes are shown to 
the left of the image (kDa). 
 
The oocyte lysates and incubation medium subjected to cross-linking prior to their addition 
on a Western gel under reducing conditions resulted in more immunoreactive GDF9 being 
retained within the high molecular weight bands, compared to that in the non cross-linked 
samples. Oocyte lysates, both before (Figure 4.10A and 4.10B, Lane 6) and after (Figure 
4.10A and 4.10B, Lane 7) incubation showed GDF9 was present in a promature form and 
in high molecular weight complexes. Although not found in all replicate samples, the 
mature monomer form was also detected in oocyte lysates of both species before (Figure 
4.10A and B, Lane 6) and after incubation (Figure 4.10B, Lane 7; not shown in the 
representative blot from bovine oocytes). Mature monomers in ovine and bovine oocyte 
lysates, before culture were detected in three out of three and two out of three replicates, 
respectively. Following culture, mature monomers were detected in two out of three, and 
one out of three, ovine and bovine oocyte lysates, respectively. High molecular weight 
complexes were consistently detected secreted into media during the incubation period 
(Figure 4.10A, B & C, Lane 8). However, for both ovine and bovine oocytes, promature 
forms were detected secreted into media in two of the three replicates. Mature monomers 
were only detected secreted into the incubation media in two out of three ovine replicates 
but were not detected in media in which bovine oocytes were cultured. 
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Figure 4.10 Western immunoblots under reducing conditions showing the 
molecular forms of GDF9 in cross-linked samples of lysates and incubation medium 
of (A) bovine and (B) ovine oocytes. The figures show the results from conditioned 
medium from HEK293 cells transfected with either: ovine GDF9 (Lane 1); o/oBMP15 
(Lane 2); h/oBMP15 (S356C) (Lane 3); co-incubated h/oBMP15 (S356C) and oGDF9 
(Lane 4a and 4b); and co-incubated o/oBMP15 and oGDF9 (Lane 5a and 5b); as well 
as lysates from freshly collected oocytes (Lane 6); lysates from incubated oocytes 
(Lane 7); and medium from incubated oocytes (Lane 8). Lanes 1-5a (A; from a 
different Western blot than that for lanes 4b – 8) were included to better illustrate the 
effect of cross-linking on recombinant proteins. Molecular sizes are shown to the left 
of the image (kDa). (C) Density plots of Lanes 6, 7 and 8. Lane 6 shown to aid 
orientation relative to (A). The faint bands in Lane 8 at high molecular sizes and 
those corresponding to promature domains are indicated (    ). 
 
4.3.5 Molecular forms of recombinant oGDF9 secreted by HEK-293 cells 
Bands corresponding to the pro-mature and mature monomeric forms of GDF9 as well as 
bands of 6-10 kDa were present under all conditions tested, non-reducing (Figure 4.8A and 
B, lane 1), reducing (Figure 4.9A and B, lane 1) and cross-linking/reducing (Figure 4.10A 
and B, lane 1). A mature dimeric form of GDF9 was only observed under non-reducing 
(Figure 4.8A and B, lane 1) and cross-linking/reducing (Figure 4.10A and B, lane 1) 
conditions. Bands of molecular sizes greater than that of the pro-mature domain were not 
observed under reducing conditions (Figure 4.9A and B, lane 1), however they were 
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present under both non-reducing and cross-linking/reducing conditions (Figures 4.8A and 
B and 4.10B, lane 1). Moreover, under cross-linking/reducing conditions, there was a 
larger number of bands which comprised a greater proportion of the total immunoreactive 
GDF9 found in these high molecular weight bands. Cross-linking of oGDF9 in either the 
presence (Figures 4.10A and B, lanes 4b and 5b respectively) or absence of h/oBMP15 
(S356C) or o/oBMP15 (Figures 4.10A and B, lane 1) did not change the position of the 
pro-mature, mature dimer or mature monomer bands of oGDF9.  
 
4.4 Discussion 
As mentioned elsewhere the anti-BMP15 monoclonal antibody (clone KM2-61A) used in 
this study binds to residues within the sequence SEVPGPSREHDGPES (McNatty et al. 
2005a). This sequence is located in a highly flexible area at the N terminal end of the 
mature growth factor domain. This flexibility has resulted in a failure to successfully 
model this region of the mature growth factor domain for any member of the TGFB family. 
 
However a three-dimensional structure model of BMP15 using promature TGFB as a 
template (Figure 5.6A), predicts this region is exposed on the surface of the protein and 
would be expected to be freely available to mab MN2-61A (Figure 4.11A). Furthermore, 
this region is adjacent to the furin-like proprotein convertase cleavage site, RXXR, an area 
that would need to be available to such an enzyme. These theoretical expectations were 
confirmed for recombinant BMP15 by the Western blotting results presented in Chapter 3. 
These results showed the ability of MN2-61A to recognise both promature and mature 
BMP15 both in the monomeric and dimeric forms, under both reducing and non-reducing 
conditions. The blocking experiments with E. coli-derived BMP15 provided evidence for 
the specificity of this antibody for bovine oocytes (Figure 4.1). The anti GDF9 monoclonal 
antibody (clone 37A) was raised against E. coli-derived ovine mature GDF9 and was 
subsequently screened and subcloned for its ability to recognise a N-terminal peptide 
sequence (Dr K. P. McNatty, personal communication). Blocking of immunostaining by 
preincubating clone 37A with excess E. coli-derived oGDF9 mature domains (Figures 
4.3A & B) confirmed the specificity of immunostaining to the bands within Western blots 
(both of recombinant GDF9 and that produced and secreted by bovine oocytes) 
corresponding to both the promature and mature forms. Importantly, antibodies raised to 
any of three overlapping sequences covering the 34-amino acid length of the N-terminal 
end of ovine GDF9 or the sequence against which mab MN2-61A recognises, have been 
shown to block, or largely inhibit the biological activities of GDF9 or BMP15 in vivo 
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(McNatty et al. 2007). However, it was not determined whether this was due to blocking 
the action of either pro-mature or mature forms or both. 
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Figure 4.11 Location of antibody binding sites. 
Homology models of (A) dimeric promature ovine BMP15 and (B) dimeric promature 
ovine GDF9. Proregion depicted in blue and mature growth factor domain in cyan, 
with sequences, within which the epitope recognised by (A) clone MN2-61A or (B) 
clone 37A are located, is shown in orange. The dimer partner is shown as proregion 
(red) and mature domain (pink). 
 
Under non-reducing conditions, the majority of immunoreactive BMP15 resides within 
bands of >100 kDa. One of these bands corresponds in size to what may represent  a dimer 
of promature BMP15 (110-115 kDa) and was observed in the recombinant proteins 
o/oBMP15 and h/oBMP15 (S356C), as well as in those proteins produced and secreted by 
both bovine and ovine oocytes (Figure 4.4A & B). Under reducing conditions, these high 
molecular weight complexes resolve into promature and mature growth factor domains 
(Figures 4.5A & B and 4.6A & B). Interestingly, cross-linking of proteins prior to their 
electrophoresis under reducing conditions (Figure 4.6A & B), failed to show the same high 
molecular weight band(s) that were observed under non-reducing conditions (Figure 4.4A 
& B). The cross-linker chemical used in this study (bis(sulfosuccinimidyl)suberate) links 
proteins by stable amide bonds between primary amines. This might potentially disrupt the 
antigenic site recognised by clone MN2-61A (located near the N-terminal end of mature 
BMP15). However, bands of high molecular weight and those corresponding to the 
promature and mature forms of BMP15 were observed. These high molecular weight 
bands (different from that seen under non-reducing conditions) suggest these complexes 
may contain proteins other than just the promature and mature domains, one likely 
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candidate protein is free prodomains (Edwards et al. 2008), and/or that some forms of 
BMP15 are aggregating into high molecular weight complexes. 
 
A ~40 kDa band which was intermediate in size to the pro-mature and the dimeric mature 
form of BMP15 (S356C) was observed in some, but not all, oocyte lysates and was only 
observed once in incubation medium. There was no consistent pattern that might explain 
the appearance of this band. It was observed in both bovine and ovine oocyte lysates and in 
lysates from both freshly-collected and cultured oocytes. If this band was correlated with 
the health status of follicles, then the way in which these pools of oocytes were collected 
may provide a potential explanation. Oocytes were retrieved from antral follicles without 
the health of these follicles first being accessed. As such, the proportion of oocytes from 
healthy follicles will vary between pools.  
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Figure 4.12 Location of ~40 kDa band relative to homodimers of BMP15 and 
GDF9. 
Western immunoblots under reducing conditions showing the molecular forms of (A) 
BMP15 and (B) GDF9 following cross-linking. In image A, the Western blot for 
GDF9 was stripped before being re-probed for BMP15 Lane 1 = co-incubated 
h/oBMP15 (S356C) and oGDF9, lane 2 = co-incubated o/oBMP15 and oGDF9, lane 3 
= lysate from freshly collected oocytes. Molecular sizes are shown to the left of the 
image (kDa). 
 
It is worth noting that the ~40 kDa band was located between the sizes of dimeric mature 
BMP15 and dimeric mature GDF9 (Figure 4.12A & B) which may be evidence for a 
heterodimer of BMP15 and GDF9. However, this band was only seen when immuno-
stained for BMP15 and never when immuno-stained for GDF9. Although the ability of 
clone MN2-61A and clone 37A to detect heterodimers of BMP15 and GDF9 has not been 
established, both MN2-61A and 37A are capable of detecting mature homodimers of 
BMP15 (Figure 4.12A, Lane 1) and GDF9 (Figure 4.12B, Lanes 1 & 2), respectively. 
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Further evidence against this band being a heterodimer is its continued presence under 
reducing conditions (Figure 4.5B, Lane 5). Alternatively, this band may be the result of 
cleavage of the promature BMP15 at an alternative site to the one that releases the mature 
domain. There are three potential furin-like (RXXR) sites that are conserved between 
bovine and ovine BMP15. In ovine BMP15, these cleavage sites are located at amino acid 
positions 57-60 (RKPR), 84-87 (RENR) and 95-98 (RLVR). Cleavage at these sites would 
result in theoretical molecular sizes of 38.1, 34.9 and 33.7 kDa, respectively, which may be 
further modified by post-translational processing. Such translational modifications have 
previously been reported for human BMP15 (Saito et al. 2008). 
 
Under reducing conditions, the forms of BMP15 detected in expression media from 
transfected HEK293 cells were mainly mature monomers along with an uncleaved 
promature form. Likewise, the forms of BMP15 secreted by bovine oocytes were also 
consistently observed in bands corresponding to both promature and mature forms. The 
amount of BMP15 secreted by ovine oocytes often proved to be at levels close to, or 
below, the detection limit of the Western blot protocol used in this study. However, both 
the promature and the mature forms were detected in at least one replicate (Table 4.1). 
Lysates from both bovine and ovine oocytes contained a large amount of promature, and a 
lesser amount of mature, domains (Figures 4.5A & B). Therefore, it would seem that 
ruminant oocytes both produce and secrete promature BMP15 largely in an uncleaved form 
together with some mature domains. These mature growth factor monomers were almost 
entirely located within high molecular weight multimeric complexes (Figure 4.5A & B), 
which are also likely to contain the prodomain (Edwards et al. 2008). Likewise, mBMP15 
was also found in expression media in both mature monomer and promature forms (Otsuka 
et al. 2000). When the normally conserved cysteine (involved in dimer formation) was re-
introduced to either human (Pulkki et al. 2012) or ovine BMP15 (Figures 4.4A & B, Lane 
3; 4.6A & B, Lane 3), dimeric mature growth factor forms were produced. However, no 
bands corresponding to mature dimers were observed for recombinant wild-type 
o/oBMP15 or among the proteins secreted and/or produced by either bovine or ovine 
oocytes (Figure 4.6A & B). However forms of mature hBMP15, with either a N-terminal 
FLAG tag (Liao et al. 2004, Hashimoto et al. 2005) or a N-terminal MycHis tag (Rossetti 
et al. 2009), have been shown to include mature growth factor dimers. Likewise, highly 
purified recombinant hBMP15, under cross-linking conditions, has also been reported to 
exist as mature dimers (Pulkki et al. 2012). 
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Recombinant oGDF9 expressed from HEK293 cells and GDF9 produced and secreted by 
bovine and ovine oocytes was found in high molecular size complexes (Figure 4.7A & B). 
These complexes may include dimeric promature forms and also uncleaved promature and 
mature domains (Figure 4.8A & B). A low molecular size protein band of 6-10 kDa was 
produced by recombinant oGDF9 expressing HEK293 cells and by both bovine and ovine 
oocytes (Table 4.2). However, (Lin et al. 2012) who also used an antibody raised against a 
near N terminal sequence of ovine GDF9, did not report the presence of this band in 
Western blotting using either recombinant mGDF9 or lysed rat oocytes. This protein band 
is likely the result of either a cross-reacting protein or a breakdown product of GDF9 and is 
possibly species-specific. In contrast to oBMP15, both monomeric and dimeric mature 
forms of recombinant oGDF9 were detected under cross-linking conditions: this finding is 
in agreement with McIntosh et al. (2008). Interestingly, under the same conditions, no such 
dimers were detected in GDF9 produced or secreted by either bovine or ovine oocytes 
(Figures 4.9A & B). This may be a consequence of differences in protein folding and/or 
post-translational modifications by HEK293 cells and by oocytes. Furthermore, cross-
linking experiments with oBMP15 and oGDF9 failed to show the presence of either 
dimeric mature BMP15 or heterodimeric GDF9/BMP15 however dimeric mature GDF9 
was observed (Figures 4.6A & B, 4.9A & B, 4.11 A & B; Edwards et al. 2008). It would 
appear that while ovine and bovine BMP15 mature growth factor monomers may be 
capable of forming dimers, probably during synthesis and secretion, the wild-type BMP15 
is unable to maintain these dimeric forms (Edwards et al. 2008). Moreover, using the same 
antibodies as used in the present study, (McNatty et al. 2006) reported that ovine oocytes 
secrete uncleaved promature BMP15 and uncleaved promature GDF9 into the follicular 
fluid. Likewise, the detection of both promature and mature domains of BMP15 and GDF9 
has been detected in bovine follicular fluid (Behrouzi et al. 2016), with the mature domains 
detected at 25 kDa. These in vivo results are in agreement with the present study. 
 
These results establish that under in vitro conditions, BMP15 and GDF9 are produced and 
secreted by both bovine and ovine oocytes. Moreover, the results show that BMP15 and 
GDF9 are present in high molecular weight complexes composed of promature and mature 
domains, and that these mature domains do not interact to form homo- or hetero-dimers 
that were detectable using Western blotting. 
  
80 
  
81 
CHAPTER 5: IN SILICO MODELLING OF BMP15 AND GDF9 AND THEIR 
INTERACTIONS WITH CELL SURFACE RECEPTORS 
 
5.1 Introduction 
Generally TGFB superfamily members are thought to signal via a cell-surface receptor-
ligand complex following the binding of mature growth factor domain dimers to two type 
I, and two type II, receptors. This in turn leads to the phosphorylation of receptor regulated 
Smads (Sections 1.3.3 and 1.3.4). However, as mentioned previously (Section 4.1), 
BMP15 and GDF9 belong to a small sub-family of TGFB proteins unable to form a 
disulphide bridge between monomers and thus are unable to form stable dimers of the 
mature growth factor domains. As discussed in Chapter 4, the molecular forms of BMP15 
and GDF9 produced and secreted (Table 5.1) by ovine and bovine oocytes were identified, 
as were the recombinant forms secreted by mammalian cells. These results support 
published evidence (McNatty et al. 2006; McIntosh et al. 2008; Lin et al. 2012) that 
suggests that both BMP15 and GDF9 are secreted in a partially unprocessed form as both 
cleaved and/or uncleaved promature proteins along with some mature growth factor 
domain. Other studies have reported a dimeric form of mature ovine and mouse GDF9 in 
vitro (Edwards et al. 2008; McIntosh et al. 2008). Results from Chapter 4 also reports the 
presence of recombinant GDF9 dimers (Figure 4.8 and 4.10) but not oocyte-secreted GDF9 
dimers (Table 5.1). Currently however, only promature forms of both BMP15 and GDF9 
have been identified in vivo (McNatty et al. 2006). Table 5.1 below provides a summary of 
the native ovine and bovine molecular forms of GDF9 and BMP15 that have been detected 
to date. 
 
Notwithstanding the synergistic effects of BMP15 and GDF9 reported in both in vivo (Yan 
et al. 2001; Hanrahan et al. 2004) and in vitro (McNatty et al. 2005a,b; Edwards et al. 
2008; McIntosh et al. 2008; Reader et al. 2011; Mottershead et al. 2012) studies, there is 
some debate as to whether BMP15-GDF9 heterodimers exist in vivo (Mottershead et al. 
2013; Peng et al. 2013a,b). Nevertheless, a biologically-active recombinant heterodimer of 
BMP15 and GDF9, termed cumulin, has been produced by transfection of mammalian 
cells with both BMP15 and GDF9 in which the cysteine residue involved in 
heterodimerisation in other TGFB members has been re-introduced (Mottershead et al. 
2015). However, the mechanism(s) to explain how BMP15 co-operates with GDF9 and/or 
with its receptors to regulate somatic cell responses has proven elusive. The aim of this 
study was to: (i) use protein modelling techniques to visualise the various molecular forms 
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of BMP15 and GDF9 and; (ii) utilise these models, in conjunction with the known forms 
secreted by oocytes (Table 5.1) and published information, to provide a hypothetical model 
of how oocyte-secreted forms of BMP15, GDF9 and their cell surface receptors interact.  
 
Table 5.1 Summary of BMP15 and GDF9 molecular forms secreted by ovine and 
bovine oocytes 
Growth 
factor 
Molecular form 
Western blot conditions 
Non-reducing Reducing Cross-linking 
Ovine Bovine Ovine Bovine Ovine Bovine 
BMP15 
High MW 
complexes 
  ND ND   
Promature ND ND     
Mature dimer ND ND ND ND ND ND 
Mature monomer ND ND  ND   
GDF9 
High MW 
complexes 
  ND ND   
Promature  ND     
Mature dimer ND ND ND ND ND ND 
Mature monomer     ND  
Present (), not detected (ND). 
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5.2 Methods 
5.2.1 Amino acid hydrophobicity 
Amino acids were allocated a hydrophobicity score as determined by Kyte and Doolittle 
(1982). For the purposes of this study, the truly hydrophobic amino acids, (I, V, L, F, C, M 
and W) and the less hydrophobic or indifferent amino acids (A, Y, T, S, P, and G) which 
have a hydrophobicity score of >-2.0 were defined as being hydrophobic while those 
amino acids with a hydrophobicity score of <-2.0 (H, E, Q, D, N, K and R) were defined as 
hydrophilic (Table 5.2). 
 
Table 5.2 Amino acid names, codes and hydrophobicity scores 
Amino acid 
Hydrophobicity 
score 
Hydrophobic (H) 
Hydrophilic (Y) 
Full name  
3 letter 
Code 
1 letter 
Code 
Isoleucine Ile I 4.5 H 
Valine 
 
 
Valine 
Val V 4.2 H 
Leucine Leu L 3.8 H 
Phenylalanine Phe F 2.8 H 
Cysteine Cys C 2.5 H 
Methionine Met M 1.9 H 
Alanine Ala A 1.8 H 
Glycine Gly G -0.4 H 
Threonine Thr T -0.7 H 
Serine Ser S -0.8 H 
Tryptophan Trp W -0.9 H 
Tyrosine Tyr Y -1.3 H 
Proline Pro P -1.6 H 
Histidine His H -3.2 Y 
Glutamate Glu E -3.5 Y 
Glutamine Gln Q -3.5 Y 
Aspartate Asp D -3.5 Y 
Asparagine Asn N -3.5 Y 
Lysine Lys K -3.9 Y 
Arginine Arg R -4.5 Y 
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5.2.2 Molecular modelling 
Two methods were utilized to generate three-dimensional structural models of promature 
BMP15 and GDF9. The protein homology/anologY recognition engine v2 (Phyre2) (Kelley 
& Sternberg 2009) was used to create models of oBMP15 (Figure 6.6A) and oGDF9 
(Figure 6.6B). Using the Protein Data Bank (www.pdb.org), the pTGFB1 (Accession 
number 3RJR; (Shi et al. 2011b) and GDF5-BMPR1B complex (Accession number 3EVS; 
(Kotzsch et al. 2009) were used as templates for the promature and receptor-bound forms, 
respectively. Additionally, a manual approach was used to model both oBMP15 and 
oGDF9. Sequence alignments for ovine promature BMP15 and GDF9 with mouse BMP9 
were prepared using the software CRUSTALW (Thompson et al. 1994). Utilizing the 
software package Quanta2008 (MIS Accelrys, San Diego, CA), amino acids were then 
replaced manually in the mBMP9 template (Accession number 4YCG; (Mi et al. 2015) to 
build models of promature oBMP15 and oGDF9. The models were then modified where 
necessary, by assigning rotomer positions, such that side chain proximities did not produce 
van der Waals interference. Subsequently, energy minimisations were run to determine the 
lowest energy conformation. Initial energy minimisations were run with the backbone 
atoms being fixed in place and where only side chain atoms were allowed to move. 
 
The UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-
01081; Pettersen et al. 2004) was used to produce molecular graphics images and to create 
models of the hetero-oligomeric signalling complexes comprised of BMP15 or GDF9 
dimers and their receptors. To visualise the positions of both type I and type II receptors 
relative to a dimer of pro-mature oBMP15 or oGDF9, a composite template was created. 
The BMP2 dimer-BMPR1A complex (Accession number 1ES7; Kirsch et al. 2000b) gave 
a base template for positioning the mature growth factor domains into a dimer. Aligning 
BMP2 associated with both BMPR1A and ACTRII (Accession number 2GOO; 
(Allendorph et al. 2006) with each of the BMP2 mature monomers present in 1ES7 
enabled visualisation of the positioning of two type I, and two type II, receptors relative to 
the mature growth factor dimer. These receptor locations were then in turn used to position 
the type 1 and II receptors relevant for BMP15, namely BMPR1B (Accession number 
3EVS; Kotzsch et al. 2009) and BMPR2 (Accession number 2HLR; (Mace et al. 2006), 
respectively. Based on these criteria, promature and mature oBMP15 and oGDF9 
(modelled on BMP9 or TGFB1) could then be positioned within this template.  
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5.3 Results 
5.3.1 Non-covalent interaction between the pro- and mature domains of oBMP15 
and oGDF9 
5.3.1.1 Hydrophobic residues in the proregion of human BMP15 and GDF9 differ 
from the conserved hydrophobic motif found in most other TGFB family 
members 
Walton et al. (2009) have identified a hydrophobic motif (HHxxHxH; H = hydrophobic, x 
= any amino acid), present in the pro-region of most human TGFB family members, which 
is involved in a non-covalent interaction with the mature region. This motif has been 
identified in 28/33 (84.8%) of the human TGFB family members (Figure 5.1). For the 
remaining 5/33 (15.2%) family members, there is an incomplete or modified motif 
(HHxxHxY; Y= hydrophilic amino acid). All of the modified motifs are unique with a 
different hydrophilic amino acid being substituted in each growth factor (hBMP15, 
glutamate; hGDF3, aspartate; hGDF9, lysine; hGDF10, glutamine and hMIS, arginine; 
Figure 5.1). 
 
5.3.1.2 A hydrophobic motif is conserved across all mammalian species of BMP15 
and GDF9 proregion 
The HHxxHxY (H = hydrophobic, x = any amino acid, Y= hydrophilic; Table 5.2) motif is 
found in 11/11 (100%) of mammalian BMP15 sequences. This can be extended to become 
HHHHHHxxHHY (BMP15 motif; Figure 5.2). Mouse and rat BMP15 sequences differ 
from those of other mammalian species with the 7th amino acid within the extended motif 
being hydrophobic, while for all other species this residue is hydrophilic. Alignment of the 
motif for all mammalian species of BMP15 reveals a 3/11 (27%) sequence homology, 
however this increases to 8/11 (73%) when mouse and rat sequences are excluded.  
 
As GDF9 is closely related to BMP15, and is also an oocyte derived growth factor, the 
conservation of this motif across mammalian species of GDF9 was also investigated. The 
HHxxHxY motif is found in 13/13 (100%) of mammalian GDF9 sequences. This can be 
extended to become YYxHHHHHHHHY (GDF9 motif; Figure 5.2). There is a 2/9 (22%) 
sequence similarity within the extended motif between all mammalian species of GDF9. A 
common hydrophobic motif (HHHHxxHHY) is found in all mammalian species of both 
BMP15 and GDF9 pro-domains (24/24), (common motif; Figure 5.2). In BMP15 and 
GDF9, this motif is preceded by hydrophobic or hydrophilic residues respectively.  
.  
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                 HH-xxHxH 
hINHα    22 LELARELVLAKVRALFL-DALGPPAV-46 
hActA    47 VPNSQPEMVEAVKKHIL-NMLHLKKR-71 
hActB    67 LGRVDGDFLEAVKRHIL-SRLQMRGR-91 
hActC    36 LESQRELLLDLAKRSIL-DKLHLTQR-60 
hActE    36 PQAERALVLELAKQQIL-DGLHLTSR-60 
hTGFβ1   38 MELVKRKRIEAIRGQIL-SKLRLASP-62 
hTGFβ2   29 MDQFMRKRIEAIRGQIL-SKLKLTSP-53 
hTGFβ3   32 FGHIKKKRVEAIRGQIL-SKLRLTSP-56 
hBMP2    34 AAASSGRPSSQPSDEVL-SEFELRLL-58 
hBMP3    164 DLSAWTLKFSRNQSQLL-GHLSVDMA-188 
hBMP4    46 RSGQSHELLRDFEATLL-QMFGLRRR-70 
hBMP5    41 -RRLRNHERREIQREIL-SILGLPHR-64 
hBMP6    69 YRRLKTQEKREMQKEIL-SVLGLPHR-92 
hBMP7    44 -RRLRSQERREMQREIL-SILGLPHR-67 
hBMP8a   34 -RRLGARERRDVQREIL-AVLGLPGR-57 
hBMP8b   34 -RRLGARERRDVQREIL-AVLGLPGR-57 
hBMP10   47 DGVDFNTLLQSMKDEFL-KTLNLSDI-71 
hBMP15   29 GQSSIALLAEAPTLPLI-EELLEESP-53 
hNODAL   42 AYMLSLYRDPLPRADII-RSLQAEDV-66 
hGDF1    29 ------PVPPGPAAALL-QALGLRDE-47 
hGDF2    51 HTFNLKMFLENVKVDFL-RSLNLSGV-75 
hGDF3    67 SRDLCYVKELGVRGNVL-RFLPDQGF-91 
hGDF5    220 QRYVFDISAL-EKDGLLGAELRILRK-244 
hGDF6    146 QKYLFDVSMLSDKEELVGAELRLFRQ-171 
hGDF7    139 QSFLFDVSSLNDADEVVGAELRVLRR-164 
hGDF8    45 RQNTKSSRIEAIKIQIL-SKLRLETA-61 
hGDF9    46 PWSLLQHIDERDRAGLL-PALFKVLS-70 
hGDF10   158 SGRPLPLGPPTRQHLLF-RSLSQNTA-182 
hGDF11   68 RQHSRELRLESIKSQIL-SKLRLKEA-92 
hGDF15   48 TEDSRFRELRKRYEDLL-TRLRANQS-72 
hMIS     68 SPLRVVGALSAYEQAFL-GAVQRARW-92 
hLefty1  22 ------LTGEQLLGSLL-RQLQLKEV-40 
hLefty2  22 ------LTEEQLLGSLL-RQLQLSEV-40 
 
Figure 5.1 Sequence alignment of prodomains of human (h) TGFB family members. 
Adapted from Walton et al. (2009). Prodomains of human TGFB family members 
were aligned using ClustalW. (Thompson et al. 1994) The amino acids are numbered 
according to the first amino acid of the signal peptide. The conserved hydrophobic 
motif (top of alignment) is marked; hydrophobic amino acids are highlighted in 
green, hydrophilic amino acids in blue. Act, activin, INHα, inhibin alpha subunit.  
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The 6th residue within the common motif is always hydrophilic in BMP15 and always 
hydrophobic in GDF9. Mouse and rat BMP15 sequences have an intermediate 
hydrophobicity pattern that falls between that of the remaining BMP15 sequences and the 
GDF9 sequences (Figure 5.2). 
 
Original motif            HHxxHxY 
BMP15 motif        HHHHHHxYHHY 
GDF9 motif       YYxHHHHHHHHY 
Common motif          HHHHxxHHY 
mBMP15   29 WPSTALLADDPTLPSILDLAKEAP 52 
rBMP15   29 WPSTTLLAENPTLPSSLDLAKEAP 52 
pBMP15   30 QPSVALLPEACTLPLIRELLEEAP 53 
cBMP15   29 QPSNALMADAPSLPLIRELLEGAP 52 
oBMP15   29 QPSIAHLPEAPTLPLIQELLEEAP 52 
gBMP15   30 QPSIAHLPEAPTLPLIQELLEEAP 53 
bBMP15   30 QPSIAHLPEAPTLPLIQELLEEAP 53 
buBMP15  30 QPSIAHLPEAPTLPLIQELLEEAP 53 
hBMP15   30 QSSIALLAEAPTLPLIEELLEESP 53 
chBMP15  30 QSSIALLAEAPTLPLIEELLEESP 53 
rhBMP15  30 QSSIALLAEAPTLPLIEELLEESP 53 
 
mGDF9  46 WSLLLPVDGTDRSGLLPPLFKVLS 70 
rGDF9   46 WSLLLPVDGTDRSGLLPPLFKVLS 70 
pGDF9   46 WSLLRPPDERHRSGLPSPLFNVLY 70 
cGDF9   45 WSLVQPLDEKDRLGFLPPLFKVLY 69 
shGDF9   45 WSLLQPLDGRERAGLLPPLFKVLY 69 
oGDF9   46 WSLLNHLGGRHRPGLLSPLLEVLY 70 
gGDF9   46 WSLLNHLGGRHRPGPLSPLLKVLY 70 
bGDF9   46 WSLLKHLDGRHRPGLLSPLLNVLY 70 
buGDF9   46 WSFLKHLDGRHRPGLLSPLLKVLY 70 
hGDF9   46 WSLLQHIDERDRAGLLPALFKVLS 70 
cmGDF9   47 WSLLQPIDERDRAGLLPLLFKVLS 71 
btGDF9   46 WSLLQPLDGKDRAGLFPPLFKVLY 70 
ogGDF9   46 WSLLQPADRRESSGLLPPLFKVLS 70 
 
Figure 5.2 Sequence alignments of mammalian BMP15 and GDF9 prodomains. 
The conserved hydrophobic motif(s) (top of alignment) are marked; hydrophobic 
amino acids (H) are highlighted in green, hydrophilic amino acids (Y) in blue. mouse 
(m), rat (r), porcine (g), cat (c), ovine (o), caprine (g), bovine (b), water buffalo (bu), 
human (h), chimpanzee (ch), rhesus monkey (rh), shrew (sh), Callicebus moloch (cm), 
bat (bt), Otolemur garnettii (og). The amino acids are numbered according to the first 
amino acid of the signal peptide.  
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 hINHα 269 ISFQELGWERWIVYPPS 285 335 MRPLHVRTTSDGGYSF 350 
 
mBMP15 298 VSFHQLGWDHWIIAPRL 314 362 FLPMSILLIETNGSIL 378 
rBMP15 297 VSFHQLGWDHWIIAPRL 313 361 FLPMSILLIEANGSIL 377 
pBMP15 300 VSFHQLGWDHWIIAPHF 316 364 YVPISILLIEANGSIL 380 
cBMP15 300 VSFHQLGWDHWIIAPHL 316 363 YVPISILLVEANGSIL 379 
gBMP15 300 VSFQQLGWDHWIIAPHL 316 364 YVPISILLIEANGSIL 380 
bBMP15 300 VSFQQLGWDHWIIAPHL 316 364 YVPISILLIEANGSIL 380 
buBMP15 300 VSFQQLGWDHWIIAPHL 315 364 YVPISILLIEANGSIL 380 
hBMP15 298 ISFRQLGWDHWIIAPPF 314 362 YVPISVLMIEANGSIL 378 
chBMP15 298 ISFRQLGWDHWIIAPHF 314 363 YVPISVLMIEASGSIL 379 
rhBMP15 298 VSFRQLGWDHWIIAPPF 314 363 YVPISVLMIEANGSIL 379 
oBMP15 299 VSFQQLGWDHWIIAPHL 315 363 YVPISILLIEANGSIL 379 
 
 mGDF9 347 LSFSQLKWDNWIVAPHR 363 411 YSPLSVLTIEPDGSIA 426 
 rGDF9 346 LSFSQLKWDNWIVAPHR 362 410 YSPLSVLTIEPDGSIA 425 
 pGDF9 350 LSFSQLKWDNWIVAPHK 366 414 YSPLSVLAIEPDGSIA 429 
 cGDF9 358 LSFSQLKWDSWIVAPHR 374 422 YSPLSVLTIESDGSIA 437 
 gGDF9 359 LSFSQLKWDNWIVAPHK 375 423 YSPLSVLAIEPDGSIA 438 
 bGDF9 359 LSFSQLKWDNWIVAPHK 375 423 YSPLSVLAIEPDGSIA 438 
buGDF9 359 LSFSQLKWDNWIVAPHK 375 423 YSPLSVLAIEPDGSIA 438 
 hGFD9 360 LSFSQLKWDNWIVAPHR 376 424 YSPLSVLTIEPDGSIA 439 
cmGDF9 362 LSFSQLKWDNWIVAPHR 378 426 YSPLSVLTIEPDGSIA 441 
btGDF9 361 LSFSQLKWDNWIVAPQR 377 425 YSPLSVLTIEPDGSIA 440 
ogGDF9 358 LSFSQLKWDNWIVAPHR 374 422 YSPLSVLTIEPDGSIA 437 
 oGDF9 359 LSFSQLKWDNWIVAPHK 375 423 YSPLSVLAIEPDGSIA 438 
 
 Finger 1 Finger 2 
 
Figure 5.3 Sequence alignments of human inhibin alpha (hINHα) and mammalian 
species of BMP15 and GDF9 mature domains. The conserved hydrophobic amino 
acids are located within the two finger domains (Figure 1.3) of the mature region are 
highlighted in green. mouse (m), rat (r), porcine (p), cat (c), ovine (o), caprine (g), 
bovine (b), water buffalo (bu), human (h), chimpanzee (ch), rhesus monkey (rh), bat 
(bt) and Otolemur garnettii (og). The amino acids are numbered according to the first 
amino acid of the signal peptide. 
 
5.3.1.3 Hydrophobic residues in the mature region are conserved across all 
mammalian species of BMP15 and GDF9 
Through targeted point mutations, five specific residues have been identified within the 
inhibin α mature subunit which are essential for correct interaction between the pro- and 
mature domains as well as subsequently, for successful dimerisation and secretion (Walton 
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et al. 2009). These five amino acids (F271, I280, P283, L388 and V340; numbering based 
on human inhibin α subunit) are all hydrophobic residues (Figure 5.3). Of the 33 human 
TGFB family members tested, the residues F271, I280, P283, L338 and V340 are 
conserved in 29/33 (87.9%), 25/33 (75.8%), 33/33 (100.0%), 10/33 (30.3%) and 11/33 
(33.3%) of members, respectively (Walton et al. 2009). Within mammalian BMP15, amino 
acids Phe (F), Ile (I), Pro (P), Leu (L) and Val (V) are conserved in 11/11 (100.0%), 11/11 
(100.0%), 11/11 (100.0%), 0/11 (0%) and 3/11 (27.3%) respectively (Figure 5.3). All 
substitutions are with replacement hydrophobic amino acids. All GDF9 species of 
mammalian origin showed complete agreement with the human inhibin α subunit (Figure 
5.3). The residues F271, I280, P283 are located on finger 1 of the mature region and the 
residues L388 and V340 on finger 2 (See Figure 1.2 for position of fingers) and together, 
these make a hydrophobic packing core (pocket).  
 
5.3.2 Identification of potential BMP15 and GDF9 receptor binding sites 
5.3.2.1 Type II receptor 
The amino acids comprising some or all of the type II receptor binding sites have been 
reported for the following ligand:ECD-receptor complexes: BMP2-ACVR2B (Weber et al. 
2007); BMP2-BMPR2 (Kirsch et al. 2000b), BMP7-ACVR2A (Greenwald et al. 2003; 
Allendorph et al. 2006); activin βA-ACVR2B (Thompson et al. 2003) and; TGFB3-
TGFBRII (Hart et al. 2002). The proteins BMP15, GDF9 and BMP2 all bind to the same 
type II receptor, BMPR2 (Vitt et al. 2002; Moore et al. 2003; Weber et al. 2007). As such, 
and for the purposes of this study, any residues which comprise the type II receptor binding 
site in BMP2, which also align with those in BMP7 or activin βA, were used to infer a type 
II binding site in oBMP15 and oGDF9 (Figure 5.4A). The type II receptor binding site of 
TGFB3 does not align with the binding sites of the other family members (Figure 5.4A), 
being nearer to the tips of the fingers than it is for BMPR2 and the activin type II receptors. 
Consequently, the TGFB3 alignment was not used to infer the type II binding sites of 
oBMP15 or oGDF9. Amino acids P313 and I366 (numbering based on oBMP15) are 
common to both the type II receptor binding site and the hydrophobic pocket.  
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A. 
TGFB3 318 RPLYIDFRQDLGW-KWVHEPKSYYANF 343 
hBMP2 299 HPLYVDFS-DVGWNDWIVAPPGYHAFY 324 
hBMP7 333 HELYVSFR-DLGWQDWIIAPEGYAAYY 358 
hBMP7 333 HELYVSFR-DLGWQDWIIAPEGYAAYY 358 
hActA 324 KQFFVSFK-DIGWNDWIIAPSGYHANY 349 
oBMP15 295 HPFQVSFQ-QLGWDHWIIAPHLYTPNY 320 
oGDF9 359 HDFRLSFS-QLKWDNWIVAPHKYNPRY 375 
 
TGFB3 377 CCVPQDLEPLTILYYVG-RTPKVEQLSNMVVKSCKCS 412 
hBMP2 360 CCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR 396 
hBMP7 395 CCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH 431 
hBMP7 395 CCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH 431 
hActA 390 CCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS 426 
oBMP15 357 SCVPYKYVPISILLIEANGSILYKEYEGMIAQSCTCR 393 
oGDF9 417 SCVPAKYSPLSVLAIEPDGSIAYKEYEDMIATKCTCR 453 
 
B. 
hBMP2 299 HPLYVDFS-DVGWNDWIVAPPGYHAFY 324  
Belclare 295 HPFQVSFQ-QLGWDHWIIAPHLYTPNY 320 
Thoka 359 HDFRLSFS-QLKWDNWIVAPHKYNPRY 375 
 
hBMP2 360 CCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR 396 
Belclare 357 SCVPYKYVPIIILLIEANGSILYKEYEGMIAQSCTCR 393 
Thoka 417 SCVPAKYSPLRVLAIEPDGSIAYKEYEDMIATKCTCR 453 
 
Figure 5.4 Sequence alignments of areas of type II receptor binding. 
(A) Amino acids comprising the type II receptor binding sites for TGFB3 (Hart et al. 
2002), hBMP2 (Weber et al. 2007), hBMP7 (Greenwald et al. 2003), hBMP7 
(Allendorph et al. 2006), hActA (Thompson et al. 2003) are marked in blue, with 
corresponding areas in oBMP15 and oGDF9 marked in pink. The residues involved 
in forming the hydrophobic pocket in oBMP15 and oGDF9 are marked in green, with 
residues also common to the type II receptor binding area marked in yellow. (B) 
Amino acids, that when mutated in hBMP2 (Kirsch et al. 2000a), have either 
decreased (red) or no change (grey) in binding affinity for the type II receptor. The 
location of Belclare (oBMP15, S367I) and Thoka (oGDF9, S427R) mutations are 
marked in orange. The amino acids are numbered according to the first amino acid of 
the signal peptide. 
 
5.3.2.2 Type I receptor 
Amino acids comprising both the GDF5:BMPR1B (Kotzsch et al. 2009) and the BMP2: 
TGFBR1 (Radaev et al. 2010) receptor binding interface were used to infer a potential type 
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I binding site for both BMP15 and GDF9 (Figure 5.5A). Ten of 21 amino acids (F409, 
M412, W414, W417, L437, H446, I476, K488, Y490, E491; 47.6%) making up the 
GDF5:BMPR1B binding site shared sequence similarity, based on conservative intra-
family amino acid substitutions (Figure 5.5B), for both BMP15 and GDF9. Moreover, 
BMP15 and GDF9 showed additional sequence similarity at positions R438 & G413 and 
H440 & D492 respectively. Likewise, both BMP15 and GDF9 shared sequence similarity 
with 13 of 29 amino acids (V308, W310, W313, L333, I344, L348, I368, S369, M370, 
L371, V380, K383, Y385; 44.8%) making up theTGFBR1 binding site of BMP2. BMP15 
exhibited sequence similarity at positions G309, N341 and V352, and GDF9 showed 
additional sequence similarity with S306, H336 and S353. Overall, both BMP15 and 
GDF9 shared sequence similarity with 12 of 21 (57.1%) and 16 of 29 (55.2%) amino acids 
making up the GDF5 and BMP2 type I binding sites, respectively. The F301, I366 and 
I368 amino acids in BMP15 and the F361, L426 and V428 amino acids in GDF9 are 
common to both the potential type I binding site and the hydrophobic pocket (Figures 5.3 
and 5.5A). 
 
5.3.3 Molecular modelling of promature oBMP15 and oGDF9 
As mentioned earlier, three-dimensional structural models for promature ovine GDF9 and 
promature ovine BMP15 were generated using either protein homology/anologY 
recognition engine v2 (Phyre2), (Figure 5.6) or manually using the software Quanta2008 
(Figure 5.7). Models of oBMP15 and oGDF9 utilising promature pTGFB1 as the template 
(hereafter referred to as the TGFB model) showed the pro-domain arching above and over 
the mature domain (Figure5.6) with dimeric promature BMP15 and GDF9 forming a ring-
like configuration, (oBMP15; Figure 5.8A). Utilising promature mBMP9 as the template 
(hereafter referred to as the BMP model), the pro-domain rotated away from the mature 
domain (Figure 5.7) and dimeric promature forms adopting a more open armed 
configuration (oBMP15; Figure 5.8B). It should be noted that due to the very flexible 
nature of the region encompassing the RRXR cleavage site in both the TGFB and BMP 
promature models, this region has not been modelled. This, together with cleavage by a 
furin-like proprotein convertase, make it uncertain as to which pro- and mature-domain 
derive from the same polypeptide chain. Shi et al. (2011) concluded that the pro-mature 
pair was likely to be the pair closest to each other (30Å versus 50Å distant) based on the 
lack of conformational change between cleaved and uncleaved forms and the maximising 
of access to furin. This convention was also applied to the BMP based models (Figure 
5.8A and B; prodomain blue or red and corresponding mature domain cyan or pink 
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respectively). In this arrangement, the TGFB based model shows the conserved 
hydrophobic motif on the prodomain (HHHHxxHH) coming into close association with the 
conserved hydrophobic amino acids located on the mature domain of its dimer partner 
(Figure 5.9). The N-terminal region of the prodomain encompassing this motif was not 
modelled for promature BMP9 [Accession number 4YCG]; (Mi et al. 2015). Thus, it is not 
known if this motif, located on the α1-helix, also interacts with the mature domain in 
BMP9. However hydrophobic residues on α5 helix are in close proximity to the 
hydrophobic motif on the mature domain (Figure 5.10). 
  
A hGDF5 395NLKARCSRKALHVNFKDMGWDDWIIAPLEYEAFHCEGLC 433 
 oBMP15 287PESNQCSLHPFQVSFQQLGWDHWIIAPHLYTPNYCKGVC 325 
 oGDF9 347FPQNECELHDFRLSFSQLKWDNWIVAPHKYNPRYCKGDC 385 
 hBMP2 291RLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGEC 329 
 
 
 hGDF5 434EFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLS 472 
 oBMP15 326PRVLHYGLNSPNHAIIQNLVSELVDQNVPQPSCVPYKYV 364 
 oGDF9 386PRAVGHRYGSPVHTMVQNIIHEKLDSSVPRPSCVPAKYS 424 
 hBMP2 330PFPLADHLNSTNHAIVQTLVNSVN-SKIPKACCVPTELS 366 
 
 hGDF5 473PISILFIDSANNVVYKQYEDMVVESCGCR 501 
 oBMP15 365PISILLIEANGSILYKEYEGMIAQSCTCR 393 
 oGDF9 425PLSVLAIEPDGSIAYKEYEDMIATKCTCR 453 
 hBMP2 367AISMLYLDENEKVVLKNYQDMVVEGCGCR 396 
 
B 
Amino acid Description Colour 
I, L, V, A, M Aliphatic/hydrophobic   
F, W, Y Aromatic  
K, R, H Positive  
D, E Negative  
S, T, N, Q Hydrophilic  
P, G Proline/Glycine (conformationally special)  
 
Figure 5.5 Sequence alignment of areas of type I receptor binding.. 
(A) Alignment of amino acid sequences showing the type I receptor binding sites for 
BMP2 and GDF5 and the potential binding sites for BMP15 and GDF9 and in (B) 
they are marked in colours according to amino acid families, as described. Mutational 
analysis of GDF5 shows (R438L;   ) increases bioactivity while (L441P;   ) renders 
GDF5 almost inactive (Seemann et al. 2005).  
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Figure 5.6 The ribbon structure of monomeric promature oBMP15 (A) and oGDF9 
(B) based on the TGFB model. The proregion is depicted in blue and the mature 
growth factor domain is depicted in cyan. The oBMP15 and oGDF9 models were 
created using the protein homology/anology recognition engine v2 (Phyre2) using pro-
mature porcine TGFβ1 (Accession number 3RJR; Shi et al. 2011b) as a template.  
 
 
A B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 The ribbon structure of monomeric promature oBMP15 (A) and oGDF9 
(B) based on the BMP model. The proregion is depicted in blue and the mature 
growth factor domain is depicted in cyan. The oBMP15 and oGDF9 were created 
manually using the software Quanta2008 using pro-mature mouse BMP9 (Accession 
number 4YCG; Mi et al. 2015) as a template. 
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Figure 5.8 The ribbon structure of dimeric promature forms of BMP15 (A) when 
utilising promature porcine TGFβ1 (Accession number 3RJR; Shi et al. 2011b) or (B) 
when utilising human BMP9 (Accession number 4YCG; (Mi et al. 2015) as the 
template. The prodomain (blue) and mature growth factor (cyan) are presumed to 
derive from a single polypeptide chain, while the remaining prodomain (red) and 
mature growth factor (pink) are presumed to derive from another single polypeptide 
chain (Shi et al. 2011b).  
  
95 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Conserved hydrophobic motifs on pro- and mature domains of oBMP15 
in the TGFB-based model. 
(A) Location of hydrophobic residues based on the TGFB model (for clarity, one 
mature domain is not shown). (B) Viewing orientation is rotated forward towards the 
reader, such that the angle of view is directly along the axis of the α1 helix of the 
prodomain, (C) as depicted by arrow. The prodomain (blue) and mature growth 
factor (cyan) are presumed to derive from a single polypeptide chain, while the 
prodomain (red) and mature growth factor (pink) are presumed to derive from 
another single polypeptide chain. The hydrophobic motif located on the prodomain is 
depicted in orange, whilst the conserved hydrophobic amino acids on the mature 
domain are depicted in green.  
1 Helix 
2 Helix 
1 Helix 
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Figure 5.10  Conserved hydrophobic motifs on the mature domain of oBMP15 in the 
BMP-based model. 
(A) Location of hydrophobic residues based on the BMP model. (B) Viewing 
orientation is rotated forward towards the reader, such that the angle of view is 
directly along the axis of the α5 helix of the prodomain, (C) as depicted by arrow. The 
prodomain (blue) and mature growth factor (cyan) are presumed to derive from a 
single polypeptide chain, while the prodomain (red) and mature growth factor (pink) 
are presumed to derive from another single polypeptide chain. The hydrophobic 
motif located on the prodomain is not modelled however, hydrophobic residues 
located on the α5 helix (depicted in orange) are in close proximity to the conserved 
hydrophobic amino acids on the mature domain (depicted in green).  
2 Helix 
5 Helix 
5 Helix 
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5.3.3.1 Conformational differences between prodomain and receptor bound mature 
growth factor domains 
Another major difference noted between the two models is the conformation of the mature 
growth factor domain while in a complex with the prodomain. The BMP model shows the 
mature growth factor domain having good conformational similarity to other BMP 
domains when associated with their type I receptor (Figure 5.11A-C). However the TGFB 
model shows, the prodomain would hold the mature growth factor domain in an alternative 
conformation compared to that when associated with its receptors (Figure 5.11D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Receptor versus promature bound forms of mature BMP15. 
Comparisons between the mature growth factor domain of oBMP15 when associated 
with its prodomain modelled on BMP9 (Accession number 4YCG; (Mi et al. 2015) (A-
C; yellow), or TGFβ1 (Accession number 3RJR; Shi et al. 2011b) (D-F; gold) or its 
receptor complex (cyan; A-F; modelled on GDF5:BMPR1B complex (Accession 
number 3EVS; (Kotzsch et al. 2009). View of the full mature domain (A & D). Partial 
view of the mature domain as seen in A or D, but with the “palm” and “finger” 
regions not shown for simplicity (B & E respectively) and partial view of the mature 
domain as seen in B or E, but rotated 90o into a transverse orientation looking from 
the “wrist” towards the” finger tips” (C and F). 
 
Note: (D – F) The views of the full mature domain together with the locations of Y331 
(pink) and Q351 (blue) in the prodomain-associated conformation and of Y331 (red) 
and Q351 (green) in the receptor-associated conformation Y331 and Q351 are 
illustrated simply to accentuate the degree of movement required to move from one 
conformation to the other.  
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From this conformation, the wrist region and the pre-helical loop must rotate almost 180o 
in the transverse plane (Figure 5.11F) before it is in a conformation which contains a 
binding site for the type I receptors. While this large conformational change occurs at the 
wrist, relatively small changes in conformation occur at the “palm” and “finger” regions 
(Figure 5.11D) 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 The prodomains of dimeric promature oBMP15 stearically hinder 
access to the binding sites of both type I and type II receptors. In both the TGFB (A) 
and BMP (B) models the prodomain (red and blue) cover the receptor binding sites 
for the type I receptor (yellow) of its associated mature domains (pink and cyan, 
respectively), whilst simultaneously blocking the binding site for the type II receptor 
(green) of its dimer partner. 
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5.3.3.2 Prodomains block access to type II receptors in the dimeric but not 
monomeric promature form 
A composite template was created (see Section 5.2.2) to visualise the positions of both type 
I and type II receptors relative to dimers of pro-mature oBMP15 or oGDF9. Promature and 
mature BMP15 and GDF9 (modelled on BMP or TGFB templates) could then be 
positioned within this template. Both models show that a consequence of forming dimeric 
promature BMP15 or oGDF9 complexes in vivo would be the blocking of both the type I 
and type II receptor binding sites. Each prodomain blocks access to the type I receptor 
binding site of its own mature domain by steric hindrance. In the TGFB model, the 
prodomain also holds the mature domain in an alternative confirmation whereby the type I 
receptor binding site cannot form (Figure 5.11D-F). At the same time, the prodomain 
covers the type II receptor binding site of its dimer partner (Figure 5.12A and 5.12B).  
 
5.3.3.3 Naturally-occurring inactivating mutations of oBMP15 and oGDF9 
Naturally-occurring inactivating mutations in both oBMP15 and oGDF9 have been 
identified, which are located close to the hydrophobic motif (Figure 5.13). The point 
mutations of V299S (Inverdale mutation; (Galloway et al. 2000), S367I (Belclare mutation 
(Hanrahan et al. 2004), and C321Y (Lacaune mutation; (Bodin et al. 2007) have been 
identified in oBMP15, and a point mutation of S427R (Nicol et al. 2009) has been 
identifed in oGDF9. The Inverdale mutation is located two amino acids downstream of the 
first hydrophobic residues on finger 1 and the Lacaune mutation is located eight amino 
acids upstream of the last hydrophobic residue on finger 1 (Figure 5.13A). The Belclare 
and Thoka mutations are located between the two residues comprising the hydrophobic 
motif on finger 2, (Figure 5.13B & C respectively) and within the type II receptor binding 
site (Figure 5.4B). Models of mature oBMP15 and oGDF9, with and without these point 
mutations, were generated using the Swiss model comparative protein modelling server 
(Schwede et al. 2003; Arnold et al. 2006; Kopp and Schwede 2006; Kiefer et al. 2009) 
with GDF5-BMPR1B complex [3EVS] (Kotzsch et al. 2009) as the template. These were 
then over-layed onto the composite models described in Section 6.3.3.2 comprised of 
prodomains of BMP15 or GDF9, (both TGFB and BMP models, type I and II receptors. 
 
The inactivating mutations mentioned above, share a common phenotype, heterozygotes 
have increased prolificacy while homozygotes exhibit ovarian hypoplasia. Another 
inactivating oGDF9 mutation R351C identified in Vacaria sheep (Souza et al. 2014), also 
shares this phenotype. This R351C point mutation disrupts the cleavage site of promature 
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GDF9, preventing the release of the mature domain. This demonstrates the absolute 
requirement of cleaving the promature domain from the mature protein for biological 
activity. In contrast, BMP point mutations in other sheep breeds (e.g. N337H in Olkuska 
and T317I in Grivette; Demars et al. 2013) or in oGDF9, F345C in Santa Inês sheep 
(Embrapa; Silva et al. 2010) and V371M in Norwegian White sheep, (Våge et al. 2013) 
show an additive effect on prolificacy. Interestingly, the V371M mutation showed an 
additive effect for increased litter size in Norwegian White Sheep but was not associated 
with prolificacy in Belclare or Camdridge ewes (Hanrahan et al. 2004). However, both the 
Belclare and Cambridge ewes carry a range of mutations, including inactivating mutations, 
in both GDF9 and BMP15. This results in extreme variation in ovulation rate between 
individuals (Hanrahan et al. 2004), potentially masking and/or confounding any effects of 
V371M on prolificacy. The dose–responsive manner of these mutations indicates they are 
still, at least partially, biologically-active.  
 
A. oBMP15 299 VSFQQLGWDHWIIAPHLYTPNYC 321 
 Inverdale 299 DSFQQLGWDHWIIAPHLYTPNYC 321 
 Lacaune 299 VSFQQLGWDHWIIAPHLYTPNYY 321 
 
 Finger 1 
 
B. oBMP15 363 YVPISILLIEANGSILY379 
 Belclare 363 YVPIIILLIEANGSILY379 
 
 Finger 2 
 
C. oGDF9 423 YSPLSVLAIEPDGSIAY439 
 Thoka 423 YSPLRVLAIEPDGSIAY439 
 
 Finger 2 
Figure 5.13 Sequence alignments of inactivating mutations in oBMP15 and oGDF9 
mature domains. 
Inverdale (V299D) and Lacaune (C321Y) point mutations within finger 1 and (B) 
Belclare (S367I) point mutation within finger 2 of oBMP15. (C) Thoka point mutation 
(S427R) within finger 2 of oGDF9 The conserved hydrophobic amino acids located 
within the two finger domains of the mature region are highlighted in green. The 
amino acids are numbered according to the first amino acid of the signal peptide. 
 
In agreement with the result for human inhibin α subunit (Walton et al. 2009), the 
hydrophobic residues in both oBMP15 and oGDF9 (Figure 5.3) formed a hydrophobic 
pocket located at the interface between the two fingers. Despite its close proximity to these 
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hydrophobic residues, the Inverdale mutation (V299D) did not appear to have any 
noticeable effect on the hydrophobic pocket itself (Figure 5.14). The promature BMP9 
based model showed it to be located in close proximity to the dimer interface (Figure 
5.14B-E) However, the TGFB-based model did not show the location of the Inverdale 
mutation to be close to the dimer interface, due to the alternative conformation of the 
mature domains α1 helix and pre-helical loop (Figure 5.11A-C). Nevertheless, upon 
separation from the prodomain and adoption of the receptor bound form, the Inverdale 
mutation did also become located within, or immediately adjacent, to the dimer interface 
(Figure 5.14C-E). The TGFB-based model shows a potential for the Inverdale mutation to 
interact with the α1 helix of the prodomain of its dimer partner (Figure 5.14A). The 
Inverdale mutation also lies within the type I receptor binding site (Figure 5.5). In both the 
TGFB and BMP based models, the Inverdale mutation lies in a critical location, and 
therefore has the potential to affect dimerization and/or interaction with the type I receptor. 
 
Both the Belclare (S267I) and Thoka (S4237R) mutations are located with their side chain 
protruding outwards from the “knuckle” side of finger 2 and away from those residues 
which comprise the hydrophobic pocket on the mature domain. However, both mutations 
lie within residues making up the presumptive type II binding site (Figure 5.4B). This area 
is depicted for Belclare and Thoka in Figure 5.15C and 5.16C, respectively. When 
oBMP15 and oGDF9 are in a dimeric promature form, the TGFB- (Figure 5.15A and 
5.16A, respectively) and BMP- (Figure 5.15B and 5.16B, respectively) based models both 
show that the Belclare and Thoka mutations will be in close association with α2 helix of 
the proregion of their dimer partner.  
 
The point mutation F345C (Silva et al. 2013) falls within the un-modelled, N-terminal 
portion of mature GDF9. However, the N337H (Demars et al. 2013) point mutation, found 
in BMP15, comprises part of the presumptive type I receptor binding site (Figure 5.5A). 
Furthermore, both hBMP2 and hGDF5 also contain an asparagine at this location (Figure 
5.5A). Similarly, the mutations V371M in GDF9 (Våge et al. 2013) and T317I in BMP15 
(Demars et al. 2013) also lie within residues making up the presumptive type II receptor 
binding site (Figure 5.4B). Moreover, the Tyr317 residue corresponds to the His321 
residue in hBMP2, which when mutated to alanine showed decreased binding affinity for 
the type II receptor (Kirsch et al. 2000a; Figure 5.4B). It seems likely N337H, V371M and 
T317I all diminish, without blocking, ligand-receptor interaction. 
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Figure 5.14 Inverdale mutation, oBMP15 (V299D). 
Legend applies to the figures on this and the facing page. The figure shows the 
position of the Inverdale mutation (V299D) relative to the pro- and mature domains 
of its dimeric partner when superimposed onto TGFB (A, this page) or BMP (B and 
C, opposite page) based models. A surface view of C shown from below (D, opposite 
page) and above (E, opposite page). The oBMP15 mature region is shown in cyan 
with the Inverdale mutation (V299D) in orange and the amino acids comprising the 
hydrophobic pocket in green. The oBMP15 mature dimer partner is shown in pink 
and the prodomain of the dimer partner in red. 
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Figure 5.15 Belclare mutation, oBMP15 (S267I). 
Legend applies to the figures on this and the facing page. The figure shows the 
position of the Belclare mutation (S267I) relative to its type II receptor and the pro- 
and mature domains of its dimeric partner when superimposed onto the TGFB (A, 
this page) or BMP (B and C, opposite page) based models. The images represent 
oBMP15 mature region (cyan) with the Belclare mutation (S267I) shown in orange 
and the amino acids comprising the hydrophobic pocket in green. The oBMP15 
mature dimer partner is in pink, the prodomain of dimer partner is in red and; 
BMPR2 is in blue.  
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Figure 5.16 Thoka mutation, oGDF9 (S427R). 
Legend applies to figures on this and the facing page. The figure shows the position of 
the Thoka mutation (S427R) relative to its type II receptor and the pro- and mature 
domains of its dimeric partner when superimposed onto the TGFB (A; this page) or 
BMP (B and C; opposite page) based models. The image represents the oGDF9 
mature region (cyan) with the Thoka mutation (S427R; orange) and amino acids 
comprising the hydrophobic pocket (green). The oGDF9 mature dimer partner is 
shown in pink, the prodomain of the dimer partner in red and BMPR2 in blue.  
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5.4 Discussion 
Currently, three-dimensional structural models of BMP15 or GDF9 are unavailable, 
however models for two closely-related proteins, namely promature pTGFB1 (Shi et al. 
2011b) and mBMP9 (Mi et al. 2015), have been reported. Using these related proteins as 
templates, two structural models of oBMP15 and oGDF9 were produced to help visualise 
and explain our current understanding of the molecular forms of BMP15 and GDF9 and 
how together, they might interact with their cell surface receptors. 
 
Hydrophobic motifs located in both the pro- and mature domains are highly conserved 
within the human TGFB superfamily members (Walton et al. 2009) as well as within 
BMP15 and GDF9 of known mammalian species (Figure 5.2 and 5.3). If the published 
information is correct on which pro and mature domains derive from the same polypeptide 
chain (Shi et al. 2011b), the motif on the prodomain can only come in close proximity to 
the conserved hydrophobic pocket on the mature domain with the assembly of dimeric 
promature forms using the TGFB-based model (Figure 5.9). However, the hydrophobic 
motif on the proregion of BMP9 does not fall within those residues making up the 
structural model of BMP9 (Mi et al. 2015) hence the location of this motif is unknown. 
Mutation of residues within the hydrophobic motifs in inhibin  leads to lowered in vitro 
production and secretion of inhibin A (Walton et al. 2009). This emphasises the 
importance of these motifs and raises the possibility that they may influence protein 
folding and thereby, the ability to form dimers prior to secretion by the cell. The complex 
assembly of multi-subunits is one of the checks performed via the endoplasmic reticulum 
(ER)- associated protein degradation (ERAD) system within the ER lumen of all 
eukaryotic cells (Ali et al. 2011). 
 
It is thought that BMPs must dimerise, prior to cleavage by a furin-like proprotein 
convertase and secretion (Hogan 1996). The presence of dimeric oBMP15 (S356C) (Figure 
4.4A & B) shows that BMP15 is bought together in an orientation to allow homodimers to 
form. However, based on the results of the studies reported in Chapter 4 and elsewhere 
(Edwards et al. 2008; McIntosh et al. 2008), it would appear that oBMP15 (lacking this 
cysteine) is unable to maintain dimeric forms following secretion from the cell.  
 
As mentioned above, several naturally-occurring mutations of oBMP15 and oGDF9 are 
known in sheep. Perhaps the most severe of these is in the Galway (Q239>stop; Hanrahan 
et al. 2004) and Hanna (Q291>stop; Galloway et al. 2000) sheep. These mutations with the 
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introduction of premature stop codons, results in the absence of or severely truncated 
mature domains respectively, most likely causing complete loss of function (Galloway et 
al. 2000). Ewes homozygous for either of the BMP15 mutations Galway, Hanna, 
Inverdale, Belclare and Lacaune or the GDF9 mutations Thoka and FecGH (Hanrahan et al. 
2004) are sterile. It is unknown if any of these mutated proteins are secreted by oocytes.  
 
The Inverdale mutation (V299D) has been suggested to interfere with dimer formation 
(Galloway et al. 2000). In the BMP-based model, the V299D mutation would result in the 
introduction of a negatively-charged asparagine residue into, or adjacent to, the dimer 
interface (Figure 5.14B and C). This may be sufficient to prevent the creation of 
homodimers or heterodimers with GDF9, either in solution or at the level of the receptor. 
However, the TGFB-based model, shows that the mature domain is held in an alternative 
configuration when associated with its prodomain, and consequently the V299D mutation 
would not then comprise part of the dimer interface. Nevertheless, it would come into close 
proximity (3.6Å) to the hydrophobic isoleucine (I43) residue present in the middle of the 
conserved hydrophobic motif located within the α1 helix of its dimer partners prodomain 
(Figure 5.14A). Interference with the correct functioning of the hydrophobic motif may 
result in lowered production and/or secretion, as is found with inhibin α (Walton et al. 
2009). Indeed, transfection of mammalian cells with the Inverdale (V299D) sequence 
resulted in lowered secretion compared to wild-type oBMP15, while co-expression of 
Inverdale BMP15 (V299D) and GDF9 resulted in less GDF9 being secreted and the 
abolition of secreted BMP15 (V299D) (Liao et al. 2003). Once the mature domain is freed 
from any conformational constraints placed upon it by the prodomain, both models show 
that the V299D mutation would be located within, or adjacent to, the dimer interface 
(Figure 5.14C). Similarly the secretion of the Lacaune BMP15 protein was also impaired 
under in vitro conditions (Bodin et al. 2007). The Lacaune (C321Y) mutation lacks one of 
the cysteines required to form the characteristic cysteine knot holding the mature domains 
in the correct conformation. It is therefore likely that oBMP15 (C321Y) protein is 
misfolded and directed into ERAD pathway. 
The Belclare (S367I) and Thoka (S427I) mutations in BMP15 and GDF9, respectively are 
located within the hydrophobic pocket on the mature domain however, neither appear 
likely to interfere directly with the functioning of this motif. This is due largely to the 
orientation of their side chains being positioned away from the hydrophobic pocket and 
towards the “knuckle” side of the fingers. However positioned as it is, within the two  
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sheets comprising finger 1 of the mature domain, it may disrupt the interaction with the α2 
helix of its dimer partners proregion: this was the case for both the TGFB and BMP models 
(Figures 5.15A & B and 5.16A & B respectively). In turn, this could therefore interfere 
with dimer formation and subsequent secretion. Alternatively, this same area falls within a 
predicted type II receptor binding site (Figure 5.4B) and both mutations might exert their 
effect by inhibiting binding to the receptor or by preventing signalling by the resultant 
receptor complex. The Ser367 residue in oBMP15 mutated in Belclare and the Ser427 
residue in oGDF9 mutated in Thoka, correspond to the Ser370 residue in hBMP2, which 
when mutated to alanine decreases its binding affinity for the type II receptor (Kirsch et al. 
2000a; Figure 5.4B). In this study, hBMP2 promature forms were not produced and only a 
mature dimer-receptor interaction was assessed. 
 
Humans produce and secrete a latent form of promature GDF9, whereas polyovular species 
such as the mouse secrete an active form (Mottershead et al. 2008; Simpson et al. 2012; Li 
et al. 2015). This is the result of a few key amino acid differences which determine the 
ease with which the proregion can be displaced (Mottershead et al. 2015). Under in vitro 
conditions, the recombinant human BMP15 secreted is biologically active whilst 
recombinant mouse BMP15 is not expressed (Mottershead et al. 2015). The ratios of 
GDF9:BMP15 mRNA expression are also different across species, with monoovular 
species expressing similar or greater quantities of BMP15 compared to GDF9, and rodent 
species such as the mouse and rat expressing greater quantities of GDF9 (Crawford and 
McNatty 2012). Moreover, BMP15 knockout mice are still fertile (Yan et al. 2001) 
therefore BMP15 does not appear to be essential in polyovular species. However in mono-
ovular species, both GDF9 and BMP15 are essential for fertility. Indeed ewes which are 
heterozygous carriers for inactivating BMP15 mutations (e.g. Inverdale), have reduced 
levels of bioactive BMP15 and consequently, express a phenotype with an increased 
ovulation rate. Thus in all mammalian species, it appears that GDF9 drives the ovulation 
rate, while BMP15 acts as a constraint on this system. It is uncertain how this relationship 
is applied. However, it may be through differences in the extent to which granulosa cells 
are driven to proliferate relative to the developmental stage of the follicle. For example, on 
average, follicles from heterozygous Inverdale ewes (with lowered BMP15 levels) develop 
functional LH receptors on granulosa cells from smaller-sized follicles compared to that in 
wild-type ewes (McNatty et al. 2009). This, in turn, requires more follicles to produce the 
necessary level of steroid to signal the appropriate feedback messages to the pituitary gland 
and thus trigger a pre-ovulatory LH surge. In so doing, more follicles with functional LH 
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receptors on the granulosa cells (pre-ovulatory follicles) will be present, and capable of 
ovulating in response to the LH surge. Thus, the extent to which granulosa cells proliferate 
appears inversely related to their subsequent ovulation rate. In mono-ovulatory species, 
such as the sheep, the mechanism by which BMP15 causes this increase in proliferation 
and therefore a decrease in ovulation rate may be by a synergistic response with GDF9. 
Thus, perhaps increasing levels of BMP15 in the presence of GDF9 results in a greater 
aquisition of granulosa cells before LH receptor acquisition occurs in this cell-type, leading 
to a corresponding decrease in ovulation rate. For example, heterozygous carriers of the 
Inverdale gene have both reduced bioactive BMP15 levels and higher ovulation rates than 
their wild-type counterparts, which produce greater quantities of bioactive BMP15 and 
have a lower ovulation rate. When GDF9 is bound with its type I receptor (TGFRI) in the 
presence of BMP15, greater quantities of phosphorylated Smad2/3 are produced than by 
GDF9 alone (Mottershead et al. 2012) and as such, BMP15 is acting as a pseudo-TGFB. 
These data provide additional support for applying the TGFB-based model to BMP15. 
 
5.4.1 Interaction with receptors 
Most evidence suggests that members of the TGF-β family capable of forming covalently 
bound dimers, do so before binding with their specific receptors (Yardin et al. 2016). 
However, it is uncertain if those TGF-β members incapable of forming covalently bound 
dimers, such as BMP15 and GDF9, utilise a similar strategy. The presence of dimeric 
oBMP15 (S356C) (Figure 4.4A & B) shows that BMP15 is bought together in an 
orientation to allow homodimers to form. However, mature homodimers of BMP15 were 
not detected amongst the molecular forms secreted by either bovine or ovine oocytes or by 
HEK cells transfected with oBMP15. Based on the results of the studies reported in 
Chapter 4, and elsewhere (Edwards et al. 2008; McIntosh et al. 2008), it would appear that 
oBMP15 (lacking this cysteine) is unable to maintain detectable dimeric forms following 
secretion from the cell. Despite this lack of detectable dimers, it is possible that the 
antibodies used in these studies were incapable of: (i) detecting low levels of homodimers 
of BMP15; or (ii) recognising heterodimeric forms of oBMP15 and oGDF9. Thus, it is not 
possible to completely discount the possibility that mature dimers/heterodimers form prior 
to binding to their respective receptors. However, based on the evidence, it seems more 
likely that such dimers/heterodimers do not form before receptor interaction but instead at 
the level of their receptors. 
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While some mature monomers of BMP15 were observed in the present studies, the 
predominant molecular forms of BMP15, following secretion by ruminant oocytes into the 
media, were the cleaved and uncleaved promature forms. It therefore seems likely that 
these forms play an important role in the signalling of BMP15. Promature hBMP15, in the 
form of pro-cumulin, has been reported to be biologically active (Mottershead et al. 2015), 
while pro-BMP2 binding to its receptors has been shown to act as an antagonist for mature 
BMP2 by binding to the type I receptor BMPRIA (Hauburger et al. 2009). Binding of pro-
BMP2 has also been shown to result in internalisation, intracellular cleavage and 
subsequent secretion of mature BMP2 (von Einem et al. 2011). 
 
The biological activities of recombinant oBMP15 and oGDF9 alone, as well as their 
synergistic effect on 3H-thymidine incorporation by granulosa cells, have been shown to be 
inhibited by a BMPR2-extra cellular domain (ECD) fused to a human IgG-Fc domain 
(BMPR2-ECD-Fc). Whereas all other type II, and all type I, receptor ECD’s had no effect 
(Edwards et al. 2008). Likewise, 3H-thymidine incorporation by rat granulosa cells in 
response to hBMP15 can also be blocked by a BMPR2-ECD-Fc (Moore et al. 2003). 
However, in contrast to oBMP15, hBMP15 was also able to associate with the BMPR1B-
ECD. The most likely reason for the discrepancy in receptivity between oBMP15 and 
hBMP15 are species differences in protein sequence. Indeed, Al-Musawi et al. (2013) has 
identified two residues (R329 and D330) within the pre-helical loop of hBMP15 which 
contributes to the affinity towards BMPR1B and subsequently, the bioactivity of hBMP15. 
The substitution of the two corresponding residues in oBMP15 into hBMP15 reduced the 
bioactivity of hBMP15 by almost 100-fold (Al-Musawi et al. 2013). 
 
Moreover, BMPR2 has been reported to undertake two conformations and it is suggested 
that these conformations represent the receptor in a ligand-bound or free (unbound) state 
(Mace et al. 2006). This fits well with the concept that monomeric promature BMP15 
could be presented to the type II receptor causing conformational changes in both the 
receptor and mature growth factor domains. 
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Figure 5.17 A proposed sequence of events involved in the formation of a 
BMP15/GDF9 heterodimer at the level of the receptor:  
(A) A monomer of cleaved promature BMP15 (cyan proregion and blue mature 
domain) binds to BMPR2 (red ribbon structure); (B) this induces an allosteric change 
in the mature growth factor domain (blue); (C) resulting in the release of the 
prodomain (cyan) and exposure of the type I binding site; (D) thus allowing binding 
to BMPR1B (green); (E) BMPR2 (red ribbon) then recruits an occupied type I 
receptor (yellow) bound to a mature GDF9 (pink) – Type II receptor (red) complex; 
(F) resulting in a functional heteromeric complex capable of activating signalling 
pathways.  
B 
A 
C 
D 
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F 
114 
A B 
 
 
 
 
 
 
 
 
C D 
 
 
 
 
 
 
 
 
 
E F 
 
 
 
 
 
 
 
 
G H 
 
 
 
 
 
 
 
Figure 5.18 A proposed equence of events involved in the formation of a 
BMP15/GDF9 heterodimer at the level of the receptor: a monomer of a cleaved 
promature (A) BMP15 (cyan proregion and blue mature domain) or (B) GDF9 
(purple proregion and pink mature domain) binds to BMPR2 (red ribbon structure); 
this in turn, induces an allosteric change in the mature growth factor domain of (C) 
BMP15 (blue) or (D) GDF9 (pink); resulting in the release of the prodomain of (E) 
BMP15 (cyan) or (F) GDF9 (purple); the concurrence of E and F results in (G) the 
formation of a BMP15:GDF9 heterodimer at the level of the receptor along with the 
formation of the complete type I binding sites allowing (H) BMPR1B (green) and 
TGFBRI (yellow) to associate. Thereby permitting a functional heteromeric complex 
capable of activate intracellular signalling pathways.  
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The conformational change at the type II binding site of BMP15, although relatively small, 
may trigger a larger allosteric change in the α1 helix and prehelical loop (Figure 5.11, 
5.17B). It is proposed that such a conformational change would cause the prodomain to be 
released (Figure 5.17C), while simultaneously exposing the type I binding site to allow 
binding of BMP15 to BMPR1B (Figure 5.17D). This binding to BMPR1B would complete 
a complex comprised of a monomer of mature BMP15, a single type II receptor and a 
single type I receptor (Figure 5.17E). In the case of BMP15 and GDF9, the evidence 
suggests that the ligands biind first to a type II receptor which then recruits a type I 
receptor to the complex (Wrana et al. 1992; Edwards et al. 2008). If this recruited type I 
receptor was part of another type II-ligand monomer-type I complex, a complex typical of 
a TGFB superfamily member would be created. This would be comprised of a mature 
growth factor domain dimer incorporated into a tetramer receptor complex of two type I 
and two type II receptors (Figure 5.17F). 
 
An alternative model worthy of consideration is one that is initiated following the binding 
of both promature forms of BMP15 and GDF9 to two type II receptors (Figure 5.18). The 
orientations of the mature domains of BMP15 (Figure 5.18A) and GDF9 (Figure 5.18B) to 
BMPR2 by their prodomains would result in a conformational change in the mature 
domains (Figures 5.18C & D) and release of the prodomains (Figures 5.18 E & F). This in 
turn, would result in the formation of a BMP15:GDF9 heterodimer at the level of the 
BMPR2 receptors. The release of the prodomains and the conformational changes to 
BMP15 and GDF9 would then allow full exposure the Type I ligand binding domains for 
BMPR1B and TGFBR1 respectively (Figure 5.18G) and the recruitment of the type I 
receptors (Figure 5.18H) into an oligomeric receptor complex capable of intracellular 
signalling. This model is a better fit of the data given that disulfide-linked homodimers of 
BMPR2-ECD-Fc but not dimeric ECD-Type 1 receptors or monomeric BMPR2-ECD-Fc 
or dimeric ECD-Type 1 receptors are required for inhibition of biological activity of both 
recombinant GDF9 and BMP15 when inducing synergistic effects on granulosa cells in 
vitro (Edwards et al. 2008). This suggests that stable dimers may form if both partners are 
also bound to BMPR2 
 
While both models depicted in Figures 5.17 and 5.18 refer to the cleaved promature form 
presenting the mature domain to the type II receptor, it is also conceivable that the 
uncleaved promature form also plays a role. Conformational changes to the uncleaved 
promature form, upon BMPR2 binding, may allow for the mature domain to bind both its 
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receptors while still attached covalently to the prodomain. Indeed Mi et al. (2015) has 
postulated that the prodomain of BMP9 may rotate between two positions, one being active 
while the other is latent. Furthermore, it has been reported that receptor bound pro-BMP2 
results in internalisation, intracellular cleavage and subsequent secretion of mature BMP2 
(von Einem et al. 2011).  Alternatively, an uncleaved promature form may act as an 
antagonist, sequestering BMPR2 in a non-signalling complex, similar to that described for 
pro-BMP2 (Hauburger et al. 2009). It is also possible that it might be the target cells ability 
to enzymatically cleave promature BMP15 that influences how they respond to the oocytes 
signal (Pankhurst et al. 2016).  
It is worth noting that purified mature domains of recombinant hBMP15, in the absence of 
a proregion, possesses biological activity in cultured ovine granulosa cells (Pulkki et al. 
2012). This indicates that the prodomain is not essential for a direct biological action of 
BMP15 in vitro. Nevertheless it is likely to be of physiological importance as 
immunisation against either of the promature sequences of mBMP15 or mGDF9 reduced 
litter size in mice (McIntosh et al. 2012). Furthermore, promature cumulin was able to 
improve oocyte quality whereas mature cumulin did not (Mottershead et al. 2015). BMP2 
can bind to preformed receptor complexes of type I and II receptors or by binding first to 
the type I and then recruiting the type II receptor (Gilboa et al. 2000; Hassel et al. 2003; 
Sieber et al. 2009), resulting in activation of either Smad or non-Smad signalling pathways 
respectively (Sieber et al. 2009). A similar mechanism may exist with BMP15 and/or 
GDF9 whereby promature forms bind first to a type II receptor while free mature growth 
factor domains are not so constrained. Indeed, mixtures of recombinant oBMP15 and 
oGDF9 containing both promature and mature forms were able to stimulate both the Smad 
and non-Smad pathways (Reader et al. 2011). Of the two models, the TGFB-based model 
would better enforce such constraints, by holding the mature domain in a conformation 
lacking the type I receptor binding site.  
 
The disassociation of the non-covalently bound prodomain from the mature domain may 
be sufficient to enable more appropriate mature protein conformations, allowing exposed 
binding sites for both the type I and type II receptors to form. This disassociation may be 
facilitated by chemical means during purification methodologies or by the presence of 
insertions such as a FLAG tag- which may decrease the strength of the non-covalent 
association between pro- and mature domains. The existence of both monomeric and 
dimeric forms of mature GDF9 in expression media raises the possibility that GDF9 may 
associate with its receptors in more than one way. While monomeric GDF9 may become 
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receptor bound in a similar fashion to that postulated for BMP15 above, dimeric GDF9 
would associate with its receptors in much the same way as other traditional TGFB family 
members comprised of covalently-bound dimers.  
 
Notwithstanding the significant synergistic effects of BMP15 and GDF9 on granulosa 
cells, there is no evidence of heterodimer formation between any forms of GDF9 and 
BMP15 secreted by oocytes (Table5.1) or when expression media is combined (McNatty et 
al. 2005a, b, Edwards et al. 2008; McIntosh et al. 2008). Thus, when BMP15 and GDF9 
are both added to a granulosa cell culture, the aforementioned model suggests that a 
monomer of BMP15 along with a monomer of GDF9 would form a heterodimer at the 
level of the receptor. Finally if the tightly-controlled ratio and species specific expression 
ratio of GDF9 and BMP15 mRNA levels (Crawford and McNatty 2012) is also maintained 
at the protein level, then the relative amounts of hetero- and homodimer receptor 
complexes and thereby control of the synergistic response will be maintained by the 
oocyte. 
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Chapter 6: GENERAL DISCUSSION 
6.1 Introduction 
From the time a primary follicle begins to grow towards ovulation, the oocyte co-expresses 
BMP15 and GDF9. Their actions play essential roles during development, in determining 
ovulation rate and in influencing oocyte “quality”. Indeed, in mono-ovulatory species, such 
as the sheep or cow, the absence of BMP15 or GDF9 results in an anovulatory and 
therefore, sterile phenotype (Galloway et al. 2000; Juengel et al. 2002; Hanrahan et al. 
2004; Juengel et al. 2009). Furthermore, these co-expressed, closely-related growth 
factors, exert important synergistic actions both in vivo (Yan et al. 2001; Hanrahan et al. 
2004) and in vitro (Figure 3.12; McNatty et al. 2005b; Edwards et al. 2008; McIntosh et al. 
2008; Mottershead et al. 2011; Reader et al. 2011). However, the manner in which BMP15 
and GDF9 interact with one another, and with their cell surface receptors remains unclear. 
The purpose of this chapter is to evaluate the strengths and weaknesses of the approach 
taken in these studies to identify the different forms of BMP15 and GDF9 produced and 
secreted by ovine and bovine oocytes. It also aims to examine how these molecular forms 
fit with published knowledge and to speculate on potential areas of future research. It then 
further develops the model of BMP15-GDF9 heterodimerisation, described in Chapter 5, to 
propose a mechanism for the synergism observed in the granulosa cell responses to the 
presence of both BMP15 and GDF9. 
 
6.2 Recombinant BMP15 and GDF9 
In the present study, recombinant o/oBMP15, h/oBMP15 (S356C) and o/oGDF9 proteins 
were produced with a 8His-tag at the N-terminus of the proregion. A human embryonic 
kidney cell line (HEK293) was used to produce these proteins as these cells contain most 
of the machinery required for post translational folding and processing of recombinant 
proteins (Thomas and Smart 2005). Moreover, HEK293 cells have previously been used to 
produce different species of biologically-active, BMP15 and GDF9 (Otsuka et al. 2000) 
(Moore et al. 2003; Liao et al. 2004). Early methods to assist purification of recombinant 
BMP15 and/or GDF9 involved the transfection of HEK293 cells with constructs with a 
FLAG tag at the C-terminus of promature BMP15 (Otsuka et al. 2000) (Moore et al. 2003; 
Liao et al. 2004). This was later thought to impair biological activity. For example, the 
placement of a 6His tag at the C-terminus of either GDF9 (Mottershead et al. 2008) or 
BMP15 (Pulkki et al. 2011) resulted in a loss of biological activity. In contrast, the 
placement of a 6His tag near the N-terminus of the mature domain of GDF9 retained 
biological activity However, these N-tagged proteins did not interact with Ni2+ based 
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IMAC, possibly due to interference by the prodomains, and therefore could not be purified 
further (Mottershead et al. 2008). Subsequently, the His tag was placed at the N-termius of 
the prodomain allowing purification of biologically active BMP15 (Sudiman et al. 2014) 
and BMP15-GDF9 heterodimers (Mottershead et al. 2015). In this present study, an 8His 
tag was placed at the N-terminus of the prodomain, allowing for the production of un-
tagged mature domains. These un-tagged mature domains have the potential to better 
mimic the in vivo interactions between the growth factors and their cell surface receptors. 
 
The results herein revealed that the forms of secreted recombinant oBMP15 comprised 
mainly of mature monomers with a lesser amount of the uncleaved pro-mature form (see 
Chapter 3). These mature growth factor monomers were almost entirely located within 
high molecular weight multimeric complexes, which are also likely to contain the pro-
region (Chapter 3; Edwards et al. 2008). Likewise, mBMP15 was also found in expression 
media in both mature monomer and pro-mature forms (Otsuka et al. 2000). In contrast, 
hBMP15 has been reported to contain mature dimers (Liao et al. 2004; Hashimoto et al. 
2005; Rossetti et al. 2009; Pulkki et al. 2012). When the normally conserved cysteine 
(involved in dimer formation) was re-introduced into either human (Pulkki et al. 2012; 
Mottershead et al. 2015) or ovine BMP15 (Chapter 3), both dimeric pro-mature and 
dimeric mature growth factor forms were produced. As mentioned previously, it appears 
that the mature oBMP15 monomer is capable of forming dimers, probably during synthesis 
and secretion but that wild-type oBMP15, in contrast to hBMP15, appears unable to 
maintain the dimeric forms. In this study, Western blotting of cross-linked recombinant 
oBMP15, did not detect o/oBMP15 mature dimers. However, at least one form of 
o/oBMP15 expressed by HEK293 cells is biologically active, as assessed by the rat 
granulosa cell proliferation assay. This suggests that the biologically active form(s) are 
either a promature form and/or that monomeric mature domains are forming homodimers 
at the level of the receptor. The current study showed recombinant oGDF9 protein 
expressed from transfected HEK293 cells was also present in high molecular weight 
complexes (Chapter 4), comprised of pro-regions, uncleaved pro-mature forms and mature 
growth factor domains. However unlike oBMP15, dimeric mature forms were also 
detected (Figure 4.10). This is in agreement with that found for mouse GDF9 (McIntosh et 
al. 2008). 
 
These recombinant proteins enabled the identification of a number of different forms, 
including homodimers, recognized by monoclonal antibodies MN2-61A (anti-BMP15) and 
121 
37A (anti-GDF9). It is worth noting, that whatever forms of BMP15 and GDF9 are 
bioactive, the aforementioned monoclonal antibodies, or polyclonal antibodies generated 
against the same target sequences are capable of immuneo-neutralising BMP15 and GDF9 
bioactivity in vivo (Juengel et al. 2002; McNatty et al. 2007) and in vitro (Lin et al. 2012). 
Nevertheless, a weakness in the present study was the inability to confirm if either 
antibody could detect heterodimers of mature BMP15 and GDF9. It is not clear whether 
this was due to the inability of either antibody to bind to heterodimers, or if heterodimers 
in ruminants are unable form in solution. In Chapter 4, the in silico model depicts the 
locations of the presumed binding sites on homodimers of BMP15 and GDF9 (see Figures 
4.10A & B respectively) indicating that they appear to be accessible to the antibodies. It 
therefore seems likely that epitopes within these regions within a heterodimer would 
remain available to the antibodies, as they do in a homodimer: this notion would be 
consistent with the evidence from the immuno-neutralisation studies assuming 
heterodimers were present albeit at very low concentrations. However, confirmation that 
the antibodies recognize heterodimers will require binding to recombinant heterodimer 
proteins (e.g. the cumulin-like proteins). For example, the transformation of HEK293 cells 
with a construct encoding either o/oGDF9 (S417C) alone or o/oGDF9 (S417C) together 
with h/oBMP15 (S356C) would enable the production of covalently bound oGDF9 
homodimers and BMP15-GDF9 heterodimers.  
 
The inability to retain soluble proteins, following purification of promature and mature 
forms of both oBMP15 and oGDF9 was another major impediment in this study. The 
production of oBMP15 prodomains, free of mature domains, was attempted in these 
studies by inserting the oBMP15 prodomain sequence into the pEFIRES vector. However, 
the E.coli transformed with this vector failed to grow colonies (data not shown). 
Production of soluble, purified prodomain, promature and matureforms would have 
enabled the different forms to be assessed for biological activity, as well as their 
interaction(s) with BMPR2 either individually, or in combinations. Such studies would 
have enabled a more rigorous interrogation of the proposed model of heterodimer 
formation at the level of the receptor.  
 
6.3 Production and secretion of BMP15 and GDF9 by ovine and bovine oocytes 
A major strength of the current study was the identification of the biological forms of both 
BMP15 and GDF9 produced and/or secreted by ovine and bovine oocytes. BMP15 and 
GDF9 secreted by ruminant oocytes under in vitro conditions were found mainly in an 
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unprocessed promature form, along with some fully processed mature domains. This is in 
contrast to another report (Lin et al. 2012), where only fully processed oBMP15 and 
oGDF9 mature forms were reported to be secreted by ovine oocytes. However, Lin et al. 
(2012) only looked at forms under reducing conditions and as such, this study did not 
preclude the presence of cleaved, non-covalently associated, proregion and mature 
subunits. Both oBMP15 and oGDF9 have only been found in an uncleaved pro-mature 
form in ovine follicular fluid (McNatty et al. 2006). In bovine (Behrouzi et al. 2016) and 
porcine (Paradis et al. 2009) follicular fluid, the forms of BMP15 have been reported to 
consist of both uncleaved promature and mature domains, although the mature domain was 
found at 25 kDa instead of a predicted 15-17 kDa. These findings in the pig and cow need 
further verification as the appropriate specificity studies were not reported. Two of these 
studies (Behrouzi et al. 2016) (Paradis et al. 2009) utilized follicular fluid from pre-
ovulatory follicles, whereas the earlier study used fluid from 3 month-old lamb ovaries 
(McNatty et al. 2006). Thus the possibility exists that there may be species differences in 
the oocyte-secreted forms(s) of BMP15 and GDF9, and/or their proportions, may also 
change with the stage of follicular development. It is known that expression of BMP15 
mRNA begins from the primary stage onwards (Table1.2) and this was also confirmed by 
the phenotype in homozygous carriers for inactivating BMP15 mutations. However, using 
the same antibody as applied in this study (MN2-61A), BMP15 protein has been detected 
in oocytes during the antral stage of growth (McNatty et al. 2006). Evidence from in situ 
hybridization studies revealed that there is an increase in BMP15 expression levels during 
preantral development. (Feary et al. 2007). This suggests that BMP15 protein production is 
also likely to increase during follicular development but further studies are needed to 
confirm this. 
 
Importantly, the results from Chapter 4 show that the BMP15 and GDF9 mature domains, 
secreted by either bovine or ovine oocytes in vitro, do not interact to form discernible 
mature homodimers or heterodimers. In contrast, Peng et al. (2013) reported heterodimers 
between a MYC-tagged mGDF9 and a FLAG-tagged mBMP15. Similarly, Mottershead et 
al. (2015) showed that promature hBMP15, when immobilized on an affinity column, 
interacts with both mature hBMP15 and hGDF9 equally. Furthermore, McIntosh et al. 
(2008) reported interactions between mBMP15 pro-domains and mGDF9 mature domains. 
The later studies of Peng et al. (2013) and Mottershead et al. (2015) may be explained by 
either the presence of mature heterodimers, or by interaction between BMP15 prodomains 
and GDF9 mature domains. In both studies, GDF9 mature domains when complexed with 
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BMP15, were purified, at least in part, by affinity binding to the BMP15 promature 
domains. It would be interesting to know if the reverse procedure would also co-purify 
BMP15.  
 
It is possible that the in vitro oocyte incubation conditions employed in the current study 
results in dimer blocking modifications, during post-translational processing. However, 
homo- or heterodimeric forms were also undetected in lysates of freshly collected oocytes. 
If oocyte-secreted ruminant BMP15 or GDF9 are not forming homodimers in solution, 
then the likelihood of heterodimer formation may be equally low, and especially if 
ruminant proBMP15 has a similar affinity for both BMP15 and GDF9, as does the human 
form. Previous publications using the Western blotting procedure to interrogate the forms 
of BMP15 in follicular fluid (in vivo production) have only employed reducing conditions 
(Behrouzi et al. 2016) (Paradis et al. 2009) (McNatty et al. 2006). As such, it remains 
uncertain if homodimers or heterodimers may actually form in vivo.  
 
6.4 Molecular form and function 
The prodomain of related TGFB family members have been shown to play several 
different roles including: (i) conferring latency on the mature domain (TGFB) (Gentry and 
Nash 1990); (ii) assembly and secretion (inhibin alpha) (Walton et al. 2009); (iii) 
localisation to the extracellular matrix (BMP7) (Gregory et al. 2005) and; (iv) interaction 
with receptors (Hauburger et al. 2009; Sengle et al. 2008b). It therefore seems likely, that 
as with other members of the TGFB family, the continued associations of pro- and mature 
growth factor domains of BMP15 and GDF9 are important in serving biological functions 
after secretion (McIntosh et al. 2012). Indeed, it has been suggested that the BMP15 
prodomain may regulate cooperation between BMP15 and GDF9 (McIntosh et al. 2008). 
For example, the point mutation in Vacaria ewes (R351C; Souza et al. 2014) disrupts the 
cleavage site of promature GDF9, preventing the release of the mature domain and 
rendering the protein biologically inactive. Therefore, it seems reasonable to assume that 
an uncleaved promature BMP15 would also be inactive. Both in vivo (McNatty et al. 2006) 
(Behrouzi et al. 2016) (Paradis et al. 2009) and in vitro (Figures 4.5A & B and 4.9A & B) 
studies have reported oocyte secretion of uncleaved promature forms. Therefore, at some 
point following secretion, it seems evident that both BMP15 and GDF9 require cleavage. 
This may well occur at it’s target cell, as has been proposed for proAMH (McLennan and 
Pankhurst 2015). It will be of interest to determine the: (i) identity; (ii) originating cell 
type; (iii) site of action (ECM or level of receptor); and (iv) mechanisms of control, for the 
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proprotein convertase(s) and/or other proteinases which cleave promature BMP15 and/or 
GDF9. 
 
An oocyte, through the paracrine action of oocyte secreted factors (OSF), acting upon 
cumulus cells, creates and maintains the cumulus cell phenotype, and thereby control over 
its own microenvironment (Gilchrist et al. 2008). It is likely that BMP15 and GDF9, as 
with other TGFB family members, exert their effects through the creation of gradients: 
being more concentrated near the oocyte (cumulus cells) and becoming less concentrated 
nearer the basement membrane (mural granulosa cells) (Gilchrist et al. 2008). Promature 
forms of recombinant hBMP15, (Sudiman et al. 2014) and human cumulin (Mottershead et 
al. 2015), were more efficacious at promoting blastocyst development in bovine and 
porcine respectively, than the corresponding mature domains. In contrast, mature covalent 
cumulin had a greater proliferative effect on mural granulosa cells than did promature-
cumulin. Therefore, the secretion of both promature and fully-processed mature forms by 
ruminant oocytes, may add an additional level of complexity to the control that oocytes 
exert over the somatic cells of the follicle. The smaller mature domains, relative to the 
larger promature forms, may better escape the cumulus cell extracellular matrix (ECM) 
that has been shown to exhibit a morphogenic gradient of OSF, with the highest 
concentrations closest to the oocyte (Hussein et al. 2005). Additionally, the promature 
forms may interact directly (GDF9), or indirectly (BMP15), with cumulus cell ECM 
components, e.g. heparin sulphate proteoglycans (Mottershead et al. 2015). In this way, the 
oocyte would be able to maintain higher concentrations of promature forms around the 
cumulus cells. Indeed these heparin sulphate proteoglycans may act as co-receptors 
(Mottershead et al. 2015).  
 
Uncleaved promature forms of GDF9 (Souza et al. 2014) are biologically inactive in vivo, 
yet cleaved promature forms show different biological activities compared to mature 
domains in vitro (Sudiman et al. 2014; Mottershead et al. 2015). It seems clear that the 
cleaved promature form must be acting at the level of the receptor. Protein modeling 
demonstrates, with both the TGFB- and BMP-based models, that dimeric promature forms 
mask all the receptor binding sites present on the mature domains (Figure 5.12A & B). 
However, a monomeric promature form, unfettered by the masking actions imposed by a 
dimer partner, would have an unmasked type II receptor binding site available for 
interactions with the BMPR2 (Figure 5.17A). As mentioned in Chapter 5 (see Section 
5.4.1), the way in which BMP15 and/or GDF9 are presented to, and interact with their 
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respective receptors, may affect the intra-cellular signal(s) sent to the cell and/or the way 
the cell uses this signal. For example, the cleaved promature form of BMP15, likely 
interacts first with BMPR2 before it interacts with BMPR1B and then subsequently this 
complex recruits a GDF9-TGFBRI-BMPR2 receptor complex (Figure 5.17), to form a 
biologically-functional oligomeric receptor complex. In turn, this would activate a specific 
combination of Smad and non-Smad intracellular signaling pathway(s) within the target 
cell (cumulus). In response to these signals, the cumulus cells provide a micro-environment 
that is optimal for the the oocyte. In contrast, the mature forms, diffusing beyond the 
cumulus-oocyte-complex, likely interact with their receptors on mural granulosa cells in a 
less constrained manner. Consequently, by initiating different combination(s) of 
intracellular signaling pathways would enable different functional end points to be 
achieved, i.e. modified proliferation and/or responsiveness to FSH or LH (Figure 1.2). 
Indeed, within overlapping gradients, the two forms may well compete for both type I and 
II receptors, thereby acting as antagonists for each other. Changes to such gradients and the 
relative strengths to each other may explain the mode(s) of action in sheep heterozygous 
for inactivating mutations. Although producing less bioactive protein than their wild-type 
counterparts, concentrations of promature forms might be locally elevated, due to being 
sequestered by the cumulus cell ECM, allowing for an unaltered rate of oocyte maturation. 
However, the promature and/or mature domains might only reach a lower concentration 
threshold in follicular fluid and thereby exert different proliferative and/or differentiative 
effects, on the mural granulosa cells. One such consequence for the heterozygous BMP15 
mutants is the acquisition of LH receptors in mural granulosa cells at smaller follicular 
diameters (i.e. earlier stage of follicular growth) leading to a greater proportion of follicles 
capable of going on to ovulate and with increased number of offspring (McNatty et al. 
2009). 
 
It is clear that BMP15 and GDF9, either alone or together, elicit a range of phenotypes in 
both cumulus and mural granulosa cells (McNatty et al. 2005a;b; McIntosh et al. 2008; 
Mottershead et al. 2015). The species of growth factor(s) and target cell(s) are also known 
to affect the downstream cellular signaling responses (Reader et al. 2011; Mottershead et 
al. 2012; Reader et al. 2014). Presently, there is little consistency between different 
laboratories researching BMP15 and GDF9. This is due to the use of different cell strains, 
cell types and constructs for the production of recombinant proteins for different species, 
different approaches to purify the proteins, different antibodies to detect them, and 
different “standards” to measure them in relative densitometry assays. The relative 
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affinities between antibodies, and the different forms of BMP15 or GDF9 (e.g. monomer 
versus dimer, mature versus promature), are also unknown in these assays. Perhaps, not 
surprisingly, the present state of research into BMP15 and GDF9, in many ways, mirrors 
the early research into another TGFB family member, inhibin. For example, inhibin 
standards originally consisted of charcoal-stripped follicular fluid, containing an unknown 
mixture of forms, both of inhibins and activins. An early radio-immunoassay, the so called 
“Monash assay” (McLachlan et al. 1986; Robertson 1990), cross-reacted particularly well 
with the biologically inactive inhibin pro-C and -N forms and was unable to distinguish 
between inhibin A and inhibin B. This resulted in the conclusions derived from these early 
studies to undergo some revision (de Kretser et al. 2002). The importance of determining 
the correct bioactive form(s) of BMP15 and GDF9 and the ability to detect and measure 
these forms in a standard manner is of paramount importance to further elucidate the roles 
and actions of these growth factors. 
 
6.5 Mechanism of synergistic action  
The synergistic actions of BMP15 and GDF9 are well documented, with Bmp15-/-Gdf9+/- 
mouse knockout models showing more pronounced defects in follicular development than 
either Bmp15-/- or Gdf9+/- alone (Yan et al. 2001). Conversely, sheep carrying heterozygous 
mutations in both GDF9 and BMP15 have higher ovulation-rates than sheep carrying either 
of these mutations alone (Hanrahan et al. 2004). In vitro studies have also shown a 
synergistic effect on proliferation of granulosa cells by oBMP15 and oGDF9 (Section 
3.3.6; McNatty et al. 2005a), mBMP15 and mGDF9 (McIntosh et al. 2008; Reader et al. 
2011), as well as a combination of mGDF9 and hBMP15 (Mottershead et al. 2012) and 
oBMP15 and mGDF9 (McNatty et al. 2005a). Moreover, these synergistic effects are also 
evident if progesterone and inhibin production by granulosa cells (McNatty et al. 2005a) or 
expression levels of a range of genes involved in cumulus expansion (i.e. Ptx3, Has2, and 
Ptgs2; Peng et al. 2013b) are used as the end-point. If it is true that heterodimers are not 
formed prior to receptor binding, GDF9 and BMP15 may exert these synergistic effects at 
the level of the receptor, and/or by cross-talk, between signalling pathways. 
 
The purified mature domain of a covalently dimerised hBMP15 has a similar bioactivity to 
monomeric wild-type domains (Pulkki et al. 2012). This therefore confirms that BMP15 
must act at the level of the receptor in a dimeric form, typical of that for other TGFB 
family members. The synergistic action of GDF9 and BMP15 on the Smad pathways 
showed an increased activation of the Smad3 pathway, relative to that for GDF9 alone. In 
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contrast, the addition of GDF9 failed to stimulate further the Smad1/5/8 pathway compared 
to that for BMP15 alone (Mottershead et al. 2012). Moreover, co-incubation with GDF9 
and either covalently-bound hBMP15 (Mottershead et al. 2015) or oBMP15 (See Figure 
3.12) homodimers, failed to elicit a synergistic response in a mouse or rat granulosa cell 
3H-thymidine incorporation assay respectively.  
 
A B 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Mechanism of synergistic action. 
(A) Hypothesized conformational changes in GDF9 in response to heterodimer 
formation in comparison to (B) homodimer formation. Small changes in the 
conformation of GDF9 due to an interaction at the secondary binding site for 
BMPR1B (B2) may result in allosteric changes in GDF9 at the primary binding site 
(B3) for TGFBR1. Similarly changes in the relative shape and location of B3 and B4 
may improve contact and/or affinity between TGFBR1 and the B3 binding site of 
GDF9 when part of a heterodimer (A) compared to that created by a GDF9 
homodimer (B). 
 
This further supports the notion that this synergism is mediated at the level of the same 
receptor complex. However, additional crosstalk between non-Smad and/or Smad 
pathways cannot be discounted. It seems reasonable to assume that the synergistic action is 
caused by a change in either the way GDF9 interacts with its type I receptor and/or by the 
way this receptor is activated by BMPR2. Both possibilities could be accommodated by the 
formation of heterodimers within the receptor complex. Upon formation of the GDF5-
BMPR1B complex, GDF5 undergoes an induced change whereby the concave surface of 
the fingers (secondary type I binding site) move towards the receptor (Kotzsch et al. 2009). 
A similar conformational change occurring between GDF9 and BMPR1B may not only 
alter the shape of the secondary binding site (Figure 6.1A, binding site B2) but also the 
potential to fine tune, through allosteric changes, the primary binding site on GDF9 (Figure 
6.1A, binding site B3) as well. Such a heterodimer would alter the shape and potentially 
also alter the relative positions of both the primary and secondary binding sites for GDF9’s 
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type I receptor, (Figure 6.1A, binding sites B3 & B4). In turn, this might result in a greater 
affinity between GDF9 and its type I receptor leading to an increased activation of the 
Smad3 pathway. Likewise, a change in the orientation of the type I receptor may also 
improve its association with, and ability to be phosphorylated by, BMPR2 and/or its 
association with other intracellular binding partners. Increased bioactivity of heterodimers 
has been described previously where heterodimers of BMP2 with BMP5, 6 or 7 and 
heterodimers of BMP4 and BMP7 possessed greater bioactivity than any of the individual 
homodimers (Israel et al. 1996). 
 
6.6 Summary 
BMP15 and GDF9 are secreted by ruminant oocytes, largely in an uncleaved promature 
form, and to date there is no evidence for homodimers or heterodimers forming anywhere 
but at the level of the receptor in vivo. These promature forms, along with mature domains, 
may well create gradients eliciting different responses from cumulus and mural granulosa 
cells. It is hypothesised that BMP15 and GDF9 interact as a heterodimer at the level of the 
receptor. It is proposed that the synergistic increase in phosphorylated Smad3 and 
subsequent somatic cell responses is the result of subtle changes in the conformation and 
subsequent orientation between such a heterodimer and its receptors as well as between 
type I and type II receptors, compared to that of a homodimer complex. 
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APPENDIX 1: DNA and protein sequence of h/oBMP15 (S356C)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1 Schematic depiction of the h/oBMP15 (S356C) construct. 
Green arrows depict major components of the sequence including rat albumin signal 
sequence; 8His tag; human BMP15 prodomain (hBMP15pro) and ovine mature 
domain (oBMP15 mat). The location of cysteines within the mature domain are 
labelled. The mutation (S356C; numbered from start of hBMP15pro) is shown as 
Cysteine 4 
 
 
Protein                          M  K  W   V  T  F   L  L  L   L  F  I  S    
DNA TGAGAATTCA CTCGAGGCCA CCATGAAGTG GGTAACCTTT CTCCTCCTCC TCTTCATCTC 60 
 
Protein   G  S  A   F  S  H   H  H  H  H   H  H  H   G  G  E   G  G  Q  S  
DNA CGGTTCTGCC TTTTCTCACC ACCATCACCA CCACCATCAT GGAGGTGAAG GAGGGCAGTC 120 
 
Protein   S  I  A   L  L  A   E  A  P  T   L  P  L   I  E  E   L  L  E  E 
DNA CTCTATTGCC CTTCTGGCTG AGGCCCCTAC TTTGCCCCTG ATTGAGGAGC TGCTAGAAGA 180 
 
Protein   S  P  G   E  Q  P   R  K  P  R   L  L  G   H  S  L   R  Y  M  L 
DNA ATCCCCTGGC GAACAGCCAA GGAAGCCCCG GCTCCTAGGG CATTCACTGC GGTACATGCT 240 
 
Protein   E  L  Y   R  R  S   A  D  S  H   G  H  P   R  E  N   R  T  I  G 
DNA GGAGTTGTAC CGGCGTTCAG CTGACTCGCA TGGGCACCCT AGAGAGAACC GCACCATTGG 300 
 
Protein ··A  T  M   V  R  L   V  K  P  L   T  S  V   A  R  P   H  R  G  T 
DNA GGCCACCATG GTGAGGCTGG TGAAGCCCTT GACCAGTGTG GCAAGGCCTC ACAGAGGTAC 360 
 
Protein   W  H  I   Q  I  L   G  F  P  L   R  P  N   R  G  L   Y  Q  L  V 
DNA CTGGCATATA CAGATCCTGG GCTTTCCTCT CAGACCAAAC CGAGGACTAT ACCAACTAGT 420 
 
Protein   R  A  T   V  V  Y   R  H  H  L   Q  L  T   R  F  N   L  S  C  H 
DNA TAGAGCCACT GTGGTTTACC GCCATCATCT CCAACTAACT CGCTTCAATC TCTCCTGCCA 480 
 
Protein   V  E  P   W  V  Q   K  N  P   T  N  H  F   P  S  S   E  G  D  S 
DNA TGTGGAGCCC TGGGTGCAGA AAAACCCAAC CAACCACTTC CCTTCCTCAG AAGGAGATTC 540 
 
Protein   S  K  P   S  L  M   S  N  A  W   K  E  M   D  I  T   Q  L  V  Q 
DNA CTCAAAACCT TCCCTGATGT CTAACGCTTG GAAAGAGATG GATATCACAC AACTTGTTCA 600 
 
Protein · Q  R  F   W  N  N   K  G  H  R   I  L  R   L  R  F   M  C  Q  Q 
DNA GCAAAGGTTC TGGAATAACA AGGGACACAG GATCCTACGA CTCCGTTTTA TGTGTCAGCA 660 
 
Protein   Q  K  D   S  G  G   L  E  L  W   H  G  T   S  S  L   D  I  A  F 
DNA GCAAAAAGAT AGTGGTGGTC TTGAGCTCTG GCATGGCACT TCATCCTTGG ACATTGCCTT 720 
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Protein   L  L  L   Y  F  N   D  T  H  K   S  I  R   K  A  K   F  L  P  R 
DNA CTTGTTACTC TATTTCAATG ATACTCATAA AAGCATTCGG AAGGCTAAAT TTCTTCCCAG 780 
 
   G  M  E   E  F  M   E  R  E  S   L  L  R   R  T  R   Q  A  G  S 
751 GGGCATGGAG GAGTTCATGG AAAGGGAATC TCTTCTCCGG AGAACCCGAC AAGCAGGCAG 840 
 
Protein   I  A  S   E  V  P   G  P  S  R   E  H  D   G  P  E   S  N  Q  C 
DNA TATTGCATCG GAAGTTCCTG GCCCCTCCAG GGAGCATGAT GGGCCTGAAA GTAACCAGTG 900 
 
Protein · S  L  H   P  F  Q   V  S  F  Q   Q  L  G   W  D  H   W  I  I  A 
DNA TTCCCTCCAC CCTTTTCAAG TCAGCTTCCA GCAGCTGGGC TGGGATCACT GGATCATTGC 960 
 
Protein   P  H  L   Y  T  P   N  Y  C  K   G  V  C   P  R  V   L  H  Y  G 
DNA TCCCCATCTC TATACCCCAA ACTACTGTAA GGGAGTATGT CCTCGGGTAC TACACTATGG 1020 
 
Protein   L  N  S   P  N  H   A  I  I  Q   N  L  V   S  E  L   V  D  Q  N 
DNA TCTCAATTCT CCCAATCATG CCATCATCCA GAACCTTGTC AGTGAGCTGG TGGATCAGAA 1080 
 
Protein   V  P  Q   P  C  C   V  P  Y  K   Y  V  P   I  S  I   L  L  I  E 
DNA TGTCCCTCAG CCTTGCTGTG TCCCTTATAA GTATGTTCCC ATTAGCATCC TTCTGATTGA 1140 
 
Protein · A  N  G S  I  L   Y  K  E  Y   E  G  M   I  A  Q   S  C  T  C 
DNA GGCAAATGGG AGTATCTTGT ACAAGGAGTA TGAGGGTATG ATTGCCCAGT CCTGCACATG 1200 
 
Protein · R  *  * 
DNA CAGGTGATAA TCTAGAAGAA TTCAGT 1226 
Figure A1.2 The DNA sequence and protein translation for h/oBMP15 (S356C). 
Restriction enzyme cut sites are highlighted: EcoRI, yellow; XhoI, green; NcoI, blue; 
BamHI, orange; and; XbaI, red. The location of proprotein convertase cleavage site is 
shown by a box and the location of mutation (S356C) within the mature domain is 
highlighted in pink. The number of base pairs is shown on the right of the figure. 
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APPENDIX 2: DNA and protein sequence of o/oBMP15 
 
 
 
 
 
 
 
 
 
Figure A2.1 Schematic depiction of o/oBMP15 construct. 
Green arrows depict the major components of the sequence including rat albumin 
signal sequence, 8His tag, ovine BMP15 prodomain (oBMP15pro) and ovine mature 
domain (oBMP15 mat). The location of cysteines within the mature domain are 
labelled. 
 
 
Protein                         M  K  W   V  T  F   L  L  L   L  F  I  S 
DNA TGAGAATTCA CTCGAGGCCA CCATGAAGTG GGTAACCTTT CTCCTCCTCC TCTTCATCTC 60 
 
Protein  G  S  A   F  S  H   H  H  H  H   H  H  H   G  G  Q   W  S  H  P    
DNA CGGTTCTGCC TTTTCTCACC ACCATCACCA CCACCATCAT GGAGGTCAGT GGAGCCACCC 120 
 
Protein  Q  F  E   K  G  G   Q  V  G  Q   P  S  I   A  H  L   P  E  A  P    
DNA GCAGTTCGAG AAAGGAGGTC AGGTAGGGCA GCCCTCTATT GCCCACCTGC CTGAGGCCCC 180 
 
Protein  T  L  P   L  I  Q · L  L  E  E   A  P  G   K  Q  Q   R  K  P  E 
DNA TACCTTGCCC CTGATTCAGG AGCTGCTAGA AGAAGCCCCT GGCAAGCAGC AGAGGAAGCC 240 
 
Protein  R  V  L   G  H  P   L  R  Y  M   L  E  L   Y  Q  R   S  A  D  A 
DNA GCGGGTCTTA GGGCATCCCT TACGGTATAT GCTGGAGCTG TACCAGCGTT CAGCTGACGC 300 
 
Protein · S  G  H   P  R  E   N  R  T  I   G  A  T   M  V  R   L  V  R  P 
DNA AAGTGGACAC CCTAGGGAAA ACCGCACCAT TGGGGCCACC ATGGTGAGGC TGGTGAGGCC 360 
 
Protein  L  A  S   V  A  R   P  L  R  G   S  W  H   I  Q  T   L  D  F  P 
DNA GCTGGCTAGT GTAGCAAGGC CTCTCAGAGG CTCCTGGCAC ATACAGACCC TGGACTTTCC 420 
 
Protein  L  R  P   N  R  V   A  Y  Q  L   V  R  A   T  V  V   Y  R  H  Q 
DNA TCTGAGACCA AACCGGGTAG CATACCAACT AGTCAGAGCC ACTGTGGTTT ACCGCCATCA 480 
 
Protein  L  H  L   T  H  S   H  L  S  C   H  V  E   P  W  V   Q  K  S  P 
DNA GCTTCACCTA ACTCATTCCC ACCTCTCCTG CCATGTGGAG CCCTGGGTCC AGAAAAGCCC 540 
 
Protein  T  N  H   F  P  S   S  G  R  G   S  S  K   P  S  L   L  P  K  T 
DNA AACCAATCAC TTTCCTTCTT CAGGAAGAGG CTCCTCAAAG CCTTCCCTGT TGCCCAAAAC 600 
 
Protein · W  T  E   M  D  I   M  E  H  V   G  Q  K   L  W  N   H  K  G  R 
DNA TTGGACAGAG ATGGATATCA TGGAACATGT TGGGCAAAAG CTCTGGAATC ACAAGGGGCG 660 
 
Protein  R  V  L   R  L  R   F  V  C  Q   Q  P  R   G  S  E   V  L  E  F 
DNA CAGGGTTCTA CGACTCCGCT TCGTGTGTCA GCAGCCAAGA GGTAGTGAGG TTCTTGAGTT 720 
 
Protein  W  W  H   G  T  S   S  L  D  T   V  F  L   L  L  Y   F  N  D  T 
DNA CTGGTGGCAT GGCACTTCAT CATTGGACAC TGTCTTCTTG TTACTGTATT TCAATGACAC 780 
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Protein  Q  S  V   Q  K  T   K  P  L  P   K  G  L   K  E  F   T  E  K  D  
DNA TCAGAGTGTT CAGAAGACCA AACCTCTCCC TAAAGGCCTG AAAGAGTTTA CAGAAAAAGA 840 
 
Protein  P  S  L   L  L  R   R  A  R  Q   A  G  S   I  A  S   E  V  P  G 
DNA CCCTTCTCTT CTCTTGAGGA GGGCTCGTCA AGCAGGCAGT ATTGCATCGG AAGTTCCTGG 900 
 
Protein · P  S  R   E  H  D   G  P  E  S   N  Q  C   S  L  H   P  F  Q  V 
DNA CCCCTCCAGG GAGCATGATG GGCCTGAAAG TAACCAGTGT TCCCTCCACC CTTTTCAAGT 960 
 
Protein  S  F  Q   Q  L  G   W  D  H  W   I  I  A   P  H  L   Y  T  P  N 
DNA CAGCTTCCAG CAGCTGGGCT GGGATCACTG GATCATTGCT CCCCATCTCT ATACCCCAAA 1020 
 
Protein  Y  C  K   G  V  C   P  R  V  L   H  Y  G   L  N  S   P  N  H  A 
DNA CTACTGTAAG GGAGTATGTC CTCGGGTACT ACACTATGGT CTCAATTCTC CCAATCATGC 1080 
 
Protein  I  I  Q   N  L  V   S  E  L  V   D  Q  N   V  P  Q   P  S  C  V 
DNA CATCATCCAG AACCTTGTCA GTGAGCTGGT GGATCAGAAT GTCCCTCAGC CTTCCTGTGT 1140 
 
Protein  P  Y  K   Y  V  P   I  S  I  L   L  I  E   A  N  G   S  I  L  Y 
DNA CCCTTATAAG TATGTTCCCA TTAGCATCCT TCTGATTGAG GCAAATGGGA GTATCTTGTA 1200 
 
Protein · K  E  Y   E  G  M   I  A  Q  S   C  T  C   R  *  * 
DNA CAAGGAGTAT GAGGGTATGA TTGCCCAGTC CTGCACATGC AGGTGATAAT CTAGAAGAAT 1260 
 
Protein 
DNA TCAGT 1265 
 
 
Figure A2.2 DNA sequence and protein translation for o/oBMP15 
Restriction enzyme cut sites are highlighted: EcoRI, yellow; XhoI, green; NcoI, blue; 
and XbaI, red. The location of the proprotein convertase cleavage site is shown in a 
box and the location of S356 (mutated in h/oBMP15 (S356C); numbered from start of 
oBMP15pro) within the mature domain is highlighted in pink. The number of base 
pairs are shown on the right of the figure. 
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APPENDIX 3: Sequencing results for hBMP15pro 
 
oBMP15pro_Forward  TGGGCCCGACGTCGCATGCTCCCGGCCGCCATGG-CGGCC-
GCGGGAATTCGATTACTCG 106 
oBMP15pro_Reverse  TGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGGCGGCCCGCGGGAATTCGATTACTCG 178 
h/oBMP15 (S356C)   ------------------------------------------TGAGAATTC----ACTCG 14 
                                                              * ******    ***** 
 
oBMP15pro_Forward  AGGCCACCATGAAGTGGGTAACCTTTCTCCTCCTCCTCTTCATCTCCGGTTCTGCCTTTT 166 
oBMP15pro_Reverse  AGGCCACCATGAAGTGGGTAACCTTTCTCCTCCTCCTCTTCATCTCCGGTTCTGCCTTTT 238 
h/oBMP15 (S356C)   AGGCCACCATGAAGTGGGTAACCTTTCTCCTCCTCCTCTTCATCTCCGGTTCTGCCTTTT 74 
                   ************************************************************ 
 
oBMP15pro_Forward  CTCACCACCATCACCACCACCATCATGGAGGTGAAGGAGGGCAGTCCTCTATTGCCCTTC 226 
oBMP15pro_Reverse  CTCACCACCATCACCACCACCATCATGGAGGTGAAGGAGGGCAGTCCTCTATTGCCCTTC 298 
h/oBMP15 (S356C)   CTCACCACCATCACCACCACCATCATGGAGGTGAAGGAGGGCAGTCCTCTATTGCCCTTC 134 
                   ************************************************************ 
 
oBMP15pro_Forward  TGGCTGAGGCCCCTACTTTGCCCCTGATTGAGGAGCTGCTAGAAGAATCCCCTGGCGAAC 286 
oBMP15pro_Reverse  TGGCTGAGGCCCCTACTTTGCCCCTGATTGAGGAGCTGCTAGAAGAATCCCCTGGCGAAC 358 
h/oBMP15 (S356C)   TGGCTGAGGCCCCTACTTTGCCCCTGATTGAGGAGCTGCTAGAAGAATCCCCTGGCGAAC 194 
                   ************************************************************ 
 
oBMP15pro_Forward  AGCCAAGGAAGCCCCGGCTCCTAGGGCATTCACTGCGGTACATGCTGGAGTTGTACCGGC 346 
oBMP15pro_Reverse  AGCCAAGGAAGCCCCGGCTCCTAGGGCATTCACTGCGGTACATGCTGGAGTTGTACCGGC 418 
h/oBMP15 (S356C)   AGCCAAGGAAGCCCCGGCTCCTAGGGCATTCACTGCGGTACATGCTGGAGTTGTACCGGC 254 
                   ************************************************************ 
 
oBMP15pro_Forward  GTTCAGCTGACTCGCATGGGCACCCTAGAGAGAACCGCACCATTGGGGCCACCATGGTGA 406 
oBMP15pro_Reverse  GTTCAGCTGACTCGCATGGGCACCCTAGAGAGAACCGCACCATTGGGGCCACCATGGTGA 478 
h/oBMP15 (S356C)   GTTCAGCTGACTCGCATGGGCACCCTAGAGAGAACCGCACCATTGGGGCCACCATGGTGA 314 
                   ************************************************************ 
 
oBMP15pro_Forward  GGCTGGTGAAGCCCTTGACCAGTGTGGCAAGGCCTCACAGAGGTACCTGGCATATACAGA 466 
oBMP15pro_Reverse  GGCTGGTGAAGCCCTTGACCAGTGTGGCAAGGCCTCACAGAGGTACCTGGCATATACAGA 538 
h/oBMP15 (S356C)   GGCTGGTGAAGCCCTTGACCAGTGTGGCAAGGCCTCACAGAGGTACCTGGCATATACAGA 374 
                   ************************************************************ 
 
oBMP15pro_Forward  TCCTGGGCTTTCCTCTCAGACCAAACCGAGGACTATACCAACTAGTTAGAGCCACTGTGG 526 
oBMP15pro_Reverse  TCCTGGGCTTTCCTCTCAGACCAAACCGAGGACTATACCAACTAGTTAGAGCCACTGTGG 598 
h/oBMP15 (S356C)   TCCTGGGCTTTCCTCTCAGACCAAACCGAGGACTATACCAACTAGTTAGAGCCACTGTGG 434 
                   ************************************************************ 
 
oBMP15pro_Forward  TTTACCGCCATCATCTCCAACTAACTCGCTTCAATCTCTCCTGCCATGTGGAGCCCTGGG 586 
oBMP15pro_Reverse  TTTACCGCCATCATCTCCAACTAACTCGCTTCAATCTCTCCTGCCATGTGGAGCCCTGGG 658 
h/oBMP15 (S356C)   TTTACCGCCATCATCTCCAACTAACTCGCTTCAATCTCTCCTGCCATGTGGAGCCCTGGG 494 
                   ************************************************************  
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oBMP15pro_Forward  TGCAGAAAAACCCAACCAACCACTTCCCTTCCTCAGAAGGAGATTCCTCAAAACCTTCCC 646 
oBMP15pro_Reverse  TGCAGAAAAACCCAACCAACCACTTCCCTTCCTCAGAAGGAGATTCCTCAAAACCTTCCC 718 
h/oBMP15 (S356C)   TGCAGAAAAACCCAACCAACCACTTCCCTTCCTCAGAAGGAGATTCCTCAAAACCTTCCC 554 
                   ************************************************************ 
 
oBMP15pro_Forward  TGATGTCTAACGCTTGGAAAGAGATGGATATCACACAACTTGTTCAGCAAAGGTTCTGGA 706 
oBMP15pro_Reverse  TGATGTCTAACGCTTGGAAAGAGATGGATATCACACAACTTGTTCAGCAAAGGTTCTGGA 778 
h/oBMP15 (S356C)   TGATGTCTAACGCTTGGAAAGAGATGGATATCACACAACTTGTTCAGCAAAGGTTCTGGA 614 
                   ************************************************************ 
 
oBMP15pro_Forward  ATAACAAGGGACACAGGATCCTACGACTCCGTTTTATGTGTCAGCAGCAAAAAGATAGTG 766 
oBMP15pro_Reverse  ATAACAAGGGACACAGGATCCTACGACTCCGTTTTATGTGTCAGCAGCAAAAAGATAGTG 838 
h/oBMP15 (S356C)   ATAACAAGGGACACAGGATCCTACGACTCCGTTTTATGTGTCAGCAGCAAAAAGATAGTG 674 
                   ************************************************************ 
 
oBMP15pro_Forward  GTGGTCTTGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCTATT 826 
oBMP15pro_Reverse  GTGGTCTTGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCTATT 898 
h/oBMP15 (S356C)   GTGGTCTTGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCTATT 734 
                   ************************************************************ 
 
oBMP15pro_Forward  TCAATGATACTCATAAAAGCATTCGGAAGGCTAAATTTCTTCCCAGGGGCATGGAGGAGT 886 
oBMP15pro_Reverse  TCAATGATACTCATAAAAGCATTCGGAAGGCTAAATTTCTTCCCAGGGGCATGGAGGAGT 958 
h/oBMP15 (S356C)   TCAATGATACTCATAAAAGCATTCGGAAGGCTAAATTTCTTCCCAGGGGCATGGAGGAGT 794 
                   ************************************************************ 
 
oBMP15pro_Forward  TCATGGAAAGGGAATCTCTTCTCCTGA--ATTCAATCACTAGTGAATTCGCGGCCGCCTG 944 
oBMP15pro_Reverse  TCATGGAAAGGGAATCTCTTCTCCTGA--ATTCAATCACTAGTGAATTCGCGGCCGCCTG 1016 
h/oBMP15 (S356C)   TCATGGAAAGGGAATCTCTTCTCCGGAGAACCCGACAAGCAGGCAGTATTGCATCGGAAG 854 
                   ************************ **  *  * *  *  **  * *       **   * 
 
oBMP15pro_Forward  
CAGGTCGACCATATGGGAGAGCTCCCAAACGCGTTGGATGCATAGCTTGAGTATTCTATA 1004 
oBMP15pro_Reverse  CAGGTCGACCATATGGGAGAGCTCCCAA-CGCGTTGGATGCATAGCTTGAGTATTCTATA 1075 
h/oBMP15 (S356C)    TTCCTGGCCCCTCCAGGGAG---CATGATGGGCCTGAAAG--TAACCAGTGTTCCCTCCA 909 
                       * * ** *   **      *   *  *   ** * *  ** *  * **   **  * 
 
oBMP15pro_Forward  GTGTCACCTAAATAGCTTACGTAATCATGATCATAGCTGTTTCCTGTGTGAATTGTATC- 1063 
oBMP15pro_Reverse  GT-TCACCTAAATAGCTGGCG-----ATGATT----CCGTTTTTTTTGAGA--TGGGGC- 1122 
h/oBMP15 (S356C)   CCCTTTTCAAGTCAGCTTCCAGCAGCTGGGCTGGGATCACTGGATCATTGCTCCCCATCT 969 
                      *   * *   ****  *        *           *   *    *        *  
FigureA3.1 Sequencing results for hBMP15pro 
Alignment (*) of h/oBMP15 (S356C) sequence with results from sequencing of 
hBMP15pro using oBMP15pro_Forward, 5’primer; [5’-
ACTCGAGGCCACCATGAAGTG-3’] and oBMP15pro_Reverse, 3’ primer; [5’-
GAATTCAGGAGAAGAGATTCCCTTTC-3’] Restriction enzyme cut sites are 
highlighted: EcoRI in yellow and XhoI in green. 
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APPENDIX 4: Sequence alignment of the sequenced pEFIRES-h/oBMP15 (S356C) 
insert against theoretical h/oBMP15 (S356C) sequence 
 
Forward primer A:           ATCCCCCAGGGGGTCCACCTCCCAGTTCAATTACAGCTCTTAAGGCTAGA 50 
h/oBMP15(S356C)_theoretical  -------------------------------------------------- 
                                                                                    
Forward primer A:           GTACTTAATACGACTCACTATAGGCTAGCCTCGAGGCCACCATGAAGTGG 100 
h/oBMP15(S356C)_theoretical -------------------TGAGAATTCACTCGAGGCCACCATGAAGTGG 31 
                                                  **  *   ********************* 
 
Forward primer A:           GTAACCTTTCTCCTCCTCCTCTTCATCTCCGGTTCTGCCTTTTCTCACCA 150 
h/oBMP15(S356C)_theoretical GTAACCTTTCTCCTCCTCCTCTTCATCTCCGGTTCTGCCTTTTCTCACCA 81 
   ************************************************** 
 
Forward primer A:           CCATCACCACCACCATCATGGAGGTGAAGGAGGGCAGTCCTCTATTGCCC 200 
h/oBMP15(S356C)_theoretical CCATCACCACCACCATCATGGAGGTGAAGGAGGGCAGTCCTCTATTGCCC 131 
   ************************************************** 
 
Forward primer A:           TTCTGGCTGAGGCCCCTACTTTGCCCCTGATTGAGGAGCTGCTAGAAGAA 250 
h/oBMP15(S356C)_theoretical TTCTGGCTGAGGCCCCTACTTTGCCCCTGATTGAGGAGCTGCTAGAAGAA 181 
   ************************************************** 
 
Forward primer A:           TCCCCTGGCGAACAGCCAAGGAAGCCCCGGCTCCTAGGGCATTCACTGCG 300 
h/oBMP15(S356C)_theoretical TCCCCTGGCGAACAGCCAAGGAAGCCCCGGCTCCTAGGGCATTCACTGCG 231 
   ************************************************** 
 
Forward primer A:           GTACATGCTGGAGTTGTACCGGCGTTCAGCTGACTCGCATGGGCACCCTA 350 
h/oBMP15(S356C)_theoretical GTACATGCTGGAGTTGTACCGGCGTTCAGCTGACTCGCATGGGCACCCTA 281 
   ************************************************** 
 
Forward primer A:           GAGAGAACCGCACCATTGGGGCCACCATGGTGAGGCTGGTGAAGCCCTTG 400 
h/oBMP15(S356C)_theoretical GAGAGAACCGCACCATTGGGGCCACCATGGTGAGGCTGGTGAAGCCCTTG 331 
   ************************************************** 
 
Forward primer A:           ACCAGTGTGGCAAGGCCTCACAGAGGTACCTGGCATATACAGATCCTGGG 450 
h/oBMP15(S356C)_theoretical ACCAGTGTGGCAAGGCCTCACAGAGGTACCTGGCATATACAGATCCTGGG 381 
   ************************************************** 
 
Forward primer A:           CTTTCCTCTCAGACCAAACCGAGGACTATACCAACTAGTTAGAGCCACTG 500 
h/oBMP15(S356C)_theoretical CTTTCCTCTCAGACCAAACCGAGGACTATACCAACTAGTTAGAGCCACTG 431 
   ************************************************** 
 
Forward primer A:           TGGTTTACCGCCATCATCTCCAACTAACTCGCTTCAATCTCTCCTGCCAT 550 
h/oBMP15(S356C)_theoretical TGGTTTACCGCCATCATCTCCAACTAACTCGCTTCAATCTCTCCTGCCAT 481 
   ************************************************** 
 
Forward primer A:           GTGGAGCCCTGGGTGCAGAAAAACCCAACCAACCACTTCCCTTCCTCAGA 600 
h/oBMP15(S356C)_theoretical GTGGAGCCCTGGGTGCAGAAAAACCCAACCAACCACTTCCCTTCCTCAGA 531 
   ************************************************** 
 
Forward primer A:           AGGAGATTCCTCAAAACCTTCCCTGATGTCTAACGCTTGGAAAGAGATGG 650 
h/oBMP15(S356C)_theoretical AGGAGATTCCTCAAAACCTTCCCTGATGTCTAACGCTTGGAAAGAGATGG 581 
   ************************************************** 
 
Forward primer A:           ATATCACACAACTTGTTCAGCAAAGGTTCTGGAATAACAAGGGACACAGG 700 
h/oBMP15(S356C)_theoretical ATATCACACAACTTGTTCAGCAAAGGTTCTGGAATAACAAGGGACACAGG 631 
   ************************************************** 
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Forward primer A:           ATCCTACGACTCCGTTTTATGTGTCAGCAGCAAAAAGATAGTGGTGGTCT 750 
h/oBMP15(S356C)_theoretical ATCCTACGACTCCGTTTTATGTGTCAGCAGCAAAAAGATAGTGGTGGTCT 681 
Forward primer B:                               GTGTCAGCAGCAAAAAGATAGTGGTGGTCT 46 
    ************************************************** 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward primer A:           TGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCT 800 
h/oBMP15(S356C)_theoretical TGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCT 731 
Forward primer B:           TGAGCTCTGGCATGGCACTTCATCCTTGGACATTGCCTTCTTGTTACTCT 66 
   ************************************************** 
 
Forward primer A:           ATTTCAATGATACTCATA                                 818 
h/oBMP15(S356C)_theoretical ATTTCAATGATACTCATAAAAGCATTCGGAAGGCTAAATTTCTTCCCAGG 781 
Forward primer B:           ATTTCAATGATACTCATAAAAGCATTCGGAAGGCTAAATTTCTTCCCAGG 116 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical GGCATGGAGGAGTTCATGGAAAGGGAATCTCTTCTCCGGAGAACCCGACA 831 
Forward primer B:           GGCATGGAGGAGTTCATGGAAAGGGAATCTCTTCTCCGGAGAACCCGACA 166 
   ************************************************** 
h/oBMP15(S356C)_theoretical AGCAGGCAGTATTGCATCGGAAGTTCCTGGCCCCTCCAGGGAGCATGATG 881 
Forward primer B:           AGCAGGCAGTATTGCATCGGAAGTTCCTGGCCCCTCCAGGGAGCATGATG 216 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical GGCCTGAAAGTAACCAGTGTTCCCTCCACCCTTTTCAAGTCAGCTTCCAG 931 
Forward primer B:           GGCCTGAAAGTAACCAGTGTTCCCTCCACCCTTTTCAAGTCAGCTTCCAG 266 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical CAGCTGGGCTGGGATCACTGGATCATTGCTCCCCATCTCTATACCCCAAA 981 
Forward primer B:           CAGCTGGGCTGGGATCACTGGATCATTGCTCCCCATCTCTATACCCCAAA 316 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical CTACTGTAAGGGAGTATGTCCTCGGGTACTACACTATGGTCTCAATTCTC1031 
Forward primer B:           CTACTGTAAGGGAGTATGTCCTCGGGTACTACACTATGGTCTCAATTCTC 366 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical CCAATCATGCCATCATCCAGAACCTTGTCAGTGAGCTGGTGGATCAGAAT 1081 
Forward primer B:           CCAATCATGCCATCATCCAGAACCTTGTCAGTGAGCTGGTGGATCAGAAT 416 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical GTCCCTCAGCCTTGCTGTGTCCCTTATAAGTATGTTCCCATTAGCATCCT 1131 
Forward primer B:           GTCCCTCAGCCTTGCTGTGTCCCTTATAAGTATGTTCCCATTAGCATCCT 466 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical TCTGATTGAGGCAAATGGGAGTATCTTGTACAAGGAGTATGAGGGTATGA 1181 
Forward primer B:           TCTGATTGAGGCAAATGGGAGTATCTTGTACAAGGAGTATGAGGGTATGA 516 
   ************************************************** 
h/oBMP15(S356C)_theoretical TTGCCCAGTCCTGCACATGCAGGTGATAATCTAGAAG-AATTCAGT---- 1231 
Forward primer B:           TTGCCCAGTCCTGCACATGCAGGTGATAATCTAGAGTCGACCCGGGCGGG 566 
Removed (C) 
Inserted (T) 
155 
   ************************************************** 
 
h/oBMP15(S356C)_theoretical --------------------------------------------------  
Forward primer B:           CCGCTCTAGCCCAATTCCGCCCCCCCC----------------------- 593 
   ****************    *  * *                         
 
Figure A4.1 Sequence alignment of the sequenced pEFIRES-h/oBMP15 (S356C) 
insert against theoretical h/oBMP15 (S356C) sequence. 
Alignment (*) of h/oBMP15 (S356C)_theoretical sequence with sequence results of 
h/oBMP15 (S356C) insert using Forward primer 1, 5’primer; [5’ –CTA-TTG-GTC-
TTA-CTG-ACA-TCC-A- 3’] and Forward primer 2, 5’primer; [5’ –CGT-TCT-GGA-
ATA-ACA-AGG-3’]. The restriction enzyme cut sites are highlighted: XhoI in yellow 
and XbaI in green. 
 
Note: Based on the review of the chromatogram files and to correct the auto read of 
the chromatogram, a cytosine was removed and a thymine inserted at positions 634 
and 670 respectively 
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APPENDIX 5: Materials 
A5.1 Reagents  
Acetonitrile  (MERCK, Darstadt, Germany, Cat. No. 1.00030.2500) 
 
Activin A, rec. Human R&D Systems; Pharmaco, Auckland, New Zealand,  
Cat. No. 338-AC 
 
Agarose, 1% (w/v) 
0.4 g LE agarose (Seakem; Alphatech, Auckland New Zealand, Cat. No. 
CAM50004) 
40 mL 1x TAE Buffer 
Carefully heated in microwave to melt. 
 
Ammonium persulphate, 10% (w/v) 
1 g  Ammonium persulphate (Sigma-Aldrich, (SIGMA), Auckland New Zealand, 
Cat. No. A3678) 
10 mL  Distilled H2O 
Stored at -20°C in 1 mL aliquots until required. 
 
Ampicilin (SIGMA, Cat. No. A9393). 
 
Biocore running buffer, 2x 
1.99 g  EDTA 
58.44 g NaCl From the laboratory of Dr T. D. Mueller, 
5.21 g Hepes Department of Plant Physiology and Biophysics,  
1.0 ml Tween 20 Julius-von Sachs Institute of the University 
1000 mL MilliQ water Wuerzburg, D-97082, Wuerzburg, Germany 
The solution was pH to 7.4 with 2 M NaOH and passed through a 0.22 m filter. 100 mL 
of this solution was removed and stored as 2x strength. The remaining solution was diluted 
with 900 mL MilliQ water to give 1x strength. 
 
Bis(sulfosuccinimidyl)suberate (BS3)  
 (Life Technologies NZ Ltd, Auckland New Zealand, Cat. No. 21580) 
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Bromophenol blue, 1.0% (w/v) 
0.1 g  Bromophenol blue (SIGMA; Cat. No. B0126) 
Reconstituted in 10 mL of distilled H2O. 
 
Dissection medium A (Medium A; DMA; for rat granulosa cells) 
1x bottle M199 (SIGMA, Cat No.M5017) 
4.76 g Hepes (SIGMA, Cat No. H3784) 
10 mL PenStrep (Life Technologies Ltd, Cat. No. 15070-063) 
900 mL Distilled H2O  
The solution was adjusted to pH 7.3 with 2 M HCl and adjusted to a final volume of 1 L. 
The solution was then passed through a 0.22 m filter into a sterile 1 L glass bottle.  
The osmolarity was tested to ensure that it read between 290 and 310 Osm (Fiske OSTM 
osmomoter; Fiske Associates, Needham Heights, Massachusetts). If required, the 
osmolarity was adjusted using a sterile solution of 2.5 g/mL NaCl (SIGMA, Cat. No. 
S3014). 
 
Dissection medium C (Medium C; for oocyte recovery) 
500 mL M199 (Life Technologies Ltd, Cat. No. 1150-059 
4.76 g Hepes (SIGMA, Cat No. H3784) 
5 mL PenStrep (Life Technologies Ltd, Cat. No. 15070-063) 
5 mL Glutamax (100x) 
The Hepes was dissolved in 50 mL M199, passed through 0.22 m filter and added back 
into remaining 500 mL M199. 
 
EDTA, 0.5M 
73.06 g Ethylenediaminetetraacetic acid, Disodium salt (BDH, Global Science, 
Auckland New Zealand, Cat. No. 100935V) 
450 mL Distilled H2O 
The solution was adjusted to pH 8.0 prior to additional distilled H2O being added to a final 
volume of 500 mL. 
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Electical chemi-luminescence (ECL) reagents: 
250 mM Luminol 
0.44 g Luminol; 5-amino-2,3-dihydro-1,4-phthalazinedione (SIGMA, Cat. No. 
45106182 
10 mL Dimethyl sulphoxide (DMSO), (SIGMA, Cat. No. D2650) 
Stored at -20oC in 100 L aliquots. 
 
90 mM p-coumaric acid 
0.15 g p-coumaric acid (SIGMA, Cat. No. C9208) 
10 mL Dimethyl Sulphoxide (DMSO), (SIGMA, Cat. No. D2650) 
Stored at -20oC in 44 µL aliquots 
 
1M Tris, pH 8.5 
30.29 g Tris(hydroxymethyl)aminomethane Life Technologies NZ Ltd, Cat. No. 
15504-020) 
200 mL Sterile MilliQ water  
Adjusted pH to 8.5 with HCl before a final volume of 250 mL was reached with sterile 
MilliQ water. 
 
Solution A 
8.85 mL  MilliQ H2O 
1 mL 1 M Tris, pH 8.5 
100 L 250 mM lumiol 
44 L 90 mM p-coumaric acid 
Solution B 
9.0 mL  MilliQ H2O 
1 mL 1 M Tris, pH 8.5 
6 L 30%(v/v) Hydrogen peroxide (Scharlau, Global Science, Auckland New 
Zealand, Cat. No. H101361000) 
Immediately prior to use, Solutions A & B were mixed together and poured over the 
nitrocellulose membrane.  
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Expression medium (HEK293 cells) 
100 g Heparin (SIGMA, Cat. No. H3149) 
0.01 g Bovine serum albumin (SIGMA, Cat. No. A450) 
1 mL Penicillin (5000 IU/mL) and streptomycin (5mg/mL) (PenStrep; Life 
Technologies NZ Ltd, Cat. No. 15070063) 
1 mL Glutamax (100x) 
98 mL Dulbecco´s Modified Eagle Medium (D-MEM):Hams F12 (1:1), Life 
Technologies NZ Ltd (Cat. No. 12634010) 
 
Fugene HD   Roche, Auckland, New Zealand (Cat No. 04709705001) 
 
Glutamax (100x) L-alanyl-L-glutamine dipeptide; Life Technologies Ltd, (Cat. No. 
35050061) 
 
Growth medium (HEK293 cells) 
10 mL Fetal Calf Serum (FCS; Life Technologies NZ Ltd) 
10 mL Penicillin (5000 IU/mL) and streptomycin (5mg/mL) (PenStrep; Life 
Technologies NZ Ltd, Cat. No. 15070063) 
10 mL 100x Glutamax (Life Technologies NZ Ltd, Cat. No. 35050061) 
1000 mL Dulbecco´s Modified Eagle Medium (D-MEM; Life Technologies NZ Ltd 
Cat. No. 11965-092) 
Adjusted pH to 7.3 with 5 M HCl, filtered through a 0.2 m filter into a sterile bottle and 
stored at 4oC. 
 
Incubation medium D (Medium D; for oocyte incubations) 
500 mL M199 (Life Technologies Ltd, Cat. No. 1150-059 
1.1 g Sodium bicarbonate (SIGMA Cat. No. S5761) 
5 mL PenStrep (Life Technologies Ltd, Cat. No. 15070-063) 
5 mL Glutamax (100x) 
Sodium bicarbonate was dissolved in 50 mL M199 then passed through 0.2 m filter back 
into remaining 500 mL M199. Stored at 4oC. 
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Incubation medium B (Medium B; 3H–thymidine incorporation bioassay) 
500 mL McCoys 5a medium (Life Technologies Ltd, Cat. No.16600-082)  
5 mL PenStrep (Life Technologies Ltd, Cat. No. 15070-063) 
1.1 g Sodium Bicarbonate (SIGMA Cat. No. S5761) 
Sodium bicarbonate was dissolved in 50 mL M199 then passed through 0.2 m filter back 
into remaining 500 mL M199. Stored at 4oC. 
 
On day of use: 
50 mL McCoys 5a medium containing NaHCO3 and PenStrep 
0.5 mL 30 mg/mL poly(vinyl alcohol)  
Passed through 0.22 m filter into tissue culture flask. Equilibrated to 37oC and 5% CO2, 
for at least 4 hours prior to use. 
LB Agar 
1 L LB Broth 
15 g Agar (Becton Dickinson, Auckland, New Zealand, Cat. No. 214010) 
Autoclaved to dissolve and sterilise. 
 
LB Broth (Lysogeny broth; (Bertani 2004)  
5 g Yeast extract (Becton Dickinson, Cat. No. 212750) 
10 g Bacto-tryptone (Becton Dickinson, Cat. No. 211705) 
10 g Sodium Chloride (SIGMA, Cat. No. S3014) 
1 L Distilled H2O 
 
LigaFast ™ Rapid DNA Ligation System  
(PROMEGA, Sydney, Australia, Cat. No. M8221) 
 
Poly(vinyl alcohol) – 30mg/mL 
30 mg Poly(vinyl alcohol) (SIGMA, Cat. No. P8136) 
10 mL Distilled H2O 
Dissolved, passed through a 0.2 m filter and store at 4oC. 
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Low salt buffer 
20 mL 1 M Tris-HCl, pH 7.5 
0.876 g NaCl (SIGMA, Cat. No. S3014) 
1 mL Tween 20 (SIGMA, Cat. No. P5927) 
950 mL Distilled H20 
Adjust pH if necessary and make up to 1000 mL with distilled H20. 
 
Peroxidise conjugated rabbit anti mouse IgG 
 Jackson Immuno Research Laboratories Ltd, West Grove, PA,  
(Cat. No. 315-035-045) 
 
Protease inhibitors (26x) 
1x tablet Complete, EDTA-free protease inhibitor cocktail 
1.92 mL Distilled Q H2O 
Divided into 50 µL aliquots and stored at -20OC. 
 
Phosphate buffered saline, pH7.4 
1x tablet SIGMA, Cat. No. P4417 
100 mL  Distilled Q H2O 
Sterilised by autoclave and stored at room temperature 
 
Puromycin dihydrochloride (10mg/mL)  
25 mg Puromycin dihydrochloride (Sigma-Aldrich, Auckland New Zealand, Cat. 
No. P8833) 
2.5 mL Sterile distilled water 
Stored at -20oC in 500 L aliquots. 
 
QIAprep spin miniprep kit (QIAGEN Pty. Ltd., Vic, Australia, Cat. No. 27106) 
 
QIAprep gel extraction kit (QIAGEN Pty. Ltd., Vic, Australia, Cat No. 28704) 
 
Restriction enzymes: 
EcoRI (Roche, Auckland, New Zealand, Cat No. 107303737001) 
XbaI (Roche, Cat No. 10674257001) 
XhoI (Roche, Cat No. 1703770001) 
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Scintillation fluid (Beta Scint) (Perkin Elmer; Sci-Med, Auckland New Zealand, 
Cat. No. SC/9200.21) 
 
SDS PAGE running Buffer, pH 8.3, (5x) 
360 g Glycine (Scharlau, Global Science, Auckland New Zealand, Cat. No. 
AC04041000) 
75 g Tris(hydroxymethyl)aminomethane (SIGMA; Auckland, New Zealand) 
25 g Sodium Dodecyl Sulphate. 
4500 mL Distilled H2O  
Adjusted pH to 8.3 with HCl and adjusted to a final volume of 5 L. The solution was 
diluted 1:5 before use with MilliQ H2O. 
 
Sodium Dodecyl Sulphate, 10% (w/v) 
10 g Sodium dodecyl sulphate (BDH; Global Science, Auckland New Zealand, 
Cat. No. 301754L) 
100 mL  Distilled H2O 
 
SYBR® Green (Life Technologies NZ Ltd, Auckland, New Zealand  
Cat. No. S7567)  
 
TAE Buffer (Tris-Acetate, EDTA, 50x) 
242 g Tris(hydroxymethyl)aminomethane Life Technologies NZ Ltd, Cat. No. 
15504-020) 
57.1 mL 17.4 M Glacial Acetic Acid (Scharlau, Cat. No. AC03442500) 
100 mL 0.5 M EDTA, pH 8.0 
Make up to 1000 mL with distilled H2O. 
Diluted 1:50 with distilled H2O before use. 
 
3H-Thymidine (~1 Ci in 1 ml) Perkin Elmer (Cat. No. NET3555001MC; Sci-Med, 
Auckland New Zealand) 
Used 0.4 µCi in each well (i.e. per 20 000 live cells). 
 
Trifluoroacetic acid  (SIGMA-Aldrich, Cat. No. 302031) 
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Tris-HCl, 0.5M, pH6.8 
6.06 g   Tris(hydroxymethyl)aminomethane Life Technologies NZ Ltd, Cat. No. 
15504-020) 
80 mL Distilled H2O.  
Adjusted pH to 6.8 with HCl, then diluted to a final volume of 100 mL. 
 
Tris, 1M, pH 7.5 
30.29 g Tris(hydroxymethyl)aminomethane (Life Technologies NZ Ltd, Cat. No. 
15504-020) 
200 mL Sterile distilled water  
Adjusted pH to 7.5 with HCl and diluted to a final volume of 250 mL with sterile MilliQ 
water. 
 
Tris-HCl, 1.5M, pH8.8 
36.34 g  Tris(hydroxymethyl)aminomethane Life Technologies NZ Ltd, Cat. No. 
15504-020) 
160 mL Distilled H2O.  
Adjusted pH to 8.8 with HCl, then diluted to a final volume of 200 ml. 
 
Tris-glycine transfer buffer (10 x) 
30.3 g Tris(hydroxymethyl)aminomethane Life Technologies NZ Ltd, Cat. No. 
15504-020) 
144 g Glycine (Scharlau, Global Science, Auckland New Zealand, Cat. No. 
AC04041000) 
1000 mL Milli Q water. 
 
1x Tris–glycine transfer buffer 
300 mL 10 x Tris-glycine stock 
600 mL Methanol (VWR; Global Science, Auckland New Zealand, Cat. No. 
20847.320) 
2100 mL Distilled water. 
Buffer was pre-chilled to 4oC before use. 
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Trypan blue, 0.4% (w/v) SIGMA, Cat. No. T8154 
 
TrypLETM Express Life Technologies NZ Ltd, Cat. No. 12605010 
 
Water (HPLC grade)  MERCK, Cat. No. 1.15333.2500 
 
Western blotting non-reducing sample buffer with SDS, (5x) 
1.0 mL 0.5 M Tris-HCl pH 6.8 
0.8 mL glycerol (SIGMA, Cat. No. G5516)  
4.6 mL 10% (w/v) Sodium dodecyl sulphate 
0.2 mL 1.0% (w/v) bromophenol blue 
2.28 mL Distilled H2O 
 
Western blotting reducing sample buffer with SDS, (5x) 
1.0 mL 0.5 M Tris-HCl pH 6.8 
0.8 mL glycerol (SIGMA, Cat. No. G5516) 
4.6 mL 10% (w/v)  Sodium dodecyl sulphate 
80 mg Dithiothreitol (BDH; Global Science, Auckland New Zealand, Cat. No. 
443852A) 
0.2 mL 1.0% (w/v) bromophenol blue 
0.8 mL Milli Q H2O 
Stored at -20OC in 300L aliquots.  
Immediately before use, an aliquot was thawed and 60 L -mercaptoethanol (SIGMA 
Cat. No. 1610710) was added to give a final concentration of 2.3 M. 
 
X-Gal 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside,  
 (Sigma-Aldrich, Auckland New Zealand, Cat. No. B4252). 
 
A5.2 Hardware 
Blotting paper Bio-Rad, Auckland, New Zealand, Cat. No. 1703932 
 
Filter (0.22 m) Corning Inc., Corning, NY, Cat. No. 431118. 
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Filter mats (90x120 mm, printed Filtermat A) (Perkin Elmer; Sci-Med, Auckland 
New Zealand Cat. No. 1450-421) 
 
HPLC reverse phase column (Jupiter, 5 m, C4, 300Å; Phenomenix, Lane Cove, NSW, 
Australia. Cat. No. OOG-4167-EO) 
 
Tissue culture Flasks (Growth flasks) 
 T25 (Nunc; Life Technologies NZ Ltd, Cat. No.136196) 
 T80 (Cat. No.178905) 
 T175 (Cat. No.178883) 
 
Sample bag Perkin Elmer; Sci-Med, Auckland New Zealand, Cat. No.1450-432 
 
Security guard cartridge Widepore, C4, Phenomenix, Lane Cove, NSW, Australia. 
Cat.No. AJO-4330 
 
6 well culture plate NUNC; Life Technologies NZ Ltd, Cat. No 140675 
 
96 well culture plate JET BIOFIL; Interlab, Wellington, New Zealand, Cat. No. 
TCP000096) 
 
 
Nitrocellulose (pore size 0.45 µm) GE Healthcare Ltd, Auckland, New Zealand, 
Cat No. 10600016) 
 
X-ray film BIOMAX XAR film, (KODAK) Carestream Health INC., 
Rochester, NY, Cat. No. 165 1454) 
 
A5.3 Equipment 
Beta counter Perkin Elmer; 1450-SLC MicroBeta Trilux; Sci-Med, Auckland, 
New Zealand 
 
Centrifugal vacuum concentrator Eppendorf®, model 5301, SIGMA 
`  
